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General Introduction
The human genome consists of ~ 6 billion base pairs, which is divided over 23 pairs of 
chromosomes. It is estimated that there are 20000-25000 protein coding genes. The 
DNA sequence in our genome is on average 99.9% identical to any other human being 1. 
The more closely related two people are, the more similar their genomes. However, every 
human being is genetically unique and variations in composition and structure of the DNA 
are found throughout the genome. Human genetic variation refers to genetic differences 
between individuals and is important for diversity in a population. Without genetic 
variability a population cannot adapt to changes in the environment. The differences in 
genotype can cause differences in phenotype with subtle or sometimes quite obvious 
effects. Despite the large amount of variation in the human genome, most sequence 
variants have no obvious functional consequences. Determining if a specific variant has 
an effect is an important part of genetic analysis. The identification of genomic variation 
in large numbers of individuals helps to distinguish neutral variants (not involved in 
disease, or ‘non-pathogenic’ variants) from variants disrupting gene function (involved 
in disease, or ‘pathogenic variants’). DNA analysis of patients with Mendelian disorders 
has resulted in the identification of a broad range of variants in genes, from definitely 
pathogenic mutations, to unclassified variants, to neutral polymorphisms. The relation 
between genomic variation and complex and quantitative human traits (i.e. obesity, 
height, multifactorial disease) has also been studied extensively. 
As new methods for studying DNA are developed, different types of genomic variation 
have been discovered. Detection of large numbers of unclassified variants (UVs), with 
unclear significance for disease, have further emphasized the importance of cataloging 
genomic variation and studying the functional effects. The major challenge for molecular 
geneticists, cytogeneticists, clinical geneticists, and genetic counsellors is assessing the 
impact of all types of genomic variation on monogenic and complex disorders, along with 
the effective communication of findings to counselees.
Genomic variation; definition of sequence variation and structural variation
Genomic variation is a general term that covers all types of possible DNA variants, ranging 
from alterations affecting entire chromosomes to single nucleotide changes.
Differences in classification and terminology of genomic variation often cause confusion, 
therefore recommendations for the description of DNA variants have been proposed by 
the Human Genome Variation Society (HGVS).
Two main groups of variation can be identified; 1) sequence variation and 2) structural 
variation. An overview of the different types of variation, definitions and the spectrum in 
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which they operate are given in Table 1a+b. Examples are shown in Figure 1a+b. 
Sequence variants can be classified as single or multi-nucleotide changes and range from 
single nucleotide differences to 1 kilobase (kb)-sized changes to full chromosome or even 
full genome changes of a segment of DNA 2. Single nucleotide changes affect only one base 
pair, whereas multi-nucleotide changes are changes in a stretch of nucleotides. Variation 
in sequence include substitutions, insertions, deletions, duplications, and inversions. Indels 
are more complex changes and can be regarded as a combination of single nucleotide 
changes and multi-nucleotide changes. Sequence variations include “mutations” and 
“polymorphisms” and are usually referred to as single nucleotide polymorphisms (SNPs) 
or single nucleotide variants (SNVs). In some disciplines the term “mutation” is used to 
indicate “a change”, while in other disciplines it is used to indicate “a disease-causing 
change”. Similarly, the term “polymorphism” is used both to indicate “a non-disease-
causing change”, a change involved in human traits or a change found at a frequency of 1% 
or higher in the population 3. To prevent this confusion, neutral terms such as “ variant” or 
“alteration” are preferred as they are less ambiguous 4. 
Structural variation is the genetic variation in structure of an organism’s chromosome. 
It is generally defined as a region of DNA 1 kb and larger in size. As the resolving power 
of genetic analysis has increased, the focus of structural variation has shifted from 
entire chromosomes (in the prebanding chromosome era), parts of chromosomes (in the 
G banding era) to kilobases (using restriction enzymes, DNA probes and the Southern 
blotting). Sequencing techniques have shown that structural variants also include much 
smaller events, and overlap with the spectrum of sequence variation. Structural variation 
includes cytogenetically detectable and submicroscopic types of variation, such as 
deletions, duplications, insertions, inversions, translocations, indels and transpositions. 
Deletions and duplications, collectively referred to as copy-number variation (CNV), are a 
subset of structural variation and result in variable copy numbers of copies of specific DNA 
sequences 5-11. CNVs are a major source of human genetic variation. Over 10,000 distinct 
CNVs have been described, ranging in size from kilobases to megabases. Most CNVs in 
humans are <50 Kb in size 12. CNVs can be defined as recurrent or nonrecurrent, depending 
on their mechanism of formation 13. Many recurrent CNVs are flanked by segmental 
duplications (also called low copy repeats; regions of DNA >1 kb present more than once 
in the genome with copies which are >90% identical) and are of a fixed size 9, 14. Because 
these repeated sequences tend to misalign during meiosis, the resultant rearrangements 
tend to recur, creating clusters of variants with common endpoints. CNVs at these loci 
arise, by a mechanism named nonallelic homologous recombination (NAHR). Nonrecurrent 
CNVs, in contrast, which are not flanked by low copy repeats but other DNA elements (ALU 
elements or other repetitive elements), are of variable size and are thought to arise via 
1
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mechanisms like nonhomologous end joining (NHEJ) and replication-based mechanisms 
such as fork stalling and template switching (FoSTeS) and microhomology-mediated break-
induced replication models (MMRDR) 15. It is becoming clear that most disease-causing 
CNVs are nonrecurrent, and generally arise via replication-based mechanisms.
Structural variants are associated with repetitive DNA, making accurate characterization 
more difficult 16. Systematic assessment of structural variation in our genome has been 
difficult, primarily due to lack of appropriate methods for analysis. As such, the nucleotide 
resolution architecture of most structural variants remains unknown.
Table 1a. Description of variation types based on HGVS definitions
Types of variation Description
Substitution One nucleotide is replaced by another nucleotide
Deletion One or more nucleotides are removed
Duplication A copy of one or more nucleotides is inserted elsewhere in the genome
Tandem duplication A copy of one or more nucleotides, directly following the original 
sequence
Insertion One or more nucleotides are inserted between two original nucleotides 
but the insertion is not a tandem duplication
Insertion-deletion
(Indel)
One nucleotide is replaced by more than one other nucleotide or More 
than one nucleotide is replaced by one or more other nucleotides
Inversion More than one nucleotide is the reverse complement of the original 
sequence and replaces the original sequence





The sequence of one chromosome inserts into another chromosome
Copy Number Variation Submicroscopic deletions and duplications, which are losses or gains of 
DNA segments
Conversion A range of nucleotides replacing the original sequence and are a copy of a 
sequence elsewhere in the genome
Table 1a: Description of variation types based on HGVS definitions
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Table 1b. The spectrum of variation in the human genome.
Variation Type Size Range
Single base pair change Substitution, deletion, 
insertion, duplication
1 bp
Multiple base pair changes Insertions, deletions, 
duplications, inversions, indels
Up to 1 kb
Full chromosome changes aneuploidy Entire chromosome/genome
Fine and intermediate scale 
structural variation
Insertions, deletions, 
duplications, inversions, indels, 
transpositions
1 kb-50 kb
Large scale structural variation Insertions, deletions, 
duplications, inversions, indels, 
transpositions
50 kb-5 Mb
Chromosomal variation translocations ~ ≥5 Mb
Light grey = sequence variation, black= structural variation. The operational spectrum partially overlaps 
with respect to size range.
Figure 1a: Types of variation in the human genome (sequence view). These can be single 
base changes (substitution, deletions, and insertions) or involve larger segments of DNA 
(deletions, insertions, inversions, indels, and duplications). Adapted from Frazer et al 17
Table 1b: The spectrum of variation in the human genome
1
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Genomic variation in the general population
Genomic variation refers to alterations at the DNA-level. Variation in DNA occurs due 
to malfunction of DNA replication during cell division or if DNA repair mechanisms fail 
after DNA damage induced by chemicals or radiation. These are random and spontaneous 
changes. Recent parent to offspring studies determined the human mutation rate (the rate 
at which variation occurs) at 1 x 10-8 per base per generation 18.
Population genetics is based on the study of genomic variation in natural selection. If a 
variant increases fitness it will undergo positive selection, and eventually be conserved 
in the genome. In contrast, a variant that has a negative effect will be selected against, 
and eventually lost. Our genome mutates spontaneously and randomly; mostly neutral, 
sometimes detrimental and, very rarely, beneficial. Ultimately, a gene pool arises which 
is best adapted to the environment. Most common genetic variants arose once in human 
history, and are shared by many individuals today through descent from common ancestors. 
Most analysis estimate that SNVs occur 1 in 1000 base pairs, although they do not occur 
at a uniform density. On average, every human being has 3 million nucleotide differences 
(SNVs) with any other human. Everyone is genetically unique. Even monozygotic twins, 
derived from the same fertilization event, have infrequent genetic differences due to early 
somatic changes (somatic variants) 19, 20. There is also significant genetic difference between 
individuals from different ethnic backgrounds and numbers may increase if indels and 
structural variation is taken into account 21. It has become apparent that human genomes 
Figure 1b: Types of variation in the human genome (chromosome view). Examples 
of structural variation. 1) transposition-transfer of segment of DNA to a new position. 2) 
translocation-balanced event where two DNA segments are interchanged. 3) Copy number 
variation: deletion and duplication-loss or gain of DNA segments.
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differ more as a consequence of structural variation than single base-pair differences 9. In 
2010 the human genome contains an estimated 15 million SNVs, 1 million short insertions 
and deletions and 20000 structural variants 1.
CNVs have been recognized as a common form of genomic structural variation. High 
resolution microarrays and sequencing approaches are able to identify 600–900 CNVs in 
a single individual 22, 23. Approximately 65% to 80% of individuals carry a CNV that is at least 
100 kbp in size, 5 to 10 % of individuals harbour a CNV at least 500 kbp, and 1% of individuals 
carry a large CNV of at least 1 Mbp in size 24. This means that larger CNVs are skewed toward 
rare variants. As the full extent of structural variation in our genome has been revealed, 
it has been estimated that CNVs account for ~ 13% of the human genome 7, 25. The de novo 
rate of large (> 100 kb) CNV formation in humans was estimated at 1.2 × 10-2 CNVs per 
genome per transmission against a high selection pressure, suggesting that each of these 
de novo CNVs persists in the population for only a few generations 26, 27 
The full extent to which CNVs are likely to contribute to the diversity of human phenotypes 
is still under assessment. It is clear that the phenotypic impact of CNVs occurs as a 
continuum from ‘neutral’ to pathogenic, and can act in more complex and sometimes 
unexpected ways. Figure 2 shows conceptual curves of projected frequencies of SNVs 
and CNVs in the population associated with their phenotypic impact. In general, SNVs 
and CNVs with a high population frequency are annotated as benign or neutral in their 
effect, while rare variants are more likely to be pathogenic. In between, CNVs and SNVs 
can be associated with degrees of function described as ‘traits’, ‘risk factors’ and, beyond 
a certain threshold, ‘disease’. After extensive phenotype-genotype studies, some of the 
SNVs and CNVs previously annotated as benign or neutral in their effect will be reclassified 
as predisposing risk factors.
Uncovering the genetic basis of human phenotypic differences requires a comprehensive 
understanding of all forms of genetic variation, both at fine scale (sequence variants) and 
large scale (structural variants). Different genomic technologies are required to detect 
structural variation at different levels. Next generation sequencing technologies will be 
used to generate comprehensive maps of human genetic variation.
Effects of genomic variation 
The decoding of information from DNA to protein begins with transcription, as messenger 
RNA (mRNA) is created from a DNA template, followed by translation. Translation is the 
process of protein synthesis from mRNA, with specific amino acids encoded by three 
nucleotide combinations (codons). Synthesis of the protein takes place in a specific reading 
frame according to these codons. As such, each type of variant may have consequences at 
different levels (DNA, RNA, protein), also depending on the surrounding genomic context 
1
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(coding or non-coding). Changes in coding or regulatory sequences are most likely to affect 
gene expression or affect the function of protein products 29. Any phenotypic effect is 
highly dependent on the location (type of tissue) and the developmental stage in which 
the sequence variant is expressed.
Classification of genomic variation can also be based on the effect at different levels (DNA, 
RNA, protein). In diploid organisms (such as humans), changes in the DNA may occur on one 
(heterozygous) or both (homozygous) alleles. Single nucleotide changes that lead to amino 
acid changes in the protein coding region of a gene may be classified into three types 
(silent, missense and nonsense), depending upon what the erroneous codon codes for. 
Synonymous variants (also known as silent variants) do not lead to a different amino acid 
being encoded (due to redundancy in the codon code). Non synonymous variants do alter 
the amino acid sequence of a protein, and can be sub-classified such as missense variants 
(encoding a different amino acid) and nonsense variants (creating a stop codon, leading to 
premature protein truncation). Frameshift variants (variants disrupting the reading frame 
such as deletions and duplications) lead to an altered, usually non-functional, protein 
product.
On RNA level any step of gene expression, post-transcriptional modification (capping, 
Figure 2: Conceptual curves of SNV and CNV characteristics. Projected frequencies in the 
population for SNVs (dashed grey) and CNVs (blue) show the relation between genomic 
variation and a spectrum of phenotypic impact. Adapted from Buchanan et al 28.
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polyadenylation, splicing) may be modulated. Most human genes can be transcribed 
into different mRNAs composed of different exons, leading to alternative splicing and 
the expression of functionally diverse protein isoforms 30. A significant fraction of exonic 
variants (including silent and missense variants) and intronic variants cause disease by 
disrupting normal splicing 31. Silent changes may affect translational efficiency, resulting in 
different protein levels or affect protein function via folding 32, 33. 
Variation can also be classified by effect on function. Variants can have no effect (neutral), 
or lead to a change in function. Loss-of-function changes result in non-functional proteins. 
When the dose of a gene product is affected and not enough for a normal function this is 
called haploinsufficiency or dosage effect. Gain-of-function changes yield a protein that 
has a new function. Dominant negative changes have an altered gene product that has 
a negative impact on normal function. Variants that prevent viability are termed lethal.
Changes not to the DNA sequence itself but modifications or addition of chemical groups 
to individual nucleotides (e.g. methyl groups or proteins introduce another type of variation 
called epigenetics. This type of variation may have an effect on phenotype by altering gene 
expression. Comparable to genomic variation, epigenetic differences between individuals 
and monozygotic twins have been described 34, 35. However, the epigenome is not the 
subject of this thesis and will not be discussed further.
Genomic variation in relation to disease: intellectual disability and/or congenital 
anomalies
The number of known pathogenic variants in human genes that underlie or are associated 
with human inherited disease is > 110000, in more than 4000 genes 36. Currently, causal 
variants for ~ 3000 Mendelian disorders have been reported in the online database for 
Mendelian disorders in man (OMIM May 2012, # entries for phenotype description, 
molecular basis known). 
Mental retardation (MR) or intellectual disability (ID) is defined as a significant impairment 
of cognitive and adaptive functions 37 and affects around 1-3% of individuals 38, 39. The 
proportion of intellectual disability that can be at least partially accounted for by genetic 
factors (chromosomal, monogenic or multifactorial) is difficult to estimate, but may 
account for ~ 30% of all cases. In approximately 50% of cases, the cause remains unknown 
40. G-banded karyotyping supplemented by (sub)telomere screening or fluorescence in-situ 
hybridization (FISH) detects significant abnormalities in up to 10% of intellectual disability 
cases 41. ~ 5% of patients have a monogenic disorder, where a causative variant in a single 
gene can be identified 42. CNVs (> 500 kb) detected by array-based technologies (aCGH, 
SNP array) explain another ~ 15% of cases 43. De novo CNVs and point pathogenic variants 
1
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of large effect may explain the majority of all intellectual disability cases in the population, 
and could thereby explain why such a disorder with reduced fecundity remains present in 
the population 44. 
In recent years, several new monogenic disease genes and numerous submicroscopic 
deletion and duplication syndromes (‘genomic disorders’) have been identified. It has been 
estimated that about 0.7-1 per 1000 live births has a genomic disorder 45 . In general, CNVs 
implicated in genomic disorders are de novo and large in size (> 50 kb). However, it seems 
likely that additional genomic disorders due to much smaller de novo CNVs remain to be 
discovered 46. 
In addition to microdeletion/microduplication syndromes, CNV’s are involved in many 
common complex traits, including autism and schizophrenia 47-51. Several genomic 
disorders involving inherited CNVs have been described (1q11.2, 1q21.1, 15q11, 16p13.11, 16p11.2, 
22q11). Microdeletions and microduplications at these loci show variable penetrance and 
expression, and are thus not necessarily recognised as clinically distinctive syndromes. 
Inherited CNVs may be involved in disease, by acting as modifiers in milder phenotypes, 
either in combination with other CNVs or with sequence variants. This is illustrated by 
the fact that 25% of ID children carry a 2nd CNV, in addition to an inherited CNV 52. Some 
authors have coined the term ‘second site’ or ‘two hit’ model for this phenomenon, which 
is confusing since those terms are widely used in the cancer field to indicate somatic 
mutations disturbing the regulation of cell growth. We prefer to stick to ‘multifactorial’ a 
term formerly used to indicate any number of unknown factors above one, but can be used 
as well for known factors. Recently, compound inheritance of a null allele (deletion 1q21.1) 
together with the presence of a SNV was proven to be associated with TAR syndrome 53. 
The effect of different combinations of (multiple) inherited CNVs and/or sequence variants 
on phenotype urgently requires further study, and identifying additional genetic and/or 
environmental factors is the challenge of our time. 
Genetic inheritance of genomic variation 
Mendelian inheritance patterns can demonstrate a greater level of complexity than 
simple dominant, recessive or X-linked inheritance, through a number of non-Mendelian 
processes including imprinting, X-inactivation, mosaicism and variation in penetrance 
and variable expressivity. When searching for the exact genetic cause of a disease, and 
calculating risk of transmission to offspring, it is important to take this level of complexity 
into account. Examples of complex inheritance includes disorders caused by more than 
one gene (di/polygenic disorders such as in Axenfeld-Rieger syndrome 54), trinucleotide 
repeat expansion disorders (such as Huntington’s disease 55) where the number of CAG 
repeats correlate with the severity of disease and the age of onset in combination with 
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the characteristic of anticipation (the tendency for progressively earlier or more severe 
expression of the disease in successive generations), genes whose expression is governed 
by parent of origin (Angelman/Prader Willi syndrome 56, Beckwith-Wiedemann/Silver 
Russell syndrome 57), triallelic inheritance (Bardet-Biedl syndrome 58). Complex inheritance 
involving co-inheritance of CNVs 52 or a CNV in combination with sequence variants 59, 53 
have also been demonstrated. 
Sequence variants and CNVs can be inherited from a parent, or occur de novo. From the 
analysis of complete genome sequences of two parent-offspring (‘trios’) studies, it has 
been estimated that each child inherits about 30 to 50 new variants 9, 18. These new variants 
can either be germline variants that have arisen during the production of gametes in the 
parental generation, or be present in a subset of cells from either parent, and represent a 
germ line mosaic with recurrence risk to subsequent offspring 60. A significantly greater 
proportion of new variants is of paternal origin, as a result of the larger number of divisions 
during spermatogenesis 61-63, a phenomenon already described by population geneticists 
more than half a century ago 61. A similar finding was reported for de novo CNVs 64.
Techniques to detect genomic variation
History
Within the past 40 years, a variety of experimental methods have emerged; typically each 
focuses on a particular class of genomic variation limited by the size range of the events. 
Early cytogeneticists studying chromosome variation can be legitimately regarded as 
the first genome pioneers 65. The establishment of the human chromosome count 66 and 
the discovery of trisomy 21 in Down syndrome 67 have been the groundwork for studying 
disease-related genomic variation. Since the 1970’s, G-banding and later high resolution 
chromosome banding techniques, enabled detection of microscopic variation (> 5 Mb). 
In the 1980’s, FISH (Fluorescent in situ hybridisation) was developed for microscopic 
detection of specific structural chromosome abnormalities 68, 69. At the same time, with 
the development of molecular markers and application of recombinant DNA techniques, 
genomic variation at DNA level (sequence variation) was discovered 70. The relative easy 
and reliable chain-termination method developed by Sanger soon became the method 
of choice for sequencing 71. In the early 90’s, Comparative Genome Hybridization (CGH) 
allowed the detection of submicroscopic structural variation 72. In the last decade, array-
based methods were developed (array-CGH, SNP-arrays) and contributed greatly to our 
knowledge of structural variation.
1
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Overview of techniques
Quantitative and qualitative changes require different detection methods. At this moment 
it is not possible to detect all types of genomic variation with just one technique. Each 
technique has advantages and disadvantages concerning not only specificity, sensitivity, 
throughput and resolution, but also costs and feasibility in the laboratory. In the field of 
clinical genetics, many techniques have been used to study our genome. The techniques 
discussed here are those used in the research comprising this thesis. Table 4 gives an 
overview of the techniques used for detection of genomic variation. In general, the 
resolution of a technique depends on its design and is rarely a fixed number. Improvement 
in resolution mainly depends on probe size and distances between probes.
Cytogenetic and molecular techniques
Karyotyping, using the light microscope to visualize G-banding patterns, enables rapid 
identification of all chromosomes in a metaphase spread in one view. This enables clonal 
analysis, but the resolution of a light microscope is limited. Large (> 5 Mb) chromosomal 
rearrangements such as deletions, duplications, translocations, inversions and insertions 
can usually be detected. FISH using probes covering the regions affected enables 
microscopic detection of structural chromosomal abnormalities directly on metaphase 
chromosomes and interphase nuclei using fluorescently labelled DNA probes. As with 
karyotyping, routine FISH analysis has a limited resolution (50 kb-2  Mb). Both techniques 
do not detect single nucleotide variants or small structural variations. The ultimate 
resolution of the microscopic approach is obtained by Fiber FISH 75 allowing the detection 
of small deletions and duplications (5 kb-500 kb).
In addition to FISH, array-based methods have been developed. Array comparative 
genome hybridisation (Array-CGH) platforms are based on the principle of combined 
hybridisation of two differentially labelled samples to hybridisation targets. As targets, 
DNA isolated from Bacterial Artificial Chromosomes (BAC clones), or PCR products there 
of, or synthetically produced long oligonucleotides are spotted onto a glass slide (array). 
Subsequently, labelled genomic DNA from a test and a reference sample are hybridised 
to the array and fluorescence intensities are measured. Relative intensity ratios are 
calculated, with imbalances indicating the presence of copy number variation. The 
resolution of array-CGH is unlimited but dependent on the spacing of the clones and their 
insert size. Arrays with 3500 BAC clones (resolution ~ 1Mb) or tiling arrays (33000 BAC 
clones) with a 10 fold higher resolution are usually used. This resolution does not allow 
the accurate determination of breakpoints. Custom high-density oligonucleotide arrays 
are available on demand, allowing the discovery of CNVs down to 500 bp and more precise 
breakpoint mapping 9. For high resolution, genome wide analysis of copy number changes, 
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SNP-based arrays can be used. There are differences in experimental design by different 
manufacturers, which will not be discussed here. In general, they are single colour assays, 
designed to be used for SNP genotyping and copy number analysis in one experiment. One 
DNA sample is hybridised per array, and copy number ratios are determined by clustering 
the intensities of each probe across many samples. A major advantage is the possibility to 
detect low level mosaicism (~>15%), uniparental disomies (UPD) and identity-by-descent 
(IBD) 76-78. An important limitation of microarrays are the difficulties of probe design in 
repeat-rich and duplicated regions, with structural variants being strongly correlated to 
these regions. Smaller CNVs (< 10kb) are also more difficult to detect routinely, which 
also leads to under-representation in CNV databases. All array-based techniques cannot 
detect very small structural deletions or duplications and balanced rearrangements (e.g. 
translocations). Although it is technically possible, SNP arrays are not routinely used to 
detect single nucleotide variants. 
Several PCR-based techniques have been developed to investigate targeted regions 
for the presence of CNVs. Multiplex ligation-dependent probe amplification (MLPA) 79 
is based upon the ligation of two adjacent-annealing oligonucleotides, followed by a 
quantitative PCR of the ligated products. This technique detects copy number variations 
of test DNA, where the relative amount of each product is correlated to the copy number 
of the locus being tested. Normalization using control probes, and normalization against 
control samples, determines the relative copy number in the test sample. Detection of 
deletions (ratio threshold under 0.75) and simple duplications (ratio threshold above 1.25) is 
relatively straightforward, but this technique is less accurate in detecting higher numbers 
of duplicates or mosaic changes. In addition, using specific probe design at the ligation 
site it is possible to detect point single nucleotide variants. At the same time, this also 
means detection of a deletion may be false positive if a SNV is present at, or close to, the 
ligation site. The advantage of this technique is the flexibility in experimental design, 
high resolution of CNV detection (45-70 bp) and the possibility to screen large numbers of 
patients for different loci in a single experiment. 
QF-PCR (quantitative PCR) or QMPSF (Quantitative Multiplex PCR of Short Fluorescent 
Fragments), like MLPA, is a quantitative assay based on PCR amplification of genomic DNA 
using fluorescently labelled primers. It monitors the amount of product generated during 
the amplification process compared to a reference. Quantitative differences are used to 
estimate a relative copy number.
In addition to the previously described techniques that allow detection of quantitative 
differences, several methods have been developed to detect qualitative differences. 
High resolution melting curve analysis (HRMA) is a method used for genotyping, single 
nucleotide variant scanning and sequence matching 80, 81 and is also suitable for detecting 
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mosaicism. It is based on the dissociation-characteristics of double-stranded DNA during 
heating. Following PCR amplification of a target region with a DNA binding fluorescent 
dye (LC-green), the amplicon is melted out by increasing the temperature in the solution. 
Double stranded DNA will become single stranded and the dye will be released. The specific 
sequence of the amplicon (primarily GC content and length) determines the melting 
behaviour. Each amplicon has a unique melting pattern, based on its sequence. DNA with 
a higher G-C content, whether because of its source or because of SNVs, will have a higher 
melting temperature than DNA with a higher A-T content. Amplicons can be compared by 
plotting the change in fluorescent signal against the melting temperature (Tm). 
DNA sequencing technology has developed at an unprecedented rate in recent years. 
Sanger sequencing is regarded as the gold standard technique to study alterations at the 
single nucleotide level. It allows easy detection of SNVs, small insertions, deletions and a 
moderate level of mosaicism (15-50%) 82, 83. There is a risk of false negative results when there 
is allelic dropout due to variants in the primer binding sites, or when the target (exon/gene) 
sequence is deleted 84. When the amplified alleles have significant size differences (e.g. 
due to insertions or deletions) preferential amplification of the shorter allele may mask the 
second allele. Current sequencing techniques (‘Next generation sequencing’ or NGS) allow 
screening of the whole genome in one experiment. Many different sequencing technologies 
and systems have emerged the past three years, utilising different methodologies. Ideally, 
complete genome sequencing followed by de novo assembly and comparison to a high-
quality reference could identify thousands of sequence variants. In practice, NGS still faces 
technical, but more importantly, substantial computational and bioinformatic challenges. 
Read lengths are <100 bp for most approaches, significantly less than the 500-1000 bp 
routinely obtainable from Sanger sequencing. Base calling error rates are dependent on the 
platform that is used, but ranges from 0.01% to 16% 85. Increasing the coverage (depth) can 
minimize false calls, allowing for accurate detection of SNVs 86.
Targeted sequencing approaches have the advantage of isolating multiple genomic 
regions of interest in a single experiment in an efficient and cost-effective manner. Whole 
Exome Sequencing (WES) captures only coding regions (~ 180000 exons) of the genome, 
and has been successfully applied in finding causative variants in many Mendelian 
disorders 87-91. The total size of the human exome is approximately 30 Mb and comprises 
~ 1% of the human genome. Therefore, when the region of interest is only protein coding 
sequences, exome sequencing is an efficient approach for obtaining the desired coverage 
for variant detection 92. For WES, publicly available programs can be used for variant calling 
and annotation. Sequenced individuals have typically had 5000-10000 variant calls, 
representing non-synonymous substitutions in exonic regions, splicing alterations or small 
1
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indels 88, 89, 93, 94. Advanced filtering based on predicted effect (silent, nonsense, missense, 
effect on splicing, frameshift) or position (intronic, UTR, exonic, intergenic) can be used 
to find pathogenic variants. Two important assumptions underlie filtering strategies. The 
first is that causal variants for Mendelian disorders are rare, and therefore unlikely to be 
present in public databases or control sequencing data. The second is that synonymous 
variants are unlikely to be causative. Both assumptions are not always true 32, 95 . Mendelian 
disorders with milder phenotypes may have been overlooked in the general population, 
and may thus be present in control databases. Also, variants involved in recessive disorders 
with a high carrier frequency can be reported in control databases. For example, the most 
common variant in cystic fibrosis has an allele frequency of about 3% in Western European 
populations. Filtering such variants might erroneously exclude those pathogenic variants 
from consideration. As synonymous variants may have functional effects, and can be 
targeted by natural selection 96, 97 it is not always appropriate to filter these. 
There are a several strategies that can be applied for the detection of structural variants. 
Various computational algorithms for identifying and characterizing variants have been 
developed. Read-pair methods assess the span and orientation of paired-end reads, and can 
be used to detect all types of structural variation (indels, inversions, tandem duplications 
and translocations) 22, 98. Read-depth methods are simply based on the theory that CNV 
regions show differences in the number of reads, and therefore assess mapping depth in 
the sequenced sample. This will detect CNVs (including aneuploidy) and large insertions, but 
not inversions and translocations. Split-read approaches are able to detect all breakpoints 
(deletions, tandem duplications, translocations and inversions) 98, 99. However, none of 
these strategies is comprehensive, and each will require substantial further development. 
Recently, an integrated computational pipeline for whole genome sequencing was 
published, enabling detection of all types of genetic variations (single nucleotide variants, 
short insertions or deletions (indels) and larger structural variations (SVs) 100 .
Interpretation of genomic variation 
The major challenge in the analysis of genomic variation is to distinguish benign variants 
from variants that have clinical consequences. Increasingly, clinical molecular laboratories 
are detecting novel CNVs and sequence variations of unclear significance (UVs) in the 
course of testing patients. Guidelines on the interpretation of such variants have been 
developed 76, 101-105. Sequence variants can consequently be classified on their phenotypic 
consequences within a spectrum of interpretations, ranging from those in which the 
variation is almost certainly of clinical significance, to those in which it is almost certainly 
not 106, 107.
When the impact of a sequence variant is undetermined, follow-up activities may be 
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useful to clarify this relationship, and assist with risk assessment. There are several lines 
of evidence suggested for designating a variant as either phenotype-modifying or neutral. 
(1) Occurrence in patients or in a control population as listed in a database, (2) Variant type 
(missense, nonsense, silent), (3) In silico prediction of effect on protein structure or RNA 
splicing, (4) Conservation among species, and or presence in a known functional domain, 
(5) Co-segregation with a phenotype in the family.
The presence or absence of a variant in established databases, ideally containing all the 
lines of evidence listed above, is of great importance. It is helpful to establish whether 
a variant has been reported before, and if there is an associated phenotype. Distinction 
should be made between variants directly linked to a phenotype or variants found by 
genome-wide association studies (GWAS) which have identified many variants with a very 
small contribution to an associated trait, in which additional genes and/or environmental 
factors also influence phenotypic outcome (multifactorial traits) 108. 
Currently, the numbers of submicroscopic imbalances that have been reported are 
increasing, but the delineation of associated clinical features remains difficult and 
incomplete. When large stretches of DNA encompassing several genes are deleted, 
complex phenotypes may emerge (so called ‘contiguous gene syndromes’). It may often 
be unclear which gene in the interval is responsible for a given part of the phenotype 
(e.g. heart malformations, limb malformations), which is another reason why CNVs are 
collected and compared in patient databases.
As described previously, the capacity of a given variant (silent, missense, nonsense, 
frameshift, splicing) to affect gene expression or the function of its protein products must 
be determined. In silico prediction of pathogenic effects using information on interspecies 
sequence conservation can be helpful. The observation that pathogenic variants are more 
likely to occur at positions that are conserved through evolution suggested that prediction 
could be based on sequence homology 109. Variants that alter conserved residues by 
replacing them with amino acids with different physical characteristics are likely to affect 
polypeptide structure and function. It was also observed that disease-causing amino 
acid substitutions have a common structural feature (for instance sites with low solvent 
accessibility, sites involved in disulphide bonds, sites involved in folding) that distinguishes 
them from neutral substitutions, suggesting that structure can also be used for predicting 
functional consequences 110, 111. 
Databases collecting information on prevalence and frequency of sequence and structural 
variants in the human genome have been established, and provide information on the 
frequency of previously reported variants in disease and control cohorts. For rare recessive 
disorders it is generally assumed that a variant is unique, or at least has a low carrier 
frequency in the general population, whereas a variant that is found at higher frequency 
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may be neutral. However, some recessive diseases are relatively frequent in subpopulations 
due to survival benefit for heterozygotes or genetic drift (for example sickle cell trait gives 
resistance to malarial infection), stressing the importance of registration of ethnicity in 
databases. 
In silico prediction of an effect of a DNA variant on mRNA splicing should be verified by 
RNA studies. Such studies are not always feasible since not all genes are transcribed in 
easily accessible tissues such as blood.
Identification of a variant in a patient should be followed by testing of the parents. De 
novo variants are more likely to be pathogenic, but since we know each child may have 
between 30 to 50 new variants 9, 18, this is by no means certain. In rare cases co-segregation 
of the variant with the disease in a family may corroborate the suspicion of pathogenicity. 
Finally, testing the gene product in a functional assay or constructing animal models (e.g. 
mouse, rat or fruit fly) carrying the same variant may provide definitive assessment of the 
phenotypic effect of the variant in vivo. A reliable functional assay is generally regarded as 
one of the best means of confirming pathogenicity, however this is rarely available as part 
of a routine diagnostic service. 
For structural variation such as CNV, it is generally considered that if a phenotypically 
normal family member carries the same chromosomal anomaly, the anomaly is of no 
phenotypic relevance 112. However, caution remains necessary since the identification 
of a CNV in a patient that is also present in an apparently healthy parent does not rule 
out pathogenicity as there could be a pathogenic variant on the other allele. Also, some 
phenotypes may be mild and therefore overlooked in a parent. As described earlier for 
inherited CNVs, the CNV may in fact be a risk factor that only reveals a phenotype when 
combined with one or more other variants in the genome. In addition, this also means that 
even if a CNV is relatively frequent in a population this does not rule it out as a risk factor as 
long as it has not been reported as homozygously deleted in a healthy population.
Tools and databases
Databases allow researchers to share knowledge and retrieve information about genomic 
sites of variation under study. However, at present there is no database summarizing all 
that is known about a certain variant. 
There are several human cytogenetic databases that link submicroscopic chromosomal 
imbalances (microdeletions/duplications/insertions, translocations and inversions) 
with clinical phenotype. These include DECIPHER (DatabasE of Chromosomal Imbalance 
and Phenotype in Humans using Ensembl Resources)113, 114 and ECARUCA (European 
Cytogeneticists Association Register of Unbalanced Chromosome Aberrations) 115. Since 
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these databases contain patient information, complete access is limited to clinicians or 
cytogeneticists. Some information is publicly available through specified tracks in genome 
browsers. The Database of Genomic Variants (DGV) is a comprehensive database for the 
deposition, retrieval and visualization of human structural variation 116. The database 
currently contains 179450 CNVs (April 2012) and reports CNVs, inversions and Indels 
(100 bp-1 Kb) in apparently healthy human cases. However, interpretation of the variants 
should be performed carefully, as different platforms have been used to detect CNVs, 
and population and medical data of the cohorts are poorly defined or absent. DbVar is 
a public repository that accepts direct submissions and provides archiving, accessioning 
and distribution of publicly available genomic structural variants 117. It accepts data from 
all species, and includes clinical data. It marks and allows searching for variants that are 
known to be pathogenic.
The dbSNP database serves as a central repository for both single base nucleotide 
substitutions and short deletion and insertion polymorphisms 118. More than 17 million 
SNPs have been documented in this database, with a false-positive rate estimated at 15-
17% 92. However, the database does contain validated SNPs (allele frequencies provided) 
and can be queried accordingly, increasing the utility of the database. Allele and genotype 
frequencies from the HapMap project 119 have also been submitted to dbSNP. In the HapMap 
project, four large populations of African, Asian, and European ancestry have been studied 
extensively to catalogue population specific variation. 
The 1000 Genomes Project 1 generated the most comprehensive map of human genetic 
variation yet, using next-generation sequencing technologies. It contains three pilot 
studies with a range of coverage. The exome variant server (EVS) 120 contains exome data 
of 6500 samples. A recent initiative is the generation of the genome of the Netherlands 
(GoNL), where whole genome sequences of 250 healthy Dutch parent-child trios are 
collected and stored in a biobank 121. 
Some databases only contain information on genetic variation causing genetic disorders or 
traits. The Human Gene Mutation Database (HGMD) includes the first example of all exonic 
and +1,+2, -1,-2 splice-site variants causing or associated with human inherited disease, plus 
disease-associated polymorphisms reported in the literature 36. Locus Specific DataBases 
(LSDB) are databases recording all variation within a gene. The databases contain accurate 
(curated), clearly referenced data naming variants at the DNA, RNA and protein level, and 
include all relevant comments relating to the clinical interpretation of the variant. Existing 
LSDBs can be checked by the URL “GeneSymbol.LOVD.nl” (e.g.MBTPS2.LOVD.nl) 122. The 
Human Genome Variation Society (HGVS) keeps a list of locus specific variant databases 123. 
Several tools have been developed to predict the effect of non-synonymous variants on 
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a protein. The Grantham score (GMS) 124 represents one of the first attempts to assess 
the effect of amino acid substitutions on protein structure based on chemical properties, 
including the side-chain composition, polarity and molecular volume. The GMS is a 
measure of dissimilarity between a human amino acid and the residues seen at the same 
site in homologs. Several studies used a GMS score less than 60 to define neutral variants, 
whereas a GMS score significantly larger than 60 indicates that the amino-acid change is 
evolutionarily intolerant 125, 126. 
Polyphen 29, 127, 128 utilizes a combination of 3D structural parameters and sequence homology 
to make a prediction about a functional effect. This prediction is based on a number of 
features comprising the sequence, phylogenetic and structural information characterizing 
the variant. It returns predictions of “probably damaging, “possibly damaging,” benign 
and “unknown.” ‘Sorting Intolerant From Tolerant’ (SIFT) 129 uses sequence homology and 
the physical properties of amino acids to predict effect on proteins. Next to SNVs, it can 
classify coding indels. It returns predictions of “affect protein function” and “tolerated” for 
each SNV. Due to differences in algorithms used for the predictions, Polyphen2 and SIFT 
may present contradictory results. 
Tools that calculate conservation scores can aid in variant interpretation. A variant that 
leads to a nonconservative substitution of an evolutionarily conserved amino acid is more 
likely to be causative of the disorder than a variant that leads to a conservative substitution 
or alters an amino acid that is not evolutionarily conserved. Both phastCons 130 and phyloP 
131 calculate conservation scores for three groups of organisms (primates, placental 
mammals and vertebrates). The two conservation scores are informative in different ways. 
Phastcons estimates the probability that a nucleotide belongs to a conserved element, 
taking neighbouring bases into account, while PhyloP predicts conservation purely at the 
base level.
UMD predictor 132 provides a combinatorial approach that associates several data such 
as localization within the protein, conservation, biochemical properties of the variant 
and wild-type residues, splice-site predictions and the potential impact of the variant on 
mRNA. Alamut 133 is a commercial package designed to help interpret variants quickly and 
uses different splice site prediction algorithms, PolyPhen, SIFT and calculates theoretical 
consequences of substitutions, insertions and deletions (effects on protein sequence, 
frameshifts, splicing effects, miRNA targets, nonsense-mediated mRNA decay).
Computational prediction of pathogenicity may also give false-negative results 134. Most 
prediction methods for protein alterations do not take DNA sequence context into account. 
As a result, they can miss changes that alter splice sites 135. Experimental verification by 
functional analysis of possible pathogenicity remains the golden standard.
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Outline and scope of this thesis
Intellectual disability (ID) with or without multiple congenital malformations (MCA) is one 
of the main reasons for referral to a clinical geneticist. Causes of this ID/MCA are extremely 
heterogeneous and range from point mutation in one single specific gene to loss or gain of 
an entire chromosome. Despite enormous progress in diagnostic techniques in the past 50 
years the cause for ID remains unknown in approximately 50% of the cases.
Establishing a diagnosis and understanding the cause of a genetic disorder is of great 
benefit for the patient and his/her family. This may provide information on prognosis, 
clinical management options, and anticipation on associated health issues for the 
patient, and may even be of therapeutic relevance in the future. Family members can be 
informed about recurrence risk and may be provided with options for prenatal (PND) and 
pre-implantation genetic diagnosis (PGD).
The main objective of the research in this thesis was to develop and apply novel molecular 
techniques to study the genetic basis of patients with intellectual disability (ID), multiple 
congenital anomalies (MCA), or other inherited disorders, and ultimately to gain insight 
into genetic disease mechanisms. 
This thesis is a mirror image of the rapid evolution of techniques for analysis of DNA between 
2006 and 2011. Many techniques described in this thesis (karyotyping, fluorescence in situ 
hybridization (FISH), array-comparative genome hybridization (CGH), single nucleotide 
polymorphism (SNP)-arrays, multiplex ligation dependent probe amplification (MLPA), 
high resolution melting curve analysis (HRMA), Sanger sequencing, and whole exome 
sequencing (WES) have been applied to find causative genome variants in our patient 
cohort. All of these techniques are now routinely used in clinical diagnostic laboratories, 
except whole exome and whole genome sequencing, implementation of which is being 
worked on. 
More detailed data on human genetic variation are now rapidly accumulating, as new 
techniques for determining the primary structure of genomes have been developed at an 
unprecedented rate. 
Although new genomic variants can arise in both the germline cells (whose DNA will be 
passed to offspring) and in somatic cells (the majority of cells in the human body), this 
thesis has a focus on the genetic characterization of germline variation.
At the outset of this work five years ago, genomic microarrays were introduced and 
have been applied in this thesis to identify structural variation in genetic disorders. 
Chapter 2 describes methods for detecting CNV in the human genome. The focus lies on 
the development of a targeted array used to study patients with intellectual disability 
of unknown aetiology. Chapter 3 shows the application of microarrays and MLPA in the 
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elucidation and delineation of a new microdeletion syndrome. Because microarrays 
increase the resolution of chromosome analysis by 100-1000 fold and because small 
deletions and duplications are a major cause of ID/MCA, conventional karyotyping was 
replaced by microarray analysis in routine diagnostics. 
Because of its speed, simplicity, and low cost, HRMA has become a popular technique for 
detection of sequence variants. The two major applications are targeted genotyping and 
gene scanning. Chapter 4 describes the versatility of HRMA as a molecular technique and 
illustrates several applications. In Chapter 5, SNP arrays were used to define the breakpoints 
of a previously defined locus for Keratosis Follicularis Spinulosa Decalvans (KFSD) and show 
the application of HRMA as a presequencing tool in the identification of the genetic basis 
of this disorder. 
The introduction of NGS techniques allowed genome wide detection of sequence 
variants in disorders of unknown aetiology. Chapter 6 and 7 describe the success of next 
generation sequencing in the identification of the genetic basis in two disorders (TOD 
and Aarskog-Scott syndrome), and shows the value of exome sequencing in detection of 
variants outside coding regions. Besides identification of the genetic cause of Coffin Siris 
syndrome. Chapter 8 outlines recent findings on the mode of inheritance and frequency of 
this monogenic disorder using exome sequencing.
Finally, in Chapter 9 the rapid evolution of techniques for genome analysis is discussed and 
alterations in the diagnostic approach to ID/MCA patients are proposed.
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Abstract
The detection of quantitative changes in genomic DNA, i.e. deletions and duplications 
or Copy Number Variants (CNV), recently gained a considerable interest. First, detailed 
analysis of the human genome showed a surprising amount of CNV, involving thousands 
of genes. Second, it was realised that the detection of CNVs as a cause of genetic disease 
was often neglected, but should be an essential part of a complete screening strategy. In 
both cases new efficient CNV screening methods, covering the entire range from specific 
loci to genome-wide, were behind these developments. This paper will briefly review 
the methods that are available to detect CNVs, discuss their strong and weak points, 
show some new developments and look ahead. Methods covered include microscopy, 
fluorescence in situ hybridisation (incl. fiber-FISH), Southern blotting, PCR-based methods 
(incl. MLPA), array technology and massive parallel sequencing. In addition we will show 
some new developments, incl. a 1400-plex CNV bead assay, fast-MLPA (from DNA to result 
in ~ 6h) and a simple Melting Curve Analysis assay to confirm potential CNVs. Using the 
1400-plex CNV bead assay, targeting selected chromosomal regions only, we detected 
confirmed rearrangements in 9% of 320 mental retardation patients studied.
Introduction - Methods to detect CNVs
Microscopy
The first report describing a CNV in the human genome was that by Leujeune et al. (1959); 
using a simple microscope he discovered that children with Down’s syndrome have an 
extra copy of chromosome 21 (“trisomy 21”). Later specific methods were developed to 
generate chromosome-banding patterns. This simplified the discrimination of individual 
chromosomes as well as resolution inside a chromosome and facilitated the identification 
of inter and intra-chromosomal rearrangements. Together these tools were used to identify 
many other rearrangements in relation to genetic disease and cancer, especially numeric 
changes (aneuploidies), Structural Variants (SVs; translocations, inversions, insertions, 
transpositions) and large CNVs (>5-10 Mb deletions and duplications).
Resolution of microscopic chromosome analysis was further improved using in-situ 
hybridisation, initially using radioactive (ISH) and later fluorescent labelled probes (FISH, 
Landegent et al. (1985)). Nowadays FISH, especially using multiple probes labelled in 
different colours, is widely used in clinical diagnostics as a screening technology to confirm 
the presence of CNVs and SVs in either patients or carriers. Using probes close to the 
telomere of human chromosomes, Flint and co-workers were able to detect the presence 
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of CNVs in a significant fraction of patients with mental retardation and an apparently 
normal karyotype (Knight et al. (2000)).
Depending on the question, metaphase chromosome spreads are most commonly 
used. However, when a higher resolution is required (closely spaced probes) or when larger 
numbers of cells need to be counted (cancer), FISH can also be performed on interphase 
nuclei. Ultimate resolution is obtained by fiber-FISH, where probes are visualised on 
stretched single DNA fibers (Florijn et al. (1995)). Fiber-FISH is currently the method preferred 
to precisely determine the genomic structure of complex CNVs (Perry et al. (2007)). 
Southern blotting
Although Southern blotting is a versatile tool for the detection of CNV, it has not been 
widely used. The main problems associated are the workload involved (DNA digestion, 
electrophoresis, blotting, hybridisation and exposure) and the fact that quantitative analysis 
is not simple; it demands technical experience and high-quality results. The exception has 
been the analysis of male samples for X-linked diseases where CNVs are frequent, e.g. in 
Duchenne and Becker muscular dystrophy (D/BMD) where hundreds of deletions have 
been revealed using Southern blotting (White and Den Dunnen (2006)). Interestingly, 
although duplications were described to be present in 5-10% of D/BMD patients early on 
(Den Dunnen et al. (1989)), only recently, using newly developed techniques, do we see 
that all screening studies report duplications (White and Den Dunnen (2006)). Similarly for 
autosomal diseases, e.g. breast cancer (Petrij-Bosch et al. (1997)) and Alzheimer (Rovelet-
Lecrux et al. (2006)), it often took many years after identification of the disease gene before 
CNVs were first reported. These examples indicate that, although Southern blotting is a 
good tool for CNV detection, it is probably not the simplest tool to apply.
In specific cases, Southern blotting has been applied more widely. This includes diseases 
where specific CNVs are recurrent, facilitating the design of an assay targeting the unique 
breakpoint fragments, e.g. in alpha- and beta-thalassemia (Craig et al. (1994)). Another 
example is Southern blotting in combination with Pulsed-Field Gel-Electrophoresis (PFGE), 
allowing CNV detection at great distance from a specific probe (Den Dunnen et al. (1987)) 
or to determine the number of repeat sequences inside a large DNA fragment like in 
facioscapulohumeral muscular dystrophy (FSHD, Van Der Maarel et al. (1999)). 
PCR-based methods
Because of its ease of use, PCR has been the most widely applied method to screen for 
CNVs. Since quantitative PCR is not that simple, PCR methods initially were used to confirm 
CNVs indirectly, i.e. by amplifying across unique deletion or duplication breakpoints, e.g. in 
delta/beta-thalassemia and hereditary persistence of fetal hemoglobin (Craig et al. (1994)). 
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Since the introduction of real-time PCR, facilitating simplified quantification, it has been 
applied as quantitative-PCR (qPCR) to directly screen for CNVs, discriminating 1 versus 2 
(deletion) or 2 versus 3 copies (duplication). The main disadvantage of qPCR approaches is 
that only one fragment can be analysed and this fragment should be inside the CNV to get 
a positive result. Since CNVs in disease genes are rarely identical but can cover any part of 
the gene, several qPCRs will be required to perform a complete CNV screen. To bypass this 
problem, multiplex-qPCR approaches have been designed, for each locus tested yielding a 
fragment with either a unique length and/or colour. Except for again X-linked diseases to 
detect patients or carrier females (Beggs et al. (1990), Yau et al. (1996)), these assays have 
not found widespread application.
Only recently more powerful PCR-based methods have been developed, including 
Multiplex Amplifiable Probe Hybridization (MAPH, Armour et al. (2000)), Multiplex 
Ligation-dependent Probe Amplification (MLPA, Schouten et al. (2002)) and Multiplex 
Amplicon Quantification (MAQ, Suls et al. (2006)). These methods largely circumvent the 
inherent problems of multiplex-PCR, i.e. each fragment having different amplification 
characteristics with overall smaller fragments give higher yields. These methods 
achieve this by combining the advantages of an optimised primer design (incl. universal 
amplification primers), carefully determined primer concentrations and specific primer-
mixes to achieve uniform amplification yields. Of these methods, MLPA has been by far 
the most successful, at the time of writing (May 2008) giving over 260 hits in PubMed. The 
winning features undoubtedly include its ease of use, the fact that standard laboratory 
equipment can be used (PCR and capillary electrophoresis) and that many disease-specific 
kits are readily available through commercial suppliers. More, recently array technology 
was applied to increase the performance of MLPA, e.g. allowing the accurate analysis of the 
entire DMD gene using 128 probes spotted in duplicate (Zeng et al. (2008)).
Array technology
The main advantage of array-based methods is their multiplexability, i.e. the number of 
loci that can be screened simultaneously, ultimately covering the entire human genome. 
Array-CGH (Comparative Genomic Hybridisation) was first developed, using arrays that 
contained ~ 3,000 probes (100-200 Kb genomic insert PAC/BAC clones), covering the 
genome at a 1 Mb resolution (Pinkel et al. (1998)). Soon these arrays contained >30,000 
clones, covering the entire genome (Ishkanian et al. (2004)). In addition, arrays for genome-
wide linkage and association studies determining alleles based on Single Nucleotide 
Polymorphism (SNP), were used early on for CNV detection (e.g. Zhou et al. (2004)). Since 
these arrays were not designed for this purpose, specific software had to be developed to 
allow quantitative analysis of the data. While the first arrays contained only 10,000 SNPs 
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(Zhou et al. (2004)), the latest arrays contain up to 1 million SNPs. Next to the SNP probes, 
these latter arrays contain yet another 1 million non-SNP probes, filling in the gaps and 
yielding the best genome coverage possible. These genome-wide SNP-arrays revealed an 
unexpectedly large and complex variability in the human genome (Redon et al. (2006)), a 
variability we still have not completely mapped (Kidd et al. (2008)). In addition these arrays 
have been instrumental in the recent discovery of many new genes and gene regions 
involved in genetic disease (Beckmann et al. (2007)). 
New methods
Although many powerful methods are available, there is always room to improve. Array-
based approaches are very powerful but overall, although prices steadily drop, they are 
relatively costly and not ideal when thousands of samples need to be screened. Furthermore, 
for diagnostic applications genome-wide screens can often not be used. Using a genome-
wide tool to determine whether there is a pathogenic CNV in the DMD gene of a suspected 
carrier female for Duchenne muscular dystrophy might reveal CNVs elsewhere in the 
genome, giving the diagnostic lab unwanted dilemmas. Similarly, CNVs might be found for 
which the phenotypic consequences are unclear, yielding an inconclusive diagnosis. With 
these considerations in mind, we set out to develop a new assay to bridge the gap between 
genome-wide (array-based) and locus-specific methods. It should facilitate the cost-
effective screening of 1000 or more loci, with a flexible choice of loci to include (custom 
design) and the possibility of automated analysis of many samples.
1400-plex CNV bead assay
The assay developed was based on Illumina’s GoldenGate assay (Fan et al. (2003)) with 
two important changes; targeting non-SNP DNA sequences and adapted to a single 
colour assay. The assay was designed to screen patients with mental retardation (MR) 
of unknown aetiology. It should detect all trisomies, telomere-end rearrangements (incl. 
unbalanced translocations), known micro-deletion/-duplication syndromes and perform 
a rough whole genome CNV scan (see M&M probe design). Initial assessment of the array 
performance was made by analysing 44 samples containing known rearrangements (see 
M&M). All known rearrangements were detected and all CNV breakpoints matched those 
known.
Detailed analysis of the first 80 MR-patient samples detected one or more CNVs in 69 
cases (Fig.1), in total 103 losses and 255 gains. Ten cases carried likely pathogenic autosomal 
CNVs. Five of these were selected and all were confirmed using a second technique (MLPA, 
FISH or SNP array - Fig.1B). Three cases could be proven to contain de novo aberrations. 59 
of the 80 patients showed CNVs in regions known to be polymorphic (Toronto Database 
2
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of Genomic Variants - http://projects.tcag.ca/variation), incl the CDKN1c, TERT, SMN1 and 
NSF genes. In addition we detected polymorphic CNVs in the FOXD3, SOX12, TBX4, HOXD1 
and TBX21 genes, not reported in the Toronto database. The results from 240 additional 
patients are currently under study. So far, likely pathogenic autosomal CNVs could be 
confirmed in 29 cases (Table 1); 1 trisomy, 7 unbalanced translocations, 7 telomeric deletions 
(incl.1 ring chromosome), 10 deletions and 4 duplications (incl. a partial tetrasomy). Overall 






Trisomy (21q) 1 Down’s syndrome
Unbalanced translocations
(telomeric deletion + duplication)
7 MCA
Ring chromosome (11) 
(11q telomeric deletions)
1 MCA
Deletion, telomeric 6 2 alpha thalessemia, 4 MCA
9p tetrasomy (9p triplication) 1 MCA
Micro-deletion 10 6 DGS, MWS, SMS, WBS
Micro-duplication 2 dup22q11, PLS
1 probe duplication 1 -
1400-plex CNV bead assay. In total 320 mental retardation patients were screened 
using the 1400-plex CNV bead assay. Data from the first set of 80 patients has been 
analysed extensively, that of the second set of 240 additional patients is still in progress. 
Shown is an overview of all confirmed CNVs and where known the diagnosis of the
phenotype in addition to mental retardation. DGS = DiGeorge syndrome, 
MCA = multiple congenital anomalies, dup22q11 = 22q11 microduplication syndrome, 
MR = mental retardation, MWS = Mowat Wilson syndrome, 
PLS = Potocki-Lupski syndrome, SMS = Smith Magenis syndrome, 
WBS = Williams Beuren syndrome
Table 1: 1400-plex CNV bead assay. In total 320 mental retardation patients were screened 
using the 1400-plex CNV bead assay. Data from the first set of 80 patients has been analysed 
extensively, that of the second set of 240 additional patients is still in progress. Shown 
is an overview of all confirmed CNVs and where known the diagnosis of the phenotype 
in addition to mental retardation. DGS = DiGeorge syndrome, MCA = multiple congenital 
anomalies, dup22q11 = 22q11 microduplication syndrome, MR = mental retardation, MWS = 
Mowat Wilson syndrome, PLS = Potocki-Lupski syndrome, SMS = Smith Magenis syndrome, 
WBS = Williams Beuren syndrome.
Fast-MLPA
Most CNV detection methods typically take one to several days to get from DNA to result. 
Although time is usually ot a critical aspect, there are diagnostic cases where the presence 
of a CNV needs to be confirmed as soon as possible. For instance newborns with multiple 
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congenital malformations and complex heart defects may require extensive surgery and 
intensive care to survive. In cases where trisomies for chromosomes 13 or 18 are present, 
prognosis is particularly unfavourable and one would prefer to refrain from operating to 
minimize the child’s suffering. Therefore we developed a test that could be performed 
within 1 day (<8 h).
In the ultimate set up, a column-based DNA isolation method was used yielding purified 
DNA from a blood sample in 30 min. The time required for the MLPA could be reduced 
to ~ 4.5h. This was achieved by reducing the over-night hybridisation step to 2.5h and by 
redesigning the probe set, selecting for those probes that allowed short MLPA reaction 
times. Time for MLPA readout, usually acquired through capillary electrophoresis taking 
several hours, was reduced to 20 min. using flow-through micro-array technology (Wu et 
al. (2004); Zeng et al. (2008)). Overall, starting from a blood sample, the time to get to a 
CNV result was ~ 6 h.
The assay was designed to detect aneusomies for chromosomes 13, 18, 21 and X. First the 
assay was tested using samples from 4 individuals with a known aberrant karyotype, incl. 
trisomy-13, -18, -21. The results obtained confirmed previous findings (Fig.2). Next the assay 
was tested using 23 blinded DNA samples of which a number had an abnormal karyotype. 
All sexes and all rearrangements were correctly scored. Two samples initially gave a 
discrepant result, one due to a mislabelling and the other because the individual involved 
had received treatment for sex-reversal, with the gender reported being her new sex.
As a proof-of-principle and to check the time required we started with freshly taken 
blood samples of four healthy individuals. DNA was isolated, MLPA performed, array 
signals measured and scored. Based on the signal of the Y-chromosome probe and the 
altered ratios of the X-probes compared to those of the other chromosomes, we were able 
to correctly score the sex for all samples in about 6.5h. Thus far the assay has been applied 
once in a clinical setting, confirming a suspected trisomy-18 case directly after birth.
hrMCA-CNV
Now that genome-wide tools are applied in diagnostic labs worldwide, hundreds of 
new CNVs are being detected and there is an urgent need for a quick, reliable and cheap 
method to confirm the initial findings. Most CNV methodologies can not be easily used 
in a custom design setting or are labour and/or time intensive to develop and thus costly. 
While screening disease genes for sequence variants using high-resolution Melting Curve 
Analysis (BRCA - van der Stoep et al, DMD - Al-Momani et al, submitted) we were impressed 
by its resolution and sensitivity. We therefore tested its performance to confirm CNVs, 
simply by comparing the melting curves of different pre-defined mixes of the opposite 
alleles and the test sample. 
2
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Figure 1: 1400-plex CNV bead assay. A) Strength of 
signal for probes on the X-chromosome obtained 
in males (M, X-axis) versus females (F, Y-axis). 
Signals are clearly different yet the difference in 
F:M signal obtained is not 1:0.5 as expected but 
1:~0.7 (see also panel 1B bottom left and 1C). B) 
Unbalanced translocation between chromosomes 
20p (top, 1 extra copy) and 9p (bottom, 1 missing 
copy) detected in MR-patient 12 using the telomeric 
ruler probes (left panels). The rearrangement 
was confirmed using a SNP-array (right panels, 
Affymetrix 250K-StyI). Besides MR the patient 
had multiple congenital anomalies. C) Deletion 
spanning at least the COPS3 (top) and DRG2 
(bottom) genes at chromosomes 17p11.2 detected in 
MR-patient 60 (confirmed to have Smith-Magenis 
syndrome). Note that in some cases only 1 of the 
probe pairs indicates a CNV (e.g. patient 18 for 
COPS3); such cases have not yet been considered.
B) 
A) 
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C) 
Figure 2: Fast-MLPA. Detection of a trisomy 21 (top left), Turner (45, X0; top right) and 49, 
XXXXY case (bottom) using fast-MLPA.
2
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The mix corresponding best with the melting curve of the test sample, resolves its allelic 
composition and confirms the CNV or not (Table 2).
An example of the sensitivity of the assay is shown in Fig.3. In the example alleles can 
be discriminated in steps of 12.5%, suggesting, besides confirming CNVs (~ 25% difference) 
it can be applied to type tetraploid and maybe octaploid organisms (plants). This is well 
within the sensitivity required to confirm CNVs where in mixed samples 3-5 alleles need to 
be discriminated. We have applied the hrMCA-CNV successfully to confirm both deletions 
and duplications detected using SNP-arrays as well as to determine the level of somatic 
mosaicism for CNVs in samples from monozygotic twins (Bruder et al. (2008)).
 
General considerations
There are many techniques and platforms available for detecting copy number changes in 
genomic DNA. The choice of the best method largely depends on project specific factors 
and the question to answer. Usually compromises have to be made with regard to the 
sample available, number of CNVs to analyse, resolution, cost and throughput. Not all CNV 
methods available can be performed with any sample. Microscopy/FISH methods require 
intact cells and/or nuclei. Southern blot analysis, especially when combined with Pulsed-
Table 2.
CNV test sample CNV confirmed when
Deletion A0? A0?/BB mix  = 1:2 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
B0? AA/B0? mix  = 2:1 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
Duplication AAA? AAA?/BB mix  = 3:2 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
AA?B AA?B/BB mix  = 2:3 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
ABB? AA/ABB? mix  = 3:2 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
BBB? AA/BBB? mix  = 2:3 AA/BB control mix and
differs from 1:1 AA/BB control mix and AB heterozygote
Confirmation of CNVs using high-resolution Melting Curve Analysis (hrMCA)
Depending on the CNV to confirm the test sample, control samples (homozygote AA, AB and 
heterozygote AB) and specific mixes of test and control samples hav  to be prepared. Shared melting 
curves indicate the allelic composition of the test sample.  
Table 2: Confirmation of CNVs using high-resolution Melting Curve Analysis (hrMCA)
Depending on the CNV to confirm the test sample, control samples (homozygote AA, AB 
and heterozygote AB) and specific mixes of test and control samples have to be prepared. 
Shared melting curves indicate the allelic composition of the test sample.  
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Field Gel-Electrophoresis, can only be performed when DNA of sufficient length is available 
(Van Der Maarel et al. (1999)). PCR-based methods are usually least demanding, although not 
all methods will work with low quality DNA (i.e. fragmented and/or contaminated (Kessler 
et al. (2004)). Overall methods that amplify short stretches of DNA perform better on low 
quality DNA compared to methods amplifying larger fragments. E.g. for whole genome 
array-based CNV studies, we obtained better results with SNP-arrays from Illumina then 
Affymetrix when low quality DNA samples were used. In rare cases the amount of DNA 
available might be limiting, making PCR-based methods most appropriate. However, even 
when only 1 or 2 cells are available, techniques like FISH are successfully applied to analyse 
CNVs in preimplantation diagnosis.
Multiplexability, i.e. the number of CNVs that can be studied simultaneously, often plays 
a decisive role. In most cases, sample throughput is inversely related with multiplexability; 
available methods do allow high-throughput analysis of a few loci but genome-wide CNV 
studies are difficult to perform for thousands of samples. In most cases the ease with 
which the assay can be automated determines the throughput that can be achieved. PCR-
based methods are generally performed in single-locus mode and can be performed to 
analyse thousands of samples per week. MLPA, MAPH and MAQ facilitate the analysis of 
20-50 loci using capillary electrophoresis and can be used to analyse hundreds of samples 
per week.
Figure 3: hrMCA CNV. High-resolution Melting Curve Analysis of two DNA samples being 
homozygous for the opposite SNP-alleles (rs213950:G>A) mixed in different proportions 
(from 8:0 to 0:8). The difference plots of all mixes can be easily discriminated, giving a 
sensitivity of at least 12.5%, suggesting that octaploid alleles could be typed.
2
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To analyse more loci per sample (50-1000), either arrays (Zhou et al. (2004)) or bead-
approaches (e.g. xMAP - Luminex, BeadArray - Illumina) can be applied. Such assays are 
ideal for diagnostic application, testing a range of targeted loci with known consequences 
only. The 1400-plex CNV bead assay described here is such an assay. The assay has the 
intrinsic possibility to score CNVs as well as specific SNPs or pathogenic mutations in one 
assay. Another design, which is also possible, is to use two different colours and either 
analyse two samples on one array (labelled in different colours, yielding improved data 
quality) or to double the number of loci analysed. When flexible custom-design is the most 
important aspect of the assay, the VeraCode technology (BeadXpress - Illumina) might 
have additional advantages, facilitating custom mixing of barcode-labelled probes.
Fast-MLPA tackles another, sometimes important aspect an assay, time-to-result. It 
allows a CNV-assay, from blood sample to result, to be performed within a working day. 
The PamChip technology used also facilitates real-time monitoring of hybridisation signals 
(Anthony et al. (2003)) and could be applied to analyse samples under very specific and 
highly stringent hybridisation conditions, e.g. to determine copy number of multi-copy 
sequences containing one or a few point mutations.
With the rapidly increasing popularity of whole genome CNV analysis using high-density 
SNP-arrays there is a great need for validation of the results obtained. While measuring 5-20 
consecutive SNPs, Wagenstaller et al. (2007), analysing patients with mental retardation 
for CNV using 100K SNP-arrays, reported a false positive rate of 30%. Smaller aberrations, 
covering less then 5 probes, although true, are even more problematic. FISH, powerful yet 
laborious, is often not suitable for confirmation; cells/nuclei might not be available, probes 
difficult to get or spanning a region bigger then the CNV. MLPA is suitable, even for smaller 
aberrations, but developed to screen 20-40 loci simultaneously and taking 2-4 weeks to 
design (White et al. (2004)). The hrMCA-CNV method presented here is easy to perform 
and simple to design, requiring only SNPs from the region of interest. Assuming the CNVs 
were detected using a SNP-array, one often has a large and easy choice.
Future developments
Looking further ahead, the near future will undoubtedly see application of the new 
massive parallel sequencing technologies. Although simple and available for decades 
sequencing-based counting methods seem, with few exceptions (Bailey et al. (2002)), not 
to have been applied for CNV detection. The new massive parallel sequencing technologies 
seem to provide a new, very powerful tool for the detection of CNVs (e.g. using SAGE-like 
approaches); the resolution required determining the number of total sequences needed. 
In addition, applying paired-end sequencing, these new technologies will allow detection 
of all structural variation (Kidd et al. (2008)); CNVs as well as insertions, inversions and 
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translocations. In addition sequencing will be instrumental to determine the structure 
of the CNV as well as breakpoint sequences, the latter facilitating direct screening by 
breakpoint PCR. 
One methodological hurdle remains to be solved; determining the exact copy number 
of multi-copy CNVs (>6-8 copies) in hundreds of samples and testing their possible 
association with specific diseases or phenotypic traits. For the latter to work, the assay 
should be exact and without errors, a demand where most current CNV methods already 
fail for copy numbers of 3-5, even when specific precautions are taken (Armour et al. (2007)). 
Massive deep sequencing technology might be applicable here but is still costly and not 
high-throughput. New innovative methods are under development, incl. automated fiber-
FISH methods (BioNanomatrix) and NanoString’s nCounter technology (Geiss et al. (2008)), 
but it is still too early to say whether they will be able to resolve this issue.
Materials and methods
Patient samples
All DNA samples were obtained from the department of Clinical Genetics (LUMC, Leiden). 
To check the performance of newly developed assays we used 44 control samples; 8 healthy 
individuals and 36 patients with known genomic rearrangements (incl. 23 DB/MD patients 
and carriers). In total 320 patients with mental retardation of unknown aetiology were 
analysed using the 1400-plex CNV bead assay, using gender information as an internal 
control. All subjects, or their representatives, gave informed consent for DNA studies.
Genomic DNA was isolated from blood samples using standard methods. DNA 
concentrations were measured using PicoGreen (Invitrogen-Molecular probes) and diluted 
to a concentration of 50ng/ul.
DNA isolation for fast-MLPA was performed using the Perfect gDNA Blood Mini kit 
(Qiagen), taking ~ 30 min; proteinase-K sample lysis (13 min), binding DNA to column (3 
min), washing (4 min), elution (4min). MLPA required ~ 4.5 h; hybridization 2.5 h, ligation 
20 min, PCR 1.5 h. PamChip®analysis ~ 20 min; hybridization 15 min, washing 3 min. Data 
analysis using ArrayPro; 10 min. Total assay time < 6 h.
1400-plex CNV bead assay
We wanted to develop a CNV assay that would facilitate the cost-effective screening of 
1000 or more loci, with a flexible choice of loci to include (custom design) and the possibility 
of automated analysis of many samples. When we used an array-based readout (Zeng et al. 
(2008)) it clearly showed the advantage of using probes of equal length to obtain uniform 
2
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yields of all fragments amplified in a highly complex multiplex PCR. Illumina’s Golden Gate 
assay uses a hybridisation-extension-ligation approach with similarities to MLPA (Fan et 
al. (2003)), allowing largely automated high-throughput screening of ~ 1600 loci using a 
bead-based micro-titer plate read-out format. Initial experiments confirmed the potential 
of this assay to detect CNVs, but also suggested that a non-SNP assay, i.e. using loci not 
covering SNPs, might have additional advantages (i.e. improved signal, simplified data 
analysis, doubling the number of loci that can be analysed).
For the 1400-plex CNV bead assay we designed in total 1324 non-SNP probes using 
standard design rules (Fan et al. (2003)). All probes for specific loci were designed in 
duplicate, i.e. separate for two closely spaced sequences, in unique sequences and where 
possible inside a gene (exonic). A telomeric ruler was created by designing probes at 0.5, 
1.0, 1.5, 2.0, 3.0, and 4.0 Mb from the end of all chromosomes, except the p arm of the five 
acrocentric chromosomes (in total 482 probes). Regions known to be involved in micro-
deletion / duplication syndromes were targeted with duplicate probes in at least one 
gene in every region selected. To determine the accuracy of the assay, control probes were 
designed for 19 exons in the DMD gene. 773 probes were designed for other loci of interest, 
incl. loci known to be copy number variable in a normal population (e.g. CCL3L1, NSF), 
containing other disease associated loci, potential regulatory regions and loci randomly 
spaced across the genome to provide a rough whole genome scan.
Per analysis we used 250 ng total genomic DNA following the manufacturer’s 
recommendations. Labelled products were purified and hybridised to a Sentrix Array Matrix 
(SAM). After hybridisation the SAM was washed and imaged on the Illumina BeadArray 
Reader. The 44 control samples were used to evaluate the assay and probe performance. 
Both probes for one locus should give the same copy number; loci for which 85% or less 
of the samples gave a concordant outcome were omitted for further analysis. Probes 
showing an unexpected CNV in >5% of the controls were studied more carefully. These 
CNVs are either false positives (e.g. due to low probe quality) or true CNVs, i.e. located in 
hitherto unknown CNV polymorphic regions.
Intensity signals were extracted, imported to MS-Excel and analysed as described 
(White et al. (2004)). Ratios between 0.75 and 1.25 are regarded as a normal (i.e. two copies), 
below 0.75 as a CNV-loss and above 1.25 as a CNV-gain. Samples with poor DNA quality 
(defined as >10% of the control probes showing copy number variation within one sample) 
were excluded. The number of CNVs was calculated per locus, when three or more patient 
samples showed CNV for a locus it was regarded as polymorphic, when only one or two 
samples showed a CNV is was considered as a possible pathogenic variant.
Initial assessment of the array performance was made by analysing 44 samples 
containing known rearrangements. Overall signals were stable and the intensities of 
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the duplicate probes showed little variation. Comparing female and male samples for 
X chromosome probe signals (Fig 1) clearly separated both sexes, yet the difference in 
signal was not 1:0.5 as expected but only ~ 1:0.7 (Fig.1A), an as yet unexplained but known 
phenomenon (Pollack et al. (1999)). The possibility that the amount of hybridising material 
was saturating the available target was ruled out by performing the hybridisation with less 
material, which resulted in lower signal but no alteration in the derived ratios.
All known rearrangements were detected at exon resolution and all deletion / 
duplication breakpoints matched those known. The DMD deletions and duplications in 23 
control samples were all detected, proving that CNVs involving a single probe could be 
ascertained. Although an increase in ratio is clearly seen when there are more then two 
copies present, it was not possible to distinguish between three and four copies of the 
DMD gene. This is not a significant problem however, as the primary purpose is to detect 
gains or losses per se. Where necessary to determine the precise copy number of a given 
locus, other methods can be applied.
Independent confirmation of CNVs was performed using several methods; custom 
design MLPA (White et al. (2004)), Fluorescence in situ hybridization (Dauwerse et al. (1992))
and whole genome SNP arrays (Illumina-317K and Affymetrix-5.0, performed according 
to the manufacturer’s protocols and analysed using Beadstudio, CNAG, dChip). PAC/BAC 
clones for FISH were obtained from the Welcome Trust Sanger Institute (Cambridge, UK).
Fast-MLPA
Fast-MLPA probe design was basically performed as described (White et al. (2004)). 
Several rounds of probe optimisation were performed, selecting probe combinations that 
allowed short MLPA hybridisation, ligation and amplification times. The final MLPA probe 
set consisted of six probes per chromosome (13, 18, 21 and X) and one probe for chromosomes 
15 and Y. Of the MLPA probe pair, each left-hand oligonucleotide contained a 20-nucleotide 
zip-sequence, facilitating selective hybridisation to a PamChip (Wu et al. (2004)), PamGene, 
Den Bosch, Nederland). All zip detector probes were spotted in duplicate on the array.
MLPA was performed as described (White et al. (2004)) with the exception of the 
hybridisation step (2.5 hours instead of overnight). PCR was performed for 33 cycles with 
either a Cy5- (control) or Cy3- (patient) labelled forward primer.
Array experiments were performd in the PamStation-4 or -FD10 (Pamgene). Before 
hybridisation, arrays were washed with 20µl 1x PBS-Tween (1 cycle of 1 min.) and 20µl 5x 
SSPE (1 cycle). Pre-hybridisation, 10 min. at 55oC, was carried out using 2µl tRNA (10µg/
µl), 5µl 20x SSPE and13µl H2O. Hybridization was performed using a mix containing 6µl 
patient DNA sample (Cy3-labelled), 6µl control DNA sample (Cy5-labelled), 1µl MAPHF and 
1µl MAPHR primer (2 µM/µl each), 5µl 20x SSPE, 1µl H2O. Hybridisation was for 10 min. at 
2
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55oC, the array was washed three times (one cycle) with fresh 20µl 5x SSPE-buffer followed 
by image capture. For experiments performed in the PamGene-FD10 all volumes were 
doubled.
Images were analysed with ArrayPro (Media Cybernetics) and the intensity data 
exported to MS-Excel. The median ratio was taken for normalization (White et al. (2004)). 
The average ratio of the duplicate spots was calculated and then the median ratio per 
chromosome. This gives tight ratios close to 1.0 with the advantage that lower thresholds 
can be set, allowing e.g. detection of mosaic cases, where an aneusomy is present in only 
a percentage of the cells, as we could prove by mixing DNA from a normal and a trisomy 21 
case in different proportions.
hrMCA-CNV
High-resolution Melting Curve Analysis (hrMCA) was performed using the LightScanner 
(Idaho Technologies) and LightCycler-480 (Roche Diagnostics). PCR  amplicons were 
designed using Primer-3 and standard design parameters, targeting fragments of 100-200 
bp covering the SNP of interest. To confirm a CNV, two SNPs in the CNV region are selected. 
The resolution of this assay depends on the shift in melting curves between a homozygous 
and heterozygous sample, with larger shifts giving higher sensitivity. Therefore, we 
selected those SNPs from the candidate CNV region that are expected to give a large shift 
(i.e. A>G changes). Next to the sample containing the potential CNV, samples carrying the 
two opposite alleles homozygously (AA and BB) are required (Table 2).
Depending on the CNV to confirm, a deletion or duplication, a set of samples mixes are 
made. For deletions a 1:1 and 1:2 mix of the AA and BB and a 1:1 mix of the test “A0?” and 
opposite homozygous BB sample. When for a deletion the mixed A0?/BB sample shares its 
melting curve with that of the 1:2 AA/BB mix (“ABB”) and not with the 1:1 AA/BB mix (“AB”) 
nor with that of the heterozygote AB control, the deletion is confirmed. For the samples 
and mixes needed to confirm duplications see Table 2.
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Abstract
Congenital limb malformations are the second most common birth defects observed 
in infants. Split hand foot malformation (SHFM), also known as central ray deficiency, 
ectrodactyly and cleft hand/foot, occurs isolated or in combination with other 
malformations. 
We report a male patient with SHFM, tetralogy of Fallot and a clinical phenotype of 
Angelman syndrome. Using array based genome analysis (3K BACs and 500K SNPs), 
we identified a de novo deletion of chromosome 19p13.11, confirmed by Fluorescent In 
Situ Hybridization analysis. The deletion is 0.99 Mb in size and contains 28 genes. The 
proximal breakpoint of the deletion is in EPS15L1, which may be involved in vertebrate limb 
development.
Subsequent screening of 21 syndromic and non-syndromic SHFM patients (TP73L mutation 
negative) for rearrangements using Multiplex Ligation-dependent Probe Amplification 
did not detect other deletions or duplications in chromosome 19. These findings suggest 
that our patient may have a new contiguous gene syndrome and indicates that SHFM is 
genetically more heterogeneous than currently known. 
Key words
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The variability of Split Hand Foot Malformation (SHFM) causes the classification to be 
very difficult. The hand and foot abnormalities range greatly in their phenotypic spectrum 
from mild abnormalities (i.e. digital shortness) to more severe abnormalities (i.e. adactyly), 
occurring in a single or in all four limbs. SHFM occurs either as an isolated malformation 
(‘non-syndromic’) or in association with other malformations (‘syndromic’). To date several 
syndromic forms have clinically been identified (EEC OMIM#129900, EEM OMIM#225280, 
LMS OMIM#603543, MMEP OMIM#601349, KNS OMI M#183800 and ADULT OMIM 
#103285). Identification of genes involved in defects in human limb patterning has not yet 
been very successful, in part, by the enormous spectrum of phenotypes.
For the development of the limb, specialized cell clusters are important. The SHFM 
phenotype is believed to be caused by an underlying defect of one of the cell clusters 
named the apical ectodermal ridge (AER). Both genetic defects and environmental factors 
may cause SHFM by interfering with the AER [Duijf et al., 2003; Seto et al., 1997]. Because 
of expression in the AER, candidate genes in the different loci have been postulated but 
mutations have not yet been identified. Currently five genomic loci, based on case and 
family studies, have been implicated. They are known as SHFM1 (chromosome region 
7q21-q22), SHFM2 (Xq26), SHFM3 (10q24), SHFM4 (3q27), and SHFM5 (2q31). Molecular 
testing is only available for SFHM4 since most EEC syndrome patients and 5-10% of non-
syndromic SHFM patients have been shown to carry mutations in the TP73L (p63) gene 
[Duijf et al., 2003; de Mollerat et al., 2003; Brunner et al., 2002]. 
So far copy number variation (CNV, i.e. the presence of deletions or duplications) in 
patients with SHFM has only been described in SHFM1, SHFM3 and SHFM5. For SHFM1 
only deletions have been described, mostly resulting from complex rearrangements and 
unbalanced translocations [Scherer et al., 1994; Bernardini et al., 2008; Sharland et al., 
1991]. To explain inconsistent translocation/inversion breakpoints and failure to identify 
mutations in the candidate genes, a position effect has been postulated. For SHFM3 only 
duplications of 10q24 have been described. Extensive study of the candidate gene Dactylin 
did not reveal how the duplication leads to the SHFM3 phenotype [Everman et al., 2006; 
de Mollerat et al., 2003]. SHFM5 has been associated with interstitial deletions suggesting 
removal of a ‘digit enhancer’ or genes involved in the AER [Boles et al., 1995; Goodman et 
al., 2002; Bijlsma et al., 2005]. For SHFM, no large deletion or duplication events on other 
chromosomes have been described.
Here, we report a patient who manifested SHFM and who was found to have a 0.99 Mb 
deletion on chromosome 19.
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Clinical report
The male patient (Fig. 1A) was born at term after an uneventful pregnancy. He is the second 
child of healthy unrelated parents. Family history for SHFM or mental retardation was 
negative.
At birth, congenital malformations of all extremities were conspicuous. Examination 
revealed a central ray deficiency of both hands and ectrodactyly of both feet. (Fig. 1B and 
1C) The left-hand showed preaxial polydactyly with a bifid thumbnail, absence of the 
third digital ray and cutaneous syndactyly of the first and second digit and the fourth and 
fifth digit. The right-hand was a split hand with central ray deficiency and a cutaneous 
Figure 1: Clinical features of the index patient. (A) Phenotype of the patient (here six years 
old) with subtle facial features including a wide mouth, fair hair and light skin. Central ray 
deficiencies as detected at birth. Left foot (B) with a cleft, hypoplasia of the second digit 
and a nubbin representing the third digit. Right foot (C) with a proximally placed first digit 
and presence of digit V. Digits II-IV are absent. Right hand (D) with a central cleft leading to 
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syndactyly of the fourth and fifth digit (Fig.1D). The left foot showed a split foot with a 
hypoplastic second digital ray and a rudimentary third digital ray. There was cutaneous 
syndactyly of the third and fourth digital ray. The right foot showed ectrodactyly where 
only the first and fifth digital rays where present. The first digital ray was positioned far 
too proximally. A Ventricular Septum Defect (VSD) and stenosis of the pulmonal artery 
was suspected, which was later diagnosed as a tetralogy of Fallot. At the time of re-
evaluation in the clinical genetics department the patient was two years old. His length 
was 88 cm (-0.3 SD) and head circumference 47 cm (-1 SD). Physical examination showed 
few dysmorphic features, brachycephaly with a flat occiput, slight upslant of his eyes, and 
broad mouth with a thin upper lip. He had very fair hair. His psychomotor development 
was slightly behind but this was considered to be normal given his physical problems early 
in life. Surgical correction of both the SHFM and the tetralogy of Fallot had taken place. 
Corrective surgery for strabismus was planned. MRI of the cranium and ultrasound of 
the kidneys was performed but showed no aberrations. EEG did not show epileptiform 
activity. The patient was re-evaluated at the age of six. By this time he had a severe delay 
in psychomotor development. His speech was severely impaired (4-5 words). He showed 
characteristic behavior with frequent laughing. Together with the previously described 
dysmorphic features this strongly suggested to the diagnosis of Angelman syndrome. 
Karyotyping did not reveal any chromosomal abnormalities (46, XY). M-FISH was normal 
and mutation screening for the TP73L gene as well as the UBE3A gene (causing Angelman 
syndrome) were negative. Also, deletions or methylation defects of UBE3A or UPD of 
chromosome 15 could not be detected. Evaluation of the patient at the current age of 10 
years did not show any significant changes in phenotype. 
Materials and methods
Subjects
The index patient was referred to our department for genetic counseling. His phenotype 
was established by examination of a clinical geneticist. Informed consent for genetic 
analyses was obtained from both his parents. Molecular testing was performed on whole 
blood genomic DNA.
Mutation analysis of the UBE3A gene and the TP73L gene were performed in diagnostic 
laboratories in the Netherlands (Erasmus MC Rotterdam, Radboud MC Nijmegen).
21 syndromic and non-syndromic SHFM patients from the Department of Clinical 
Genetics (Radboud MC Nijmegen) were ascertained for a MLPA based study and collected 
on the basis of clinical (and radiographic) findings. Patients were known to be negative for 
3
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TP73L mutations and had normal karyotypes. Array based genome analysis has not been 
performed on these patients. Informed consent was obtained from all participants.
DNA analysis
DNA was isolated from blood samples using standard methods. DNA concentrations were 
measured using a nanodrop.
Fish
Fluorescence in situ hybridization (FISH) was performed following standard protocols 
[Dauwerse et al., 1992]. The PAC/BAC clones RP11-413M18, CTD-2231E14 and CTD-3149D2, 
located at 19p13.11, were used for confirmation of the deletion. Clones were obtained from 
the Welcome Trust Sanger Institute, Cambridge, UK.
Array platforms
For array-comparative genomic hybridization (CGH), 1Mb spaced large insert clone arrays 
were used [Knijnenburg et al., 2005]. This platform contains ~3500 large insert clones 
spotted in triplicate at approximately 1Mb density over the full genome. The clone set 
was distributed by the Wellcome Trust Sanger Institute. All laboratory processing and 
hybridizations were performed according to published protocols [Fiegler et al., 2003].
The Affymetrix 500K oligonucleotide array was used according to manufacturer’s 
protocols (http://www.affymetrix.com). Regions of copy number gain and loss were 
detected using the hidden markov model output of CNAG 2.0 [Nannya et al., 2005]. 
Deletions detected were described according to the recommendations of the HGVS (http://
www.hgvs.org/mutnomen/).
Multiplex Ligation-dependent Probe Amplification
In total, 22 MLPA probe pairs were designed for genes of interest in and outside the deleted 
19p region (Table 1).The probes were divided between two probe sets. Within each probe 
set, control probes for unlinked loci were included as a reference. Sequences are available 
on request. Peak ratios between 0.75 and 1.25 are considered normal (i.e. two copies).
Probe design and the MLPA reaction and analysis were performed as described [White 
et al., 2004; Schouten et al., 2002] Genescan (Applied Biosystems) and Genemarker 1.51 
(Softgenetics) were used for data analysis.
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RefSeq DNA ID Gene Name Mlpa probe Gene Start (bp) Gene End (bp)
NM_032493 AP1M1 X 16169731 16207149
NM_016270 KLF2 X 16296637 16299683
NM_021235 EPS15L1 X 16333408 16443762
NM_145046 CALR3 X 16450888 16468003
NM_032207 C19orf44 X 16468205 16493163
NM_006387 CHERP X 16489700 16514263
NM_024881 SLC35E1 X 16523584 16544193
NM_004831 MED26 X 16546718 16600015
NM_024104 C19orf42 X 16617967 16631968
NM_024074 TMEM38A X 16632938 16660814
NM_001007525 NWD1 16703001 16789756
NM_015260 SIN3B X 16801218 16852164
NM_003950 F2RL3 X 16860826 16863830
NM_015692 CPAMD8 X 16864765 16998625
NM_033417 AC020908.7 17021573 17047343
NM_004145 MYO9B X 17073466 17185093
NM_018467 USE1 17187155 17191638
NM_024578 OCEL1 X 17198055 17201027
NM_005234 NR2F6 X 17203694 17217151
NM_031941 USHBP1 X 17221838 17236573
NM_014173 C19orf62 17239232 17251162
NM_152363 ANKLE1 X 17253454 17259455
NM_024527 ABHD8 X 17263941 17275282
NM_023937 MRPL34 X 17277477 17278652
NM_024050 DDA1 17281350 17292098
NM_020959 TMEM16H 17295034 17306638
NM_133644 GTPBP3 17309379 17314530
NM_031310 PLVAP 17323264 17349159
NM_004335 BST2 X 17374750 17377401
NM_138401 FAM125A 17391856 17397140
NM_138454 NXNL1 17427236 17432725
NM_198580 SLC27A1 X 17442300 17477977
Genes inside the deleted 19p11 region (indicated in yellow) and outside the deleted region (indicated in white). 
MLPA probes were designed for 22 genes (human reference sequence NCBI Build 36.1)
Table 1.
Table 1: Genes on Chromosome 19p13.11
Results
Index Patient
Array-CGH revealed a deletion of 1 BAC clone RP11-413M18. Flanking clones (CTD-3149D2, 
CTD-2231E14) on chromosome19p13.11 were not deleted, giving an estimated maximal 
deleted size of 1.44 Mb (Fig. 2A).
3
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Figure 2: (A) Array-CGH showed one deleted BAC clone (RP11-413M18) on 19p13.11 at 16.8 Mb 
with a maximal deleted size of 1.44 Mb. (B) SNP array refined the deletion from rs10411936 
(19: 16,409,375) - rs4808641 (19:17,408,292) with a maximal deleted size of 0.99 Mb 
FISH analysis using RP11-14M18 confirmed the deletion in chr.19p13.11, with flanking 
probes CTD-3149D2 centromeric and CTD-2231E14 telomeric giving normal signals (data 
not shown). 
To determine the extent of the deletion more precisely, a 500 K oligonucleotide array 
(Affymetrix) was used. This array showed a deletion (rs12460131_rs10411936)_(rs4808641_
rs6512194). Rs10411936, the first deleted SNP, is positioned in an intron of EPS15L1. Rs4808641, 
the last deleted SNP, is a SNP localized between two genes (FAM125A and a novel gene). The 
deletion spans ~ 0.99 Mb and contains 28 genes (Fig. 2B).
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To study the deletion on chromosome 19p13.11 in more detail and to facilitate the 
screening of a larger set of patient samples, we designed a MLPA kit for twenty-two genes 
in the 19p13.11 region. MLPA analysis confirmed the deletion on chr. 19p13.11 in our patient. 
The deletion was not present in either parent, so proven to be de novo (Fig. 3A). Genes 
located proximal (KLF2, AP1M1) and distal (SLC27A1) from the deleted region were present in 
two copies in the index patient (Fig 3B).
SHFM patients
Twenty-one SHFM (TP73L mutation negative) patients were collected to asses whether 
copy number variation on chromosome 19p13.11 occurred more frequent in this patient 
group. The MLPA kit was used for additional screening of rearrangements in the 19p13.11 
region. This did not reveal copy number changes in any of the tested patients. 
Discussion
We present a case study in which a de novo deletion of chromosome 19p13.11 was found. 
The patient we report has, apart from SHFM, a congenital heart defect and mental 
retardation with a clinical phenotype suspected of Angelman syndrome. None of the 
genes within this deletion could obviously be related to the phenotype. Since the SHFM 
was such a salient feature in our patient, we decided to focus on limb malformations. 
This is the first case where a deletion on chromosome 19 has been associated with SHFM. 
The proximal breakpoint of the de novo deletion is in EPS15L1, a gene coding for epidermal 
growth factor receptor pathway substrate 15-like 1. The encoded protein seems to be a 
constitutive component of clathrin-coated pits that is required for receptor-mediated 
endocytosis. EPS15L1, like its homologue Eps15 on chromosome 1, functions as a substrate 
for the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) [Wong 
et al, 1995].The epidermal growth factor receptor signaling pathway is one of the most 
important pathways that regulate growth, survival, proliferation and differentiation. It 
has been implicated in vertebrate and invertebrate limb development, including the AER 
[Simcox et al., 1997; Omi et al., 2005; Clifford et al., 1989]. Moreover, there is evidence 
that p63 regulates EGFR expression [Nishi et al., 2001], suggesting EPS15L1 to be a serious 
candidate gene for SHFM. However, no copy number changes in EPS15L1 were found in 
any of the other SHFM patients suggesting that a deletion or duplication of this gene is 
not frequently involved in the pathogenicity of SHFM. Nevertheless, point mutations as a 
possible mechanism can not be excluded.
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To exclude Copy Number Variations in the SHFM1-SHFM5 loci as a possible cause for 
the ectrodactyly, both our index patient and the 21 SHFM patients were tested with MLPA. 
A candidate gene in each SHFM locus (DSS1, FGF13, FBXW4, TP73L, DLX2) was tested. Our 
patient did not show any dosage abnormalities in these genes.
A previous linkage study on EEC syndrome in a large Dutch family originally mapped a 
gene to a region of chromosome 19 comprising 19p13.11 [O’Quinn et al., 1998]. However, a 
causative mutation in the p63 gene on chromosome 3q27 was later identified in this family, 
which refuted the presence of an SHFM locus on chromosome 19 [van Bokhoven et al., 
2001]. However, the possibility of a chromosome 19 linked modifier effect in this family 
cannot be excluded. Copy number changes in chromosome 19p13 have been described by 
Thienpont et al., et al. using array-CGH to study patients with congenital heart defects 
[Thienpont et al., 2007]. They describe a patient (DECIPHER CHG00001031) with a de 
novo duplication (19) (p13.12-p13.11) which has recently been shown to be a more complex 
intrachromosomal rearrangement including a microduplication and two microtriplications 
spanning 3.2 Mb [Thienpont et al., 2008]. A small part of the first triplication and the major 
part of the duplication overlaps the region deleted in our patient, thus containing the 
same genes. Interestingly, the clinical phenotype of mental retardation, microcephaly, 
muscular VSD, short stature, strabismus and speech delay partly resembles the phenotype 
of our patient. However, the lack of overlap in facial dysmorphism and the absence of 
SHFM are under dispute. In general in microdeletion/duplication syndromes, phenotypes 
corresponding to the duplication are different and milder than those found in deletion 
cases. In OMIM none of the 19p13.11 deleted genes in our patient have been implicated with 
disease. Only a common variant located in the MYO9B gene has been associated with celiac 
disease [Monsuur et al., 2005].
At present, the interpretation of detected copy number changes is not straightforward, 
given the fact that as much as 11% of our genome shows copy number variations that do 
not appear to be clearly disease-related [Redon et al., 2006]. To distinguish pathogenic from 
innocent variants not only data from patients should be collected, but especially those 
found in ‘normal’ individuals. The Database of Genomic Variants (http://projects.tcag.ca; 
version April 2008), in which variants not known to cause disease are collected, reports 
one case with a duplication on chromosome 19 (19:16,998,070-16,999,171) that lies within 
our deleted region [de Smith et al., 2007]. The duplicated gene CPAMD8 encodes the C3 
and PZP-like, alpha-2-macroglobulin domain containing 8. This protein belongs to a family 
of the complement component-3, involved in innate immunity and damage control. No 
other genes within our deletion have been reported in the Database of Genomic Variants. 
Elucidating the underlying cause of known and new syndromes remains highly 
challenging. 
3
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Copy Number Variants can impact gene function in several ways. The formation of a fusion 
gene as a possible pathogenic mechanism is not plausible because the distal border of our 
deletion is intergenic. The phenotype of our patient may be due to a dosage effect on one 
or multiple genes but it is still very likely that other mechanisms underlie pathogenicity 
such as disruption of a regulatory element that influences flanking genes. Notably, no 
miRNA’s are encoded by genes in the deleted area.
Based on the phenotype of our patient, the size and high gene content of the deletion, 
the fact that it is de novo and its absence in the Database of Genomic Variants, we believe 
that this deletion is causative and represents a new contiguous gene syndrome. Moreover, 
our finding suggests SHFM to be even more genetically heterogeneous than previously 
suggested. Collecting larger sets of patient data in databases such as DECIPHER and 
ECARUCA may confirm this assumption, and should ultimately help to narrow down the 
critical region, and eventually pinpoint relevant genes or regulatory sequences. 
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Abstract
Transition of the double-stranded DNA molecule to its two single strands, DNA denaturation 
or melting, has been used for many years to study DNA structure and composition. Recent 
technological advances have improved the potential of this technology, especially
to detect variants in the DNA sequence. Sensitivity and specificity were increased 
significantly by the development of so-called saturating DNA dyes and by improvements 
in the instrumentation to measure the melting behavior (improved temperature precision 
combined with increased measurements per time unit and drop in temperature).
Melt analysis using these new instruments has been designated high-resolution melting 
curve analysis (HRM or HRMA). Based on its ease of use, simplicity, flexibility, low cost, 
nondestructive nature, superb sensitivity, and specificity, HRMA is quickly becoming the 
tool of choice to screen patients for pathogenic variants. Here we will briefly discuss the 
latest developments in HRMA and review in particular other applications that have thus far 
received less attention, including presequence screening, single nucleotide polymorphism 
(SNP) typing, methylation analysis, quantification (copy number variants and mosaicism), 
an alternative to gel-electrophoresis and clone characterization. Together, these diverse 
applications make HRMA a multipurpose technology and a standard tool that should be 
present in any laboratory studying nucleic acids. 
Key words
mutation detection; methodology; melt curve analysis; HRM; HRMA




Several suppliers produce systems for high-resolution melting curve analysis (HRM 
or HRMA). Overall, these systems perform as can be expected but resolution may differ 
significantly [Herrmann et al., 2006, 2007]. The most sensitive system currently available 
is the HR-1 (Idaho Technology Inc., Salt Lake City, UT) generating fluorescence data from 
55–95oC at a temperature transition rate of 0.1oC/sec and 200 data points/oC. Some assays, 
for example, multiplex SNP-typing [Seipp et al., 2008], critically depend on this resolution. 
The HR-1 uses capillaries and can analyze only one sample at a time; other capillary systems 
analyze up to 32 samples. Microtiter plate systems are more popular, facilitating the 
analysis of 96 or 384 samples simultaneously. Another distinction is whether the system 
is used for HRMA only or whether it is a combined (real-time) polymerase chain reaction 
(PCR) and HRMA instrument. As nicely demonstrated by Rouleau et al. [2009], combined 
qPCR and HRMA instruments allow detection of both quantitative (deletion/duplication) 
and qualitative (nucleotide) changes in one assay. 
In most systems small well-to-well temperature differences exist that negatively influence 
sensitivity. To bypass this problem, Seipp et al. [2007] added control temperature calibration 
probes: one melting at low and one at high temperature. The analysis software can use 
the melt positions of these probes to compensate for temperature differences between 
wells, decreasing Tm  SD by 38% [Seipp et al., 2007] notably increasing sensitivity. Note that 
the software available on HRMA instruments is an important element determining the 
ultimate sensitivity achieved [Herrmann et al., 2007], and not all packages yet facilitate the 
use of temperature calibration probes. 
LC-Green was the first saturating dye available [Wittwer et al., 2003]; now there are many 
more, including LCGreens®+ (Idaho Technology Inc.), Syto9® (Invitrogen, Carlsbad, CA), 
EvaGreen® (Biotum) and LightCycler® 480 ResoLight Dye (Roche, Indianapolis, IN). Pricing 
of the dyes differs significantly; all have slightly different characteristics, and they often 
demand slightly different PCR buffers and conditions. 
Implementation of HRMA is quite straightforward. In the most simple setting, requiring 
no modifications of existing conditions, dye is added post-PCR directly prior to melting. 
This simple approach allowed us, for example, to immediately discriminate all possible 
apoE alleles (Fig. 1A). ApoE typing with other techniques is often problematic, mostly 
requiring typing of each allele separately. Ultimately, performing HRMA in a closed-tube 
assay by adding the dye pre-PCR is more attractive. For existing assays this demands 
modification of PCR conditions, usually increasing Mg2+ concentration 2–3 µM and the 
annealing temperature by 1–5°C will be sufficient. When Mg2+ addition raises the Tm above 
the maximum instrument temperature, additives like DMSO (10%) or betaine (0.5 M) can 
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be added to lower the Tm. For difficult cases, a gradient PCR-cycler can be used to quickly 
determine the most optimal annealing temperature. 
HRMA demands no big changes in the laboratory and does not require specific skills; 
it is a simple PCR performed under slightly modified conditions and in the presence of a 
specific dye. The most expensive element is acquisition of the instrument. However, with 
€ 10; 000; 50; 000, depending on the system, even this compares favorably to some other 
technologies. Because HRMA, unlike many other techniques (e.g., SSCA, dHPLC, DGGE, or 
capillary electrophoresis), does not require post-PCR separation, significant cost savings 
are achieved. Furthermore, HRMA is a nondestructive method, and subsequent analysis by, 
for example, gel-electrophoresis or sequencing, can still be performed after melt analysis.
Figure 1: Sequence variant detection using HRMA. A: detection of all six possible ApoE-
alleles combinations; LC-Green+ was added post- PCR, before HRMA (the PCR contained 
10% DMSO). The ApoE 3/3 allele was set as standard (horizontal gray line). B–D: SNP typing 
using an unlabeled amino-blocked melt probe covering three independent variants in 
the first exon of the MBL2 gene (Roos et al., in preparation). B: overall derivative plot; C: 
enlargement of the low (melt probe) and D: high (PCR fragment) Tm peaks. Using the 









HRMA has been developed for the detection of DNA sequence variants and it was 
applied first for genotyping [Wittwer et al., 2003]. Simplicity, low cost, ease of use, and 
a high sensitivity/ specificity have been the most prominent features, making HRMA an 
attractive new tool for genotyping and application in diagnostic labs. In Supp. Table S1 we 
give a comprehensive list of all (human) gene-based assays we could find. HRMA systems
come with powerful software tools facilitating automated scoring that is very robust, 
although a quick manual check remains advisable. Using HRMA for mutation detection 
has been reviewed recently [Erali et al., 2008]; therefore, we will make general comments 
only. Furthermore, this issue of Human Mutation contains several papers describing 
application of HRMA for sequence variant detection, elegantly demonstrating its current
state of the art (see also Supp. Table S1). 
Tindall et al. [2009] compared two instruments and fluorescent dyes in particular 
regarding the detection of combinations of DNA variants present in GC-rich fragments. 
They demonstrated the current limitations of HRMA and called for caution when using it 
as the sole method to make a clinical diagnosis. Nguyen-Dumont et al. [2009] showed the 
power of including a melt probe to improve identification of rare variants in combination 
with a known SNP as well as to dramatically reduce sequencing effort. Van Der Stoep et 
al. [2009] followed a similar approach designing a sequence variant screen covering the 
BRCA1 gene, including melt probes against known frequent SNPs. In the setting of the 
EuroGenTest consortium, the authors went through the effort to perform an elaborate 
interlaboratory evaluation and validation of HRMA and generated guidelines for setting 
up and implementing it as a scanning technique for new genes. In a blind study on 28 
patient samples the protocol resulted in a 100% detection sensitivity at a specificity of 
98%, indicating a low incidence of false positives. Rouleau et al. [2009] used the possibility 
provided by some instruments to perform quantitative PCR and HRMA in one instrument 
to scan for both quantitative (deletions/duplications) and qualitative nucleotide changes 
in one assay. Finally, Dobrowolski et al. [2009] described the use of HRMA to scan the 
entire 16.6 kb human mitochondrial genome (mtDNA) for sequence variants in less then 
2 hr. Identification of mtDNA variants is complicated, as many are heteroplasmic, with the 
variant allele present at highly variable percentages. The fact that the authors successfully 
identified variants present at levels ranging from 1–100% heteroplasmy nicely shows the 
sensitivity of the assay as well as the power of HRMA to detect quantitative changes (see 
Quantification).
Although HRMA of fragments up to 600 bp and more has been reported, our experience 
4
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is that the technology is more sensitive for smaller fragments. For fragment screening, 
fragments of 150–250 bp are used, that is, in general, one fragment per exon. When assays 
are designed to type specific variants (SNP typing) we target fragment sizies of 80–100 
bp. We find it critical for high sensitivity that the melt profile contains not more then 
one to two melt domains. When fragments contain more melt domains chances increase 
that not all variants are detected. Today the design of new assays is simplified by the 
availability of powerful design programs, often delivered together with the instrument.
In early HRMA experiments we have seen that a second and sometimes even a third 
melt of the PCR products may improve results. Similarly, especially when the concentration 
of the DNA fragments to analyze differ considerably, results can be improved by adding 1 
µl high salt buffer (1.0M KCL, 0.5M Tris-HCl [pH58.0]) followed by a new melt (Fig. 2). Salt 
addition may increase resolution and improve clustering, but success of the method is 
unpredictable and depending on the samples, fragments, and variants analyzed
 When a few simple rules are taken into account (i.e., avoid long fragments and multiple 
melt domains), designing a HRMA screen for a gene is rather straightforward. We have 
successfully designed assays to screen a range of genes of which the DMD gene with  90
fragments covering 79 exons was the largest (Al-Momani et al., in press). As Nguyen-
Dumont et al. [2009] and Van Der Stoep et al. [2009] show, it is time and cost saving to 
include unlabeled melt probes to positively identify known nonpathogenic variants. This
prevents unnecessary sequencing of such fragments, while it at the same time safeguards 
against overlooking other variants in the same fragment (see Presequence Screening).
It should be noted that the shape of an HRMA curve in itself is usually not sufficient 
to type a specific variant [Tindall et al., 2009]; to achieve this either a melt probe should 
be added or the fragment should be sequenced. The power of adding an unlabeled melt 
probe to discriminate specific variants or multiple alleles is astonishing. An example is 
shown in Figure 1B–D (Roos et al., in preparation). Using a melt probe containing the wild-
type sequence we were able to discriminate all 10 possible alleles deriving from a series of 
three closely spaced variants in the MBL2 gene. 
The cheapest block available to prevent extension during PCR of the melt probe is a 
30 phosphate. Unfortunately, this block is unstable, and after time undesired additional 
melt peaks may emerge. Other blocks are more stable but also more expensive. Zhou et 
al. [2008] elegantly solved this issue by using a so-called snapback primer, that is, a 50 
tailed primer including a loop region and a sequence complementary to its extension 
product, covering the variant to scan. A potentially weak point of HRMA is the detection 
of homozygous variants. Although recent developments have further improved resolution 
[Gundry et al., 2008], the difference for some variants (e.g., A–T to T–A changes) are so 
subtle that they can easily be missed. Especially when samples from different sources have 
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to be analyzed, sample-to-sample variation and thus experimental noise increases and 
subtle changes might go undetected. Therefore, in sequence variant scanning applications 
(clinical diagnostics) we consistently use sample mixing to generate hetero-duplexes. 
First, samples are melted to obtain a standard melt profile. Next, using the scheme shown 
(Fig. 3, designed for DMD, an X-linked disease), samples are mixed and then a second melt 
curve is generated. The simple mixing scheme results in two heteroduplexes for each 
sample (note that sample mixing can be easily automated). Homozygotes will result in 
two wells with heteroduplexes, greatly improving their detection. Heterozygotes will be 
detected from the standard premixing melt curves, although they will usually be obvious 
from the mixed samples as well (1:3 ratio, see Quantification). The scheme shown will only 
fail when samples with identical variants are mixed but this can be simply prevented by 
adding more controls or by mixing samples from unrelated individuals only. It should be 
noted that the scheme presented (Fig. 3) has the potential to discriminate hemizygous 
from true homozygous alleles as well. 
It should be noted that the sensitivity of HRMA to detect heterozygotes is much better 
than that of DNA sequencing (see Quantification). Consequently, when HRMA indicates 
the presence of a variant that cannot be confirmed using sequencing it might well be 
that this variant is present in a relatively low fraction of the sample (somatic mosaicism). 
Other techniques, for example, cloning1sequencing or single molecule dilution1PCR and 
HRMA, might be required to confirm these variants. 
Pressequence Screening 
Using HRMA for presequence screening, in particular for larger genes, may yield 
significant cost savings; Provaznikova et al. [2008] reported avoiding unnecessary 
sequencing of more than 85% for the MYH9 gene. In the example of the DMD gene, 
where 79 exons need to be analyzed (Al-Momani et al., in press), assuming bidirectional 
sequencing costs h10 per exon, screening a patient amounts to ~ €800. PCR per exon 
(€1) and HRMA (€0:10 dye) would cost ~ €90 per patient. Assuming 5 exons show a melt 
shift requiring verification by sequence analysis (including one pathogenicvariant, three 
nonpathogenic variants and a false positive) would add €50, making a total of €140. A cost 
saving of more then €650 per patient that can be further reduced when melt probes are 
included to confirm the presence of the most frequent nonpathogenic variants. In fact, 
based on these figures, HRMA prescreening of a five-exon gene is already cost-effective. 
In addition, to detect somatic changes or heteroplasmy [Dobrowolski et al., 2009], HRMA 
seems more sensitive then sequencing (see Quantification). 
4
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SNP typing
HRMA for SNP-typing can be very attractive. Assay design is cheap, simple, and fast. 
When in a specific region one or two PCRs covering a SNP are designed, at least one and 
usually both will give a good assay. To increase sensitivity, the fragment should preferably 
Figure 2: Effect of high-salt. A: HRMA analysis of a series of samples. B: The same samples 
as in A analyzed after addition of 1 ml 1.0MKCl/ 0.5M Tris-HCl (pH58.0) and remelting. 
Note the improved separation and sharpening of the three groups.
Figure 3: Generating heteroduplexes. To ensure the detection of all homozygous variants 
the scheme shown can be used. Wells 1–12 contain PCR products from different fragments 
(exons) amplified for each sample (patients A–F and wt5wild-type control). Row 8 is empty. 
After a first HRMA mixing starts with taking half of the sample from row 7 (wt, 5–10 ml 
of the PCR product) and transferring this to row 8. Subsequently, half the volume of from 
row 6 is transferred to row 7, half of row 5, to row 6, etc. Finally, the content of row 8 is 
transferred to row 1 and the fragments are melted again.
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be small (80–100 bp) and when a choice is available (e.g., in a haplotype block) one should 
select a G to A variant (predicted to give the largest melt shift) [Reed andWittwer, 2004]. 
Addition of an unlabeled melt probe [Nguyen-Dumont et al., 2009; Zhou et al., 2008] is 
recommended, giving a double check in the assay and improved scoring for homozygote 
variants. When ordered primers arrive, it should not take more then one or two PCRs to test 
amplification conditions and the assay is ready. Assay costs are then just PCR, and cost for 
assay design (an often largely underestimated factor) are negligible. Unless thousands of 
samples need to be typed, dye cost should compare favorably to assays including specific
labeled probes (e.g., TaqMan). HRMA sample throughput can be increased using robotic 
plate loading, available as an extension on some systems or by installing an additional 
loader. 
Based on the positive results described above one wonders whether variable number 
Figure 4: CA repeat analysis using HRMA. Six different DNA samples were analyzed in 
duplicate, all heterozygotes. Top panel: normalized temperature shifted melting curves. 
Bottom panel: derivative plot. Allele lengths were 1=18/21, 2=17/21, 3=14/17, 4=14/18, 5=15/21, 
6=14/21.
4
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tandum repeats (VNTRs), especially CA repeats, could be typed using HRMA (Fig. 4). 
Although in the example shown all curves can be clearly discriminated, we found that 
all possible allele combinations are so many that heterozygous CA repeat typing cannot 
be performed with certainty. It is possible though in small families to detect differences 
between family members and to use HRMA to study loss of heterozygosity (LOH) in 
heterozygous samples. As indicated by the experiments of Intemann et al. [2009], it can 
be speculated that addition of a melt probe spanning the smallest and/or largest allele 
might increase resolution further. 
A weak point of HRMA is that it cannot easily be applied in multiplex mode, that is, to type 
variants in several different fragments at the same time. Theoretically, multiplexing can 
be achieved by exploiting color differences, temperature differences, or both. Seipp et al. 
[2008] used the simplest approach, that is,
Tm-differences to successfully design a quadruplex genotyping assay. However, such 
design is time consuming and its success critically depends on high sample DNA quality 
and the sensitivity of the HRMA system used. 
Methylation 
Lately, genomic studies frequently involve the analysis of epigenetic marks, especially 
methylation at CpG dinucleotides in relation to gene expression, imprinting, and cancer 
(Ehrich et al., 2006). A critical step in these procedures is bisufite treatment of the genomic 
DNA, changing unmethylated C nucleotides (but not methylated Cs) to Us. HRMA can be 
used in such studies in two stages. First, success of the bisulfite treatment can be checked 
by PCR of a control genomic segment devoid of methylated CpGs and comparison of its 
melt profile with that of a 100% converted fragment (cloned) and an untreated sample. 
The closer the melt profile resembles that of the 100% converted fragment, the better the 
bisulfite treatment worked [Worm et al., 2001]. Second, HRMA can be used to determine 
the percentage of C to U conversion, either directly, in combination with a melt probe 
[Maat et al., 2007], or after cloning (see Clone Characterization). 
Quantification—Mosaicism and Copy Number Variant (CNV) Confirmation
Depending on the melt shift obtained, HRMA can also be used for quantitative 
analysis; the larger the shift, the smaller the quantitative differences that can be detected. 
To quantify the fraction of variant molecules frequently used technologies are dideoxy 
sequencing (resolution limit down to 20–30%) and pyro-sequencing (down to 1–10%). 
Although powerful, pyro-sequencing is laborintensive, costly, and demands specific 
equipment. We have successfully applied HRMA for the quantification of different alleles 
[Aten et al., 2009; Bruder et al., 2008], and shown that detection in steps of 12.5% (1 in 8) 
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is usually possible [Aten et al., 2009]. Application for the detection of the level of somatic 
mosaicism in colon cancer is shown in Figure 5. Using a dilution series as a ruler we could 
readily determine the level of somatic mosaicism in three patients suspected to carry a 
specific pathogenic variant down to a level of 5–10%. The data obtained matched perfectly 
with those obtained using pyro-sequencing [Hes et al., 2008], yet the assay was less 
expensive and simpler to perform. It should be noted that when melt probes are included 
resolution can be improved to below 5%. Other qHRMA applications are the determination 
of differences in allelic expression, based on the presence of a variant in the mRNA and 
the detection of heteroplasmy in mtDNA [Dobrowolski et al., 2009]. 
Recently, we used the same approach to estimate the fraction of cells carrying a 
somatic deletion identified in one individual from an identical twin pair [Bruder et al., 
Figure 5: Quantification using HRMA. A: Dilution series for a pathogenic A4G variant in 
APC exon 8. B: Superposition of the HRMA profiles from three mosaic samples (S1–S3) and 
the estimation of the level of somatic mosaicism. Pyro-sequencing of the samples gave 
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2008]. The approach can also be used to confirm CNVs (both deletions and duplications) 
detected using whole genome SNP arrays while screening patients of diverse diseases for 
genomic rearrangements. Depending on the setting, techniques like FISH, MAPH [Armour 
et al., 2000], MLPA
[Schouten et al., 2002], MAQ [Suls et al., 2006], and qPCR can be applied to confirm the 
array findings. However these techniques are either costly or demand considerable time 
to develop. For confirmation with HRMA one can use any SNP from the suspected region. 
Samples homozygous for the two opposite alleles (AA and BB) of these SNPs are used to 
generate a reference ruler as well as a 1:1 mix with the sample potentially carrying the 
rearrangement. Assume the test sample carries the A allele and is either A0 or AA. When 
mixed 1:1 with a homozygous BB sample the deletion is confirmed when the melt profile 
comigrates with the 1:2 AA:BB sample mix (A0BB). The deletion is absent when the melt 
profile comigrates with the 1:1 AA:BB sample mix (AABB). A duplication will be confirmed 
when the 1:1 mix with a homozygous BB sample comigrates with the 3:2 AA:BB sample 
mix (AAABB).
Alternative for Gel Electrophoresis
The current standard to check the result of a PCR or digestion is analysis of the 
product using agarose gel electrophoresis and ethidium–bromide staining. Identity of the 
fragment is characterized by its length, purity by the absence of other fragments, and 
yield by the strength of the fluorescence of the band. HRMA is an attractive alternative; 
identity characterized by the melting profile, purity by the absence of distortions from 
the control melt curve (and absence of additional melt peaks), and yield by the amount of 
fluorescence signal (Fig. 6). The advantages of using HRMA are clear; one does not have 
to pour gels and use hazardous chemicals (ethidium–bromide), melting is faster then 
electrophoresis, and data analysis can be performed automatically. Furthermore, because 
it is a nondesctructive method, when HRMA would not give clear results fragments can 
still be analyzed on gel. In our laboratory HRMA is quickly replacing gel electrophoresis
for the characterization of PCR products. Dye is added post- PCR (1 µl LC-Green1[10 stock] 
per 10 µl sample), sample is 5 min incubated at 95°C, cooled down to room temperature, 
and melted. Figure 5A shows an example where five different fragments were analyzed, 
all clearly discernable by their individual melt behavior. Primer–dimer formation would 
be recognized by the presence of a melt peak at low Tm . Out et al. (manuscript submitted) 
used HRMA instead of gel electrophoresis to check amplification as well as to determine 
long-range PCR yield guiding equimolar pooling before sequencing of the MUTYH gene. 
The authors could successfully show detection of nearly all variants in the expected 
frequencies down to 0.5% (1/200 chromosomes). 
4
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Clone Characterization
Several studies generate large series of clones that need to be sequenced to determine 
their identity. These include in vitro mutagenesis experiments, methylation studies, cDNA 
cloning to determine levels of differential splicing and/or allelic expression, and phage 
display selections. HRMA provides an attractive tool to prescreen the clones to detect 
those that share the same insert and those that differ, generating considerable savings 
for subsequent sequencing. An example is shown in Figure 6C, showing the result of a 
second round phage display selection. The experiment resulted in several groups of clones 
with identical melt curves, indicating that the experiment was successful in positively 
selecting several different phage display clones. Subsequent sequencing of representative 
clones per group confirmed the HRMA results; sequence differences between groups 
and sequence identity within groups [Pepers et al., 2009]. Previously, clone inserts were 
fingerprinted using restriction digestion and gel electrophoresis, a less sensitive and 
much more laborious method [Verheesen et al., 2006].
Conclusion 
The advantageous characteristics of HRMA make it a technology that quickly attracts 
a range of new users. Its ease of use, simplicity, flexibility, low cost, nondestructive nature, 
superb sensitivity, and specificity, make HRMA the method of choice to screen patients 
for pathogenic variants. As reviewed above, HRMA has several attractive additional 
applications, making it a versatile multipurpose analytical tool to analyze nucleic acids 
in general. Because HRMA is still a rather young technology, one can only expect exciting 
further developments. The company Fluidigm markets a nanoliter qPCR system [Spurgeon 
et al., 2008], today facilitating the analysis of 96 samples 96 PCR assays (i.e., 9,216 assays 
simultaneously); imagine the power of such a system when it would facilitate HRMA.
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Supporting Information
Supp. Table S1: Published assays using high-resolution melting analysis (HRMA)
Gene  Assay  Reference
ABL1  variants  Polakova KM et al. 2008 Leuk Res 32:1236-1243
ACADM  gene  McKinney JT et al. 2004 Mol Genet Metab 82:112-120
ACVRL1  gene  Vandersteen JG et al. 2007, Clin Chem 53:1191-1198
AKT1  variants  Do H et al. 2008 BMC Res Notes 1:14
APOB  variants  Liyanage KE et al. 2008 Ann Clin Biochem 45:170-176
APOC2  gene  Chang YT et al. 2008 J Clin Gastroenterol 2008 Epub Nov 20
APOE  variants  Poulson MD & Wittwer CT 2007 Biotechniques 43:87-91
ARG1  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
ASL  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
ASS1  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
ATP7B  variants Zhao X et a. 2008 Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25:515-519
BRAF  variants  Willmore-Payne C et al. 2005 Hum Pathol 36:486-493
BRCA1  gene  Van Der Stoep et al. 2009 Hum Mutat 30 (this issue, e-pub 
pending)
BRCA1/2  variants Takano EA et al. 2008 BMC Cancer 8:59
 gene De Leeneer K et al. 2008 Clin Chem 54:982-989
 gene  de Juan I et al. 2008 Breast Cancer Res Treat. Jun 5 - E-pub ahead
CFTR  gene Montgomery J et al. 2007 Clin Chem 53:1891-1898
CPS1  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
CXCR7  variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
CYP2C9  variants Hill CE et al. 2006 Am J Clin Pathol 125:584-591
EGFR  variants Do H et al. 2008 BMC Cancer 8:142
 variants Smith GD et al. 2008 J Clin Pathol. 61:4874-93
ENG  gene Vandersteen JG et al. 2007, Clin Chem 53:1191-1198
ERBB2  variants Willmore-Payne C et al. 2006 Mod Pathol 19:634-640
EXT1/2  gene Lonie L et al. 2006 Hum Mutat 27:1160
F2  variants Seipp MT et al. 2008 Clin Chem 54:108-115
F5  variants Seipp MT et al. 2008 Clin Chem 54:108-115
F8  gene Lin SY et al. 2008 BMC Med Genet 9:53
FGFR3  variants Hung CC et al. 2008 Clin Biochem 41:162-166
FLT3  variants Tan AY et al. 2008 J Hematol Oncol 1:10
GALT  variants Dobrowolski SF et al. 2003 J Mol Diagn 5:42-47
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GJB1  gene  Kennerson ML et al. 2007 Clin Chem 53:349-352
HBB  variants  Herrmann MG et al. 2000 Clin Chem 46:425-428
HRAS  variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
IGF1  gene  Palles C et al. 2008 Hum Mol Genet 17:1457-1464
IL10  variants  Tedde A et al. 2008 Scand J Gastroenterol 43:712-718
JAK2  variants  Rapado I et al. 2009 J Mol Diagn 11:155-161
KIT  variants  Holden JA et al. 2007 Am J Clin Pathol 128:230-238
KRAS  variants  Do H et al. 2008 BMC Cancer 8:142
 variants  Krypuy M et al. 2006 BMC Cancer 6:295
LDLR  gene  Laurie AD et al. 2008 Clin Biochem Epub Dec 11
  Vossen et al., Human Mutation 2
LPL  gene  Chang YT et al. 2008 J Clin Gastroenterol 2008 Epub Nov 20
LRRK2  variants  Tedde A et al. 2007 Cell Mol Neurobiol 27:877-881
MBL2  variants  Vossen RHAM et al. 2009 Hum Mutat 30 (this issue, e-pub
  pending)
 variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
MLH1  gene  Rouleau E et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
MTHFR  variants  Sinthuwiwat T et al. 2008 Mol Cell Probes 22:329-332
MYH  gene  rovaznikova D et al. 2008 Platelets 19:471-475
NAGS  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
NF2  gene  Sestini R et al. 2008 Genet Test 12:311-318
NKX3-1  variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
NPM1  variants  Tan AY et al. 2008 J Hematol Oncol 1:10
NPY  variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
OTC  gene  Dobrowolski SF et al. 2007 Hum Mutat 28:1133-1140
PAH  gene  Dobrowolski SF et al. 2007 Mol Genet Metab 91:218-227
PDGFRA  variants  Holden JA et al. 2007 Am J Clin Pathol 128:230-238
PHEX  gene  Gaucher C et al. 2009 Hum Genet Feb 15
PIK3CA  variants  Simi L et al. 2008 Am J Clin Pathol 130:247-253
RASEF  gene  Maat W et al. 2008 Invest Ophthalmol Vis Sci 49:1291-1298
RET  (gene)  Margraf RL et al. 2006 Clin Chem 52:138-141
RUNX2  variants  Pal T et al. 2007 Clin Genet 71:589-591
RYR1  variants  Grievink H & Stowell KM 2008 Anal Biochem 374:396-404
SCN5A  gene  Millat G et al. 2008 Clin Biochem Epub Nov 6
SERPINA1 variant  Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
SLC22A5  gene  Dobrowolski SF et al. 2005 Hum Mutat 25:306-313
SLC25A13  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
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SLC25A15  gene  Mitchell S et al. 2009 Hum Mutat 30:56-60
SNRPN  variants  White HE et al. 2007 Clin Chem 53:1960-1962
TGM1  gene  Herman ML et al. 2008 Hum Mutat E-pub Dec 18
TP53  gene  Bastien R et al. 2008 Hum Mutat 29:757-764
 gene Garritano S et al. 2009 BMC Genet 10:5
VDR  variant Tindall EA et al. 2009 Hum Mutat 30 (this issue, e-pub pending)
mtDNA genome Dobrowolski SF et al. 2009 Hum Mutat 30 (this issue, e-pub   
  pending)
Legend
Indicated are the gene (official HGNC gene symbol), whether the assay was designed to 
scan the entire gene or only specific variants, and the reference(s). When papers to both 
screen-specific variants and complete gene scans were published, we list only the latter.
A regularly updated table can be found at http://www.LGTC.nl/HRMA including links to 
the primer and melt probe sequences used (when known).
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Abstract
Keratosis Follicularis Spinulosa Decalvans, (KFSD) is a rare genetic disorder characterized 
by development of hyperkeratotic follicular papules on the scalp followed by progressive 
alopecia of the scalp, eyelashes and eyebrows. Associated eye findings include photophobia 
in childhood and corneal dystrophy. Due to the genetic and clinical heterogeneity of similar 
disorders, a definitive diagnosis of KFSD is often challenging. Towards identification of 
the causative gene we re-analysed a large Dutch KFSD family. 1M SNP arrays redefined 
the locus to a 2.9 Mb region at Xp22.12-Xp22.11. Screening of all 14 genes in the candidate 
region identified MBTPS2 as the candidate gene carrying a c.1523A>G (p.Asn508Ser) 
missense mutation. The variant was also identified in two unrelated X-linked KFSD families 
and cosegregated with KFSD in all families. In symptomatic female carriers, skewed 
X-inactivation of the normal allele matched with increased severity of symptoms. MBTPS2 
is required for cleavage of sterol regulatory element-binding proteins (SREBPs). In vitro 
functional expression studies of the c.1523A>G mutation showed that sterol responsiveness 
was reduced by half. Other missense mutations in MBTPS2 have recently been identified in 
patients with IFAP syndrome. We postulate that both phenotypes are in the spectrum of 
one genetic disorder with a partially overlapping phenotype.
Key words
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Keratosis Follicularis Spinulosa Decalvans (KFSD; MIM# 308800) is a rare genetic disorder 
showing variable expression with women usually less severely affected than men. In 1926, 
Siemens was the first to describe KFSD in a large German family and several Dutch cases 
(Siemens HW, 1926). These Dutch cases belonged to a large family that was described by 
Lameris (Lameris, 1905) under the name ‘Ichthyosis Follicularis’. In the two large pedigrees 
described by Lameris and Siemens (Lameris, 1905; Siemens HW, 1926), inheritance is clearly 
X-linked. However, generally, 50% of carrier females show symptoms of KFSD, which made 
Siemens postulate that inheritance in KFSD was of the X-linked intermediate type. More 
X-linked pedigrees have been described (Porteous et al., 1998). However inheritance is not 
always clear and isolated cases and autosomal dominant inheritance (i.e. male-to male 
transmission) has been described as well (Baden and Byers, 1994; Castori et al., 2009; 
Kuokkanen, 1971; Oosterwijk et al., 1997). KFSD manifests in infancy or early childhood 
with thorny keratotic follicular papules, progressive alopecia of the scalp, eyelashes and 
mainly lateral parts of the eyebrows with variable degrees of inflammatory change. Ocular 
abnormalities such as photophobia in childhood, punctate defects of the cornea, corneal 
dystrophy and blepharitis are common findings. Hyperkeratosis of elbows, knees, palms 
and soles as well as nail dystrophy may occur (Oosterwijk et al., 1997; Rand and Baden, 1983; 
Siemens HW, 1926; van Osch et al., 1992) 
Due to the clinical and genetic heterogeneity of KFSD, a definite diagnosis is often 
challenging. KFSD resembles other dermatological entities such as keratosis pilaris and 
ulerythema ophrygenes (MIM# 604093), keratitis ichthyosis deafness syndrome (KID; 
MIM# 148210), ichthyosis follicularis atrichia photophobia (IFAP; MIM# 308205), keratosis 
pilaris atrophicans and atrophoderma vermiculatum.(Oranje et al., 1994). The question 
remains whether these syndromes are in actual fact variations of the same entity or truly 
independent disorders.
Using linkage analysis in the Dutch KFSD family, the locus was mapped to Xp21.2-
22.2 (Oosterwijk et al., 1992b). Subsequently, the disease location was narrowed down 
to Xp22.13-p22.2 (Oosterwijk et al., 1995) and later refined to Xp22.13-p22.11 (Oosterwijk 
et al., 1997). This locus was confirmed in an X-linked family from the UK (Porteous et al., 
1998), but lack of informative crossovers prevented detection of the KFSD gene. In 2002, 
spermidine/spermine N(1)-acetyltransferase (SSAT; MIM# 313020) was postulated as the 
causative gene for KFSD (Gimelli et al., 2002) . However, the SAT1 gene is not included in the 
Dutch KFSD interval. 
In order to identify the causative gene, we studied the large Dutch family and some other 
families with a clinical diagnosis of KFSD using new molecular tools. 1M SNP arrays were 
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used to refine the locus and to exclude the involvement of large deletions and duplications. 
Subsequently, genes in the candidate gene interval were screened for possible pathogenic 
variants using High Resolution Melting curve Analysis (HRMA).
Here, we show that KFSD patients carry mutations in the MBTPS2 gene and that this affects 
the normal function of the protein by lowering MBTPS2 activity. While this work was in 
progress, deficiencies in the MBTPS2 gene were shown to also cause IFAP syndrome (Oeffner 




An extended multigenerational Dutch pedigree with 21 affected males, 15 unaffected 
males and 12 female carriers was available for molecular analysis (Figure 1a). Female carriers 
showed a variable phenotype ranging from severely affected to total absence of KFSD 
symptoms (van Osch et al., 1992).
Other families and cases with a clinical diagnosis of KFSD were available for MBTPS2 
analysis. Two families showed a clear X-linked mode of inheritance, confirmed by 
microsatellite marker analysis: a family from the USA as seen by one of us (unpublished 
data V.P.Sybert ), and a family from the UK that was published previously (Herd and Benton, 
1996; Porteous et al., 1998). The American family (Figure 1b) consisted of five affected 
males, five unaffected males and three carrier females. Four individuals were available 
for DNA analysis. Seven family members from the UK family (pedigree available in Herd 
and Benton et al, 1996) (Herd and Benton, 1996) were available for DNA analysis. Clinical 
features and MBTPS2 genotypes are summarized in Table 1.
DNA and RNA analysis
DNA was extracted from whole blood following standard protocols. Total RNA was 
extracted from whole blood lymphocytes and from cultured fibroblasts using RNA-bee 
Tm (Bioconnect). cDNA was made using 1ug of total RNA according to standard protocols. 
Fibroblasts were cultured in DMEM (Gibco) with 10% FCS, 1% Penicilin + Streptomycin, 1% 
glutamine and 1% glucose at 370 C and 5%CO2. Cells were harvested at 90% confluency 
prior to RNA isolation.
Array platforms
For SNP typing and CNV analysis, the Illumina Human1M BeadChip (Illumina Inc., 
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San Diego, CA, USA) was used and a total of 750 ng DNA was processed according to the 
manufacturer’s instructions. SNP copy number (log R ratio) and B-allele frequency were 
assessed using the software programs BeadStudio version 3.2 (Illumina).
High Resolution Melting Curve Analysis
High Resolution Melting curve Analysis (HRMA) was used as a pre-mutation screening in 
the Dutch KFSD family. Primers were designed to cover all exons and intron/exon boundaries 
of the 14 candidate genes (Fig 2) using Lightscanner primer design (Idaho). Known SNPs 
were avoided as much as possible. Sequences are available on request. Fragments were 
amplified using a touchdown PCR (650-590) directly followed by melting (LightCycler 480 
Roche). To detect possible heteroduplex formation, patient DNA was mixed with DNA from 
unaffected male individuals in a 1:1 ratio. Melting curves of mixed samples were compared 
to those of unmixed samples and healthy controls. Samples showing aberrant melting 
curves were selected for direct sequence analysis.
Sequence analysis
PCR products were purified using spin columns according to the manufacturer’s 
instructions (Qiagen, The Netherlands) and directly sequenced using Sanger sequencing 
(ABI 3730). High-throughput PCR products were purified using magnetic beads (Ampure) 
and prepared for sequencing with Sephadex plates (Edge Biosystems). Sequencing analysis 
was performed using the Mutation Surveyor program (SoftGenetics, USA). The human 
assembly (GRCh37/Hg 19) was used as a reference sequence. Nucleotide numbering 
follows HGVS recommendations and is based on a coding DNA reference sequence with 
nucleotide 1 corresponding to the A of the ATG translation initiation codon (www.hgvs.
org/mutnomen). For MBTPS2 exon 11 all available subjects from the Dutch pedigree were 
sequenced to study the segregation of the MBTPS2 c.1523A>G mutation in this family. 
Cases from two other X-linked KFSD families from the USA and UK were also tested for 
this variant. The remaining 6 families were screened for all exons of the MBTPS2 gene. 
50 healthy unrelated controls were sequenced and data from pilot study 1 of the 1000 
genome project (www.1000genomes.org, version October 2009) was used to study the 
variant frequency in the healthy population. 
To confirm our findings on RNA level and to study possible differences in expression, 
MBTPS2 mutation screening was performed at both RNA and genomic DNA levels. Possible 
damaging effects of missense mutations were assessed by PolyPhen and SIFT software. A 
web based MBTPS2 gene variant database using the LOVD platform (Fokkema et al., 2005) 
was initiated to store and share all data collected (see www.LOVD.nl/MBTPS2).
5
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X-chromosome inactivation 
The methylation status of the X-chromosome was determined using the Androgen 
Receptor (AR) locus (Kubota et al., 1999). The maternal and paternal X chromosomes are 
distinguished by polymorphisms of a CAG repeat element in the AR gene while X-inactivation 
level is determined by the methylation of CpG dinucleotides in the AR gene.. Four carrier 
females and one affected male of the Dutch pedigree were genotyped for their CAG repeat 
length in the AR gene (Xq12) using blood derived DNA. The sequence of the forward primer 
with the fluorescent dye FAM was 5’-ACCGAGGAGCTTTCCAGAAT-3’. The sequence of the 
reverse primer was 5’-CTCATCCAGGACCAGGTAGC-3’. To determine the methylation status 
of the AR gene alleles in the carrier females, DNA was treated with bisulphite followed by 
a methylation specific PCR (according to the manufacturer’s protocol EZ DNA methylation-
Gold kit Tm, Zymo research). Methylation differences were estimated based on peak heights 
in the PCR fragment analysis (Genemarker V1.70, Softgenetics).
Complementation assay
Growth of stably transfected CHO-K1-M19 cells was measured in cholesterol rich 
medium compared to cholesterol deficient medium. CHO-K1-M19 cells (MBTPS2 deleted) 
were grown in a 1:1 mixture of Ham’s F-12 medium and DMEM containing Glutamax 
(Invitrogen), nonessential amino acids, penicillin, streptomycin (Medium A), supplemented 
with 10% FCS and maintained at 370 C and 5%CO2. Cells were stably transfected with 1.5 ug of 
a plasmid (pcDNA3.1 vector expressing a neomycin resistance gene, Invitrogen) expressing 
WT human MBTPS2 or the N508S mutant MBTPS2. Stable transfection of CHO-K1-M19 cells 
with WT human MBTPS2 restores the enzyme defect, thereby allowing growth in sterol 
deficient media. Cell growth of the N508S mutant transfected CHO-K1-M19 and WT 
transfected cells was measured in medium with- (Medium A with 5% FCS, 5µg/ml water-
soluble cholesterol, 1 mM sodium mevalonate and 20 µM sodium oleate) and without 
sterols (Medium A with 5% lipoprotein deficient FCS). Growth of the stable transfected 
CHO-K1-M19 cells was measured after 6 days of culturing. Cells were harvested at day 6 
and cells were counted in a hemocytometer. The complementation assay was performed 
as described by Oeffner et al (Oeffner et al., 2009).
Luciferase Reporter Assays
This assay, an indirect measure of the ability of MBTPS2 cDNAs to restore sterol-regulated 
transcriptional activity in transfected M19 cells with a firefly pSRE-Luciferase reporter 
plasmid, was performed as described by Oeffner et al (Oeffner et al., 2009; Zelenski et 
al., 1999). In short, CHO-K1-M19 cells were transfected with expression plasmids without 
MBTPS2 cDNA insert, wild-type or mutant MBTPS2 and a reported plasmid (pSRE-GL4.23) 
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in which the luciferase reporter gene is under transcriptional control of the human LDL 
receptor promotor (Sterol Regulatory Element, SRE) and a Renilla luciferase plasmid (pRL-
SV40) as a transfection control. Cells were cultured for 16h in Medium A and then switched 
to medium B. Firefly- and Renilla-luciferase activity were measured in a luminometer Auto 
Lumat LB953 (Berthold Technologies).
A 
B 
Figure 1: A. Dutch KFSD pedigree with twenty-one affected males and twelve carrier 
females. The family shows a clear X-linked pattern of inheritance, as proven by microsatellite 
marker analysis. Key recombinants (VII:12 and VI:29) determine the KFSD locus. B. KFSD 
family from the USA with five affected males and three carrier females, suggestive of 
X-linked inheritance.
5
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Immunohistochemistry
Skin biopsies of four carrier females and two affected males were obtained and stored 
at -80°C. Cryosections were cut at 0,05µm. Sections were fixed for 5’ in cold acetone and 
blocked for 20’ 0,12% H2O2 in demi water. After washing, sections were blocked in 1% NGS in 
Family/Proband Clinical Features MBTPS2 Genotype affected 
individuals
1 Dutch van Osch et al., 1992 c.[1523A>G]+[0] in males 
c.[1524A>G]+[=] in females
2 UK Herd and Benton et al., 1996 c.[1523A>G]+[0] in males
c.[1524A>G]+[=] in females
3 USA/ II:1 dry bumpy skin, facial erythema, 
lack of eyebrows, absence body 
hair, photophobia, cracked feet 
with hyperkeratosis, unspecified 
alopecia
 c.[1523A>G]+[0]
3 USA/III:1 dry skin, slightly thinned 
eyebrows with full eyelashes. 
sparse body hair
c.[1524A>G]+[=]
3 USA/IV:1 dry bumpy skin, lack of 
eyebrows, intact eyelashes, 
facial erythema, hyperkeratotic 
heels, severe photophobia, 
recurrent episodes of 
blepharitis, no hair loss on 
scalp, no scarring. Normal 
tooth development, Normal 
fingernails and cuticles.
c.[1523A>G]+[0]
3 USA/IV:2 dry bumpy skin, lack of 
eyebrows, lack of lower 
eyelashes, photophobia, facial 
erythema. Normal tooth 
development.
c.[1523A>G]+[0]
4-9 miscellaneous Diagnosed by clinician as ‘KFSD’ c.[=]+[0] in males
c.[=]+[=] in females
All sequence information is based on GenBank reference sequence NM_015884.2.
Nucleotide numbering follows HGVS recommendations and is based on a coding DNA reference 
sequence with nucleotide 1 corresponding to the A of the ATG translation initiation codon
 (www.hgvs.org/mutnomen). c.[=] denotes a normal wild type sequence, c.[0] indicates that no
paternal allele is present.
Table 1: Clinical features and MBTPS2 genotypes of affected individuals  and carrier females 
in 9 KFSD families.
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PBS and incubated with primary antibody overnight. Rabbit αMBTPS2 (Cell Signaling) (1:200 
dilution in 1%NGS in PBS) and Mouse αKeratin 10 as a positive control (NeoMarkers Inc 
Fremont, California, USA.) (1:50 dilution in 1% NGS in PBS) were used as primary antibodies. 
Secondary antibody (Invitrogen) incubation in a 1: 1000 dilution for 1 hour was followed by 
incubation with Streptavidine-HRP antibody (Southern Biotechnology Associates) for one 
hour (1:2000). DAP+ was used to develop staining and sections were counterstained using 
Haematoxylin.
Results
Descendants of an extended Dutch pedigree (Oosterwijk et al., 1992a; Oosterwijk et al., 
1992b; Oosterwijk et al., 1995; Oosterwijk et al., 1997) were subject to clinical and molecular 
analysis. First, to map the locus more accurately we analysed several members of each 
family using 1M SNP arrays. Analysis included the critical recombinants VII-12 and VI-29 
(Figure 1a Dutch Pedigree) which defined the borders of the KFSD locus. Disease segregation 
fully matched with published linkage data (Oosterwijk et al., 1997). In addition we were able 
to redefine the region more precisely to a ~ 2.9 Mb region with the proximal breakpoint 
between chrX:19390769G>C and rs5955562 and the distal breakpoint between rs6528097 
and rs4408025. Copy number variations (>5 consecutive SNPs) were not detected in this 
region or in any other genomic region, thereby excluding deletions or duplications as a 
possible genetic cause.
This refined region in Xp22.12-Xp22.11 contains 14 genes (Figure 2). High-Resolution 
Melting curve Analysis (HRMA) was used to screen these genes for sequence variants 
(Figure 2) in patients versus controls. Aberrant melt curves in one or more samples and 
thereby sequence variants were detected in 4 genes (Supp. Table S1). The variant in the 
MBTPS2 gene was considered as the most promising disease-causing variant since it 
occurred in all affected males and changes a highly conserved amino acid (p.Asn508Ser) 
The c.1523A>G variant showed full co-segregation with the disease in the Dutch family 
(Figure 3a). We analysed the MBTPS2 gene in two other KFSD families with an established 
X-linked inheritance, an UK family reported by Porteous et al (Herd and Benton, 1996; 
Porteous et al., 1998) and a USA family ascertained and investigated by Sybert (personal 
communication, unpublished data). In both families exactly the same c.1523A>G 
(p.Asn508Ser) variant was identified. The mutation was not detected by direct Sanger 
sequencing of 86 control chromosomes. Haplotype analysis around MBTPS2 made a close 
relationship between these families very unlikely, the maximum region of overlap being at 
most 50.1 Kb (Supp. Table S2).
5
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Skin biopsies and whole blood samples were obtained from 7 individuals from the 
Dutch family. RNA analysis showed the expected variant in the RNA (c.1523A>G). Since the 
variant lies in the last exon we analysed a potential effect on RNA splicing using 3’RACE, 
but no effect could be detected. Carrier females showed variability in the expression of the 
mutated and the wild type allele (Figure 3b). To exclude RNA stability differences, the allelic 
expression was correlated to the level of X-inactivation (Xi) using a methylation assay. 
Imbalances in allelic expression perfectly matched with skewed levels of X-inactivation and 
Figure 2: The KFSD locus. The KFSD linkage locus was redefined at Xp22.12-Xp22.11. High 
Resolution Melting curve Analysis (HRMA) identified MBTPS2 as a candidate gene in the 
Dutch KFSD family. The detected variant in MBTPS2 is indicated in red/gray. Previously 
identified mutations in IFAP syndrome are indicated in black. 
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more interestingly with the clinical phenotype. This was most striking in a mother (VI-19) 
and her two daughters (VII-10 and VII-11). The mother preferentially expresses the mutant 
allele and has a moderate phenotype. One of her two daughters without any symptoms of 
KSFD only expresses the wild-type allele, while the second, mildly to moderately affected 
daughter expresses both the disease-and wild-type allele (Table 2). 
Expression of MBTPS2 mRNA in fibroblasts was studied by qRT-PCR using RNA isolated 
from two male KFSD patients and five carrier females. MBTPS2 has two transcripts. The 
shorter transcript ranges from exon 1 up to exon 7, the full length transcript ranges 
from exon 1 up to exon 11. Using transcript specific primers, no significant differences in 
expression of the shorter or longer transcripts were found in fibroblast derived mRNA from 
carrier females (data not shown). Significantly higher expression of the full length MBTPS2 
transcript was found in carrier females (n=3) compared to controls (n=5), while there are 
no significant differences in expression in affected males (n=2) compared to controls (n=3) 
(Supp. Figure S1). 
The amino acid Asn508 is located in an evolutionary conserved hydrophobic 
transmembrane region of the protein. Online prediction tools (Polyphen and Sift) indicate 
that the Asn508Ser amino acid substitution, which shows the same polarity, is benign. To 
test the effect on protein function, in particular the effect on sterol responsiveness, we 
used the in vitro tests developed by Oeffner et al. (Oeffner et al., 2009). Wild-type MBTPS2 
stably transfected into CHO-M19 cells were compared to Asn508Ser MBTPS2 transfected 
cells and examined using complementation analysis. The number of cells transfected 
with the mutant MBTPS2 able to grow in absence of sterols was lower compared to cells 
transfected with wild-type MBTPS2 (Figure 4a). The luciferase reporter assay showed 
a clear reduction in sterol responsiveness in Asn508Ser MBTPS2 transfected CHO-M19 
cells, as compared to wild-type MBTPS2 transfected cells (Figure 4b). The effects on the 
normal function of MBTPS2 were in the same range as those found in IFAP syndrome cases 
(Oeffner et al., 2009).
To study whether a functional effect of the c.1523A>G MBTPS2 mutation could be 
detected; we have made an in vivo plasma lipid profile of an affected male. No abnormal lipid 
levels as compared to standard reference levels were detected (Cholesterol:  4.9  refs: 3.9-
7.3 mmol/L, Triglycerides:1.7   refs: 0.8-2.3 mmol/L, HDL: 0.95 refs: 0.9-1.41 mmol/L, LDL:  3.18 
refs: <3.0 mmol/L ). Ultracentrifuge lipid profiling did not show abnormalities in VLDL-
triglyceride value (0.95 mmol/L) or VLDL cholesterol/ratio (0.53).  Immunohistochemical 
staining of MBTPS2 in skin biopsies (Supp. Figure S2 and S3) was performed for four carrier 
females and two affected males and three controls. The results did not show any clear 
differences between patients and controls and indicate normal expression MBTPS2 levels 
for affected males, carrier females and controls.
5
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Figure 3: MBTPS2 mutation analysis in the Dutch KFSD family. a) Sanger sequencing of 
exon 11 in the MBTPS2 gene identified a c.1523A>G (p.Asn508Ser) in all affected males of 
the Dutch KFSD family, not present in WT controls. The variant co-segregates with the 
disease in this family; affected male (VI-20) c.1523A>G , carrier female (VI-27) c.1523AG and 
unaffected male (VII-6) c.1523G. b) RNA analysis in fibroblasts in the Dutch KFSD family. 
cDNA sequencing in fibroblasts confirmed the presence of the c.1523A>G variant in an 
affected male. Carrier females (VI-19, VII-11, VI-27, and VII-10) showed variability in the 
expression of the mutated and the wild type allele.
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Pedigree/sex (m/f) DNA *L RNA *F Phenotype Xi pattern
V-20/m G G full -
VII-10/f AG AG mild-moderate 50%-50%
VII-11/f AG A none 100%-0%
VI-19/f AG G moderate 100%-0%
VI-27/f AG a*G mild 100%-0%
Levels of X-inactivation in carrier females were compared to the differences in RNA expression in 
fibroblasts. a* = less expression of the wild type allele compared to other carrier females.
The clinical phenotype of carrier females matched with differences in X-inactivation.
Table 2. X-inactivation patterns in the Dutch KFSD family.
Discussion
Based on the criteria for designating a mutation as phenotype-modifying (Cotton and 
Scriver, 1998), the results from the current study provide enough evidence to establish 
that the c.1523A>G variant in MBTPS2 cause X-linked KFSD. Screening of all genes in the 
candidate disease gene region, identified only one potential disease-causing variant, a 
missense change c.1523A>G (p.Asn508Ser) in MBTPS2. The variant was identified in two 
other unrelated X-linked KFSD families and perfectly co-segregates with the disease in 
all three families. The c.1523A>G variant was not detected by direct Sanger sequencing 
of 86 control chromosomes, it is not listed in the results of pilot study 1 of the 1000 
genomes (www.1000genomes.org, checked October 2009) nor has it been reported in 
dbSNP. To facilitate future studies, in particular clinical diagnostic studies of skin defects, 
we established a gene variant database for MBTPS2 (http://www.LOVD.nl/MBTPS2) 
following HGVS reccomendations (www.HGVS.org). The database currently contains 30 
different variants of which 9 have been associated with pathogenicity (including KFSD 
and IFAP syndrome). The c.1523A>G variant affects a well conserved amino acid in a highly 
conserved gene. Differences in allelic expression of MBTPS2 could be correlated to the 
clinical phenotype of carrier females. In fibroblasts and skin biopsies, qRT-PCR data and 
5
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Figure 4: Complementation assay and luciferase reporter assay. Functional studies of the 
c.1523A>G (p.Asn508Ser) variant using an in vitro assay testing sterol responsiveness. A. 
Complementation assay: Growth of stably transfected CHO-K1-M19 cells (lacking hamster 
MBTPS2) was measured in cholesterol rich medium (blue) and cholesterol deficient medium 
(red). The proportion of cells capable of growth is documented as framed photographs of 
the cultures and, graphically in bars by counts of growing stably transfected cells. Colours 
indicate absence (red) or presence (blue) of sterols. B. Luciferase reporter assay: luciferase 
activity functions as an indirect measure of the ability of MBTPS2 mutants to restore sterol-
regulated transcriptional activity in transfected CHO-K1-M19 cells. Cells transfected with 
the c.1523A>G (p.Asn508Ser) variant are less able to restore sterol-regulated transcription 
compared to wild type when transferred from a cholesterol rich (blue bars) to a cholesterol 
deficient medium (red bars).
A 
B 
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immunohistochemical staining of MBTPS2 show normal expression levels in affected 
males. Western blot analysis and immunofluorescence experiments in fibroblasts (Supp. 
Figure S4) are in agreement with these findings and show normal expression levels and 
protein localization. Functional analysis of the mutant gene however, showed significant 
reduction in sterol responsiveness, indicating loss of proteolytic activity of the MBTPS2 
protein. 
In total, we have studied nine families with a clinical diagnosis of KFSD and identified 
the same mutation in the MBTPS2 gene in 26 cases (three families). In six small families, 
lacking a clear X-linked mode of inheritance, the molecular basis of the disease is as yet 
unidentified. Although detailed clinical and histological data of these cases/families are not 
available, it is possible that they were misdiagnosed due to the similarity of KFSD to several 
other dermatological entities. Another possibility is that KFSD is a locus heterogeneous 
disorder and that there are other causative gene mutations. A critical review of these and 
other mutation negative cases may lead to other diagnosis or other loci. MBTPS2 mutations 
have recently been identified in IFAP patients (Oeffner et al., 2009). In IFAP syndrome, the 
clinical severity varies to a large degree, while in KFSD most affected individuals have a 
relatively mild phenotype. This could be due to a genotype-phenotype effect, depending 
on the position of the mutation in MBTPS2. Elucidation of the MBTPS2 crystallography and 
its biochemical function is necessary to make clear correlations.
Until now, the diagnosis of KFSD has been based on clinical findings and its differential 
diagnosis has long been under debate (Oranje et al., 1994). Siemens described clinical 
findings of non-inflammatory, flesh-colored spinous ‘thorns’ leaving follicular scars 
where the skin subsequently becomes atrophic. It affects hair growth on the scalp, lateral 
eyebrows and eyelashes accompanied with the onset of alopecia during early adolescence. 
Patients can also have punctate defects on the cornea, palmoplantar hyperkeratosis 
with normal nails. IFAP (Macleod and Collins, 1908) was described coincidently also as 
‘Ichthyosis Follicularis’ with noninflammatory spiny excrescences, hyperkeratosis and 
noncicatricial alopecia and photophobia. IFAP syndrome shares several features with 
KFSD, but differentiation is believed to be made on a congenital nonscarring nature of 
the alopecia. Until now, the small number of published cases, the phenotypic variability 
in both IFAP and KFSD with clinical overlap and the absence of a molecular cause made it 
impossible to determine if these syndromes were actual variations of the same entity or 
truly independent disorders. Much confusion has been generated in literature because of 
erroneous reporting of cases with lack of clinical details and reports of autosomal modes 
of inheritance. For instance the case report in which KFSD-like signs were present in a boy 
due to an unbalanced X-chromosomal duplication led to the notion that SAT1 (Gimelli et 
al., 2002) was the plausible gene for KFSD. But putriscine levels and SSAT activity were 
5
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normal in the Dutch KFSD family, which makes SSAT overexpression a very unlikely cause 
for isolated (i.e. nonsyndromic) KFSD.
The pathogenesis of KFSD is largely unknown. An epidermal defect is highly likely since 
cells from the skin, hair and the cornea are involved. The epidermis has a protective function 
as the outer layer of the skin. The cornification of the skin’s surface is compensated for by 
renewal of the epidermis, controlled by proliferation and differentiation of keratinocytes. 
As they move towards the upper layers, the keratinocytes become flatter and produce a 
mixture of lipids, cholesterol, free saturated fatty acids and ceramides into the intercellular 
spaces and thereby contributes to making the epidermis an effective barrier. Decreased 
cholesterol content in the stratum corneum could be attributable to the barrier function 
abnormality (Elias et al., 2008; Williams and Elias, 1981).
Several human genodermatoses have been described with mutations of genes involved 
in various aspects of lipid metabolism (Elias et al., 2008), such as Ichthyosis prematurity 
syndrome (Klar et al., 2009) , lamellar ichthyosis (Lefevre et al., 2003) , harlequin ichthyosis 
(Kelsell et al., 2005), Conradi-Hünermann-Happle syndrome, (Braverman et al., 1999), CHILD 
syndrome (Konig et al., 2000) and X-linked Ichthyosis (Basler et al., 1992), to which MBTPS2 
is now added, causing both IFAP and KFSD. 
MBTPS2 functions as a metalloprotease, required for cleavage of sterol regulatory 
element-binding proteins (SREBPs). Within a feedback mechanism the active domain of 
SREBPs is cleaved by S2P and transported to the nucleus to function as a transcription 
factor of several targets genes, amongst which the LDL receptor gene. For both men and 
women, residual protease activity of MBTPS2 will most likely determine the severity of 
disease. However, measurements of proteolytic activity of MBTPS2 are not straightforward. 
Changes in proteolytic activity may have their effect elsewhere in the sterol regulated 
pathway which may result in general lipid abnormalities. Our study of serum lipids in one 
KFSD patient does support this hypothesis but rigourous investigation in a case-control 
study is needed given all the factors which affect this pathway.
When the X-activation is skewed towards expression of the mutated allele, an X-linked 
recessive disorder may affect female carriers, and the residual enzyme activity of MBTPS2 
determines their phenotype. Therefore, skewed X-inactivation has been postulated as 
an explanation for heterogeneity in KFSD carrier females given the fact that the number 
of symptomatic carrier females seems larger then expected on the basis of random 
lyonisation. We have shown that differences in Xi-pattern expressions indeed may be 
correlated to the severity of KFSD symptoms in females. It is remarkable that while in 
some X-linked recessive diseases (Duchenne Muscular Dystrophy; MIM# 310200, Red-
Green Colour blindness MIM#s 303800, 303900) females rarely show symptoms, in 
others, like KFSD and OTC (MIM# 311250), this is frequent. Interestingly, Siemens used KFSD 
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as the first disorder in which he recognised X-linked intermediate inheritance (Siemens 
HW, 1926). However, the distinction between different modes of X-linked inheritance is 
a mere quantative aspect of several underlying mechanisms, one of them being skewed 
Lyonisation. The standard concepts of dominance or recessiveness do often not apply to 
X-linked diseases (Dobyns et al., 2004) and KFSD should therefore also be simply described 
as X-linked inheritance.
Conclusion
This study supports a new approach towards patients who are referred to a medical clinic 
with KFSD or IFAP. First, critical assessment of all the symptoms together with a thorough 
family history is important for establishing a differential diagnosis. In patients that show 
the triad of follicular ichthyosis (follicular hyperkeratosis), total or subtotal atrichia of scalp, 
eyebrows or eyelashes and photophobia at a young age, IFAP/KFSD should be considered. 
When X-linked inheritance cannot be excluded, mutation analysis for MBTPS2 is warranted 
and will be crucial to confirm this diagnosis. To prevent more confusion in the nosology 
of this disorder, we propose a new name should be chosen for KFSD/IFAP syndrome and 
suggest this name will be used when a MBTPS2 mutation has been detected. If MBTPS2 
mutation analysis is negative, the extension ‘-like syndrome’ should be added. This new 
nomenclature should be introduced when DNA analysis has been performed in enough 
KFSD/IFAP and KFSD/IFAP-like families and all clinical features have been reviewed.
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Supplementary information
Figure S1: MBTPS2 levels in KFSD males compared to control males.
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Figure S2: Skin biopsies stained with αMBTPS2 (brown) with (A) and without Hematoxylin 
(B). 40x and 20x magnification. 
Epi=epidermis, SC=stratum corneum, SG=stratum granulosum, SS=stratum spinulosum, 
SB=stratum basale. 
Figure S3: Skin biopsy stained with 
αKeratin-10 (A) and only counterstaining 
with Hematoxylin (B). 20x and 10x 
magnification. Keratin-10 is expressed 
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Figure S4: Cellular localisation of MBTPS2 in fibroblasts. There is no difference between a 
control male (a) and a male KFSD patient VII-12 (b). MBTPS2 (green fluorescence) is found 
both in the cytoplasm and nucleus. Nuclei are stained in blue with DAPI. Red is a control 
staining of β-actin.







All sequence information is based on GenBank reference sequences.
Nucleotide numbering follows HGVS recommendations and is based on a 
coding DNA reference sequence with nucleotide 1 corresponding to the A 









rs5951636: [T] T T T 0.750
rs16981675:[T] T T T 1.00
rs5951640:[C] C C C 0.983
rs4446856:[T] T T T 0.992
rs6653655:[C] C C C 1.00
Genotype analysis around the c.1523A>G variant in MBTPS2 of affected KFSD males from three 
families (UK, USA, Dutch) showed a common haplotype between SNP rs5951636 and rs6653655 
with a maximum region of overlap of 50.1 Kb. Allele frequencies of SNPs in this interval indicate 
a close relationship of these families is not plausible. Polymorphism nomenclature follows 
dbSNP identifiers and HGVS recommendations (www.hgvs.org/mutnomen) with [..] indicating
 the major allele.
Table S1:. Variants detected in the Dutch KFSD family using High Resolution Melting curve 
Analysis.
Table S2: Haplotype comparison around MBTPS2.
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Summary
Terminal Osseous Dysplasia (TOD) is an X-linked dominant male-lethal disease characterized 
by skeletal dysplasia of the limbs, pigmentary defects of the skin and recurrent digital 
fibroma with onset in female infancy. After performing X-exome capture and sequencing 
we identified a mutation at the last nucleotide of exon 31 of the FLNA gene as the most 
likely cause of the disease. The variant c.5217G>A, was found in 6 unrelated cases (three 
families and three sporadic cases) and not in 400 control X chromosomes, nor pilot data 
from the 1000 Genomes Project or the FLNA gene variant database. In the families the 
variant segregated with the disease and it was transmitted four times from a mildly 
affected mother to a more seriously affected daughter. We show that, due to non-random 
X-inactivation, the mutant allele was not expressed in patient fibroblasts. RNA expression 
of the mutant allele was only detected in cultured fibroma cells obtained from 15-year old 
surgically removed material. The variant activates a cryptic splice site, removing the last 
48 nucleotides from exon 31. At the protein level this results in a loss of 16 amino acids 
(p.Val1724_Thr1739del), predicted to remove a sequence at the surface of filamin repeat 
15. Our data show that TOD is caused by this single recurrent mutation in the FLNA gene.
hoofdstuk 6a.indd   132 10-12-12   8:48
133
6
Terminal Osseous Dysplasia (OMIM 300244) is a rare condition, characterized by terminal 
skeletal dysplasia, pigmentary defects of the skin, and recurrent digital fibromata during 
infancy. It has been described as a male-lethal X-linked dominant disease in the previously 
reported families and cases1. Linkage studies mapped the mutation to Xq27.3-q282. 
However, no disease-causing gene was discovered yet.
In the present study, we examined TOD in three families and three sporadic cases 
(patients 1, 2 and 3 described by Horii3, Drut4 and Breuning5). The Dutch (Figure 1A, family 
1) and Italian families (Figure 1A, family 2) have been described before (Breuning5 and 
Baroncini6). The third family (Figure 1A, family 3) has not been reported before, it is non-
consanguineous and of Israeli-Arab origin. All patients, a mother and her two daughters 
have normal cognitive development. The mother (3I:2) suffers from chronic mild obstructive 
lung disease and vitamin B12 deficiency. Since her childhood she had multiple minor 
surgeries to remove small skin lesions from her hands and legs. On clinical examination at 
age 25 years her head circumference was 54 cm (25-50%), height 170 cm (75-90%), arm span 
171 cm. Her right hand showed brachydactyly of digit III-V, a short fingernail on digitus IV 
and lateral deviation of the 5th digit. On her left hand there was lateral deviation of the 
4th digit with a small lesion on the lateral aspect of the distal phalanx and clinodactyly of 
the 5th digit (Figure 1B). Her right foot showed a short and highly implanted 4th digit. There 
was bilateral widening of the distal portion of the 2nd-5th digit. She had no gingival extra 
frenulum and no pterygium. A skeletal X-ray survey revealed unilateral flattening of her 
vertebral bodies at L1-L3, secondary right scoliosis and wedging of her L1 vertebral body. 
Her daughter (3II:4) underwent surgery at 2 months of age to remove small skin lesions 
from her hands, feet and gingiva. On clinical examination at age three she had a head 
circumference of 48 cm (25-50%), a height of 85 cm (<3%) and a of weight 11.1 kg (<3%). She 
showed hypertelorism - interpupillary distance of 5.4cm (>97%), a right epicanthal fold, 
a normal palate, an upper and lower accessory frenulum (Figure 1C), a short neck and a 
short thorax. Despite earlier surgery, she had bilateral skin lesions on her 2nd and 5th digits 
and bilateral clinodactyly of the 5th digit (Figure 1D). Her feet showed a lesion in her 3rd 
toes and thickening of the nail of the 5th toes bilaterally. A skeletal X-ray survey revealed 
bilateral lytic lesions in the proximal humerus, the proximal femur, and multiple soft tissue 
lesions in her feet and hands. The youngest daughter (3II:5) was born with multiple lesions 
on her hands and feet including bilateral camptodactyly of the 3rd digit, and bilateral 
overriding of the 4th toe. On the echocardiogram she had persistent foramen ovale at 
birth. On clinical examination at age six months her head circumference was 42 cm (25-
50%), height 58.8 cm (<3%) and weight 5.1 kg (<3%). She has mild hypertelorism, three 
brownish pigmented spots of different size (3 mm to 1.5 cm) in her right temporal groove, 
mild retrognathia, a right upper accessory frenulum and a cleft palate, a short neck and a 
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short thorax. She has a bilateral axillary pterygium (Figure 1E), which is more severe on the 
right side. Bilaterally, there is limited extension of her elbows with normal supination and 
pronation of her hands. In her right hand (Figure 1F) she had multiple skin lesions on her 
2nd - 5th digits, clinodactyly and lateral deviation of her 2nd and 3rd digits and a narrow 
5th digit with an absent distal crease. Her left hand showed skin lesions on her 2nd - 4th 
digits. Her 2nd digit was narrow and laterally deviated. There was camptodactyly of the 
3rd-5th digits, brachydactyly and clinodactyly of the 5th digit and absence of a distal 
crease. In her feet she had bilateral plantar pits. The right foot has distal broadening of 
2nd-5th toe, brachydactyly of the 2nd and 3rd toe accompanied by syndactyly. There was 
overriding of the 3rd and 4th toe. On her left foot the 2nd-5th toes were distally broad. 
She had a overlapping of the 2nd and 4th toes over her 3rd toe, brachydactyly of the 3rd 
Figure 1: The pedigrees and the phenotype of family 3. (A) The pedigrees investigated in 
this study, in family 3 X inactivation patterns show the silencing of the X chromosome 
which carries the mutant allele. (B) shows the hands of 3I:2. (C) Multiple frenula of 3II:4. (D) 
The right hands of 3II:4. She has clinodactyly and digital fibroma. (E) shows the right upper 
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toe that was a high implanted. A skeletal X-ray survey revealed bilateral lytic lesions of the 
proximal humerus, lytic lesions of the left proximal femur, and multiple soft tissue lesions. 
She had underdeveloped tarsal bones in her feet. The phenotypes from different patients 
are summarized in Table 1. 
DNA of patients and family members were extracted from peripheral blood (family 
1, 2, 3), buccal cells (patient 1) or paraffin embedded tissue (patient 2, 3). Two probands 
(1II:4, 2III:5) of the Dutch and the Italian families were tested using the X-exome target 
enrichment methodology (SureSelect, Agilent) and next generation sequencing (Illumina 
Genome Analyzer II). The methods used for sequence capture, enrichment and elution 
followed instructions and protocols provided by the manufacturers (SureSelect, Agilent) 
with a little modification. In brief, 500ng of DNA was fragmented (Bioruptor, Diagenode) 
according to manufacturer’s instructions to yield fragments from 200-300 bp. Paired-
end adaptor oligonucleotides from Illumina were added to both ends. The DNA-adaptor 
ligated fragments were then hybridized to 250ng of SureSelect X-chromosome Oligo 
capture library (SureSelect, Agilent) for 14 hours. After Hybridization, washing and elution, 
the elute was amplified to create sufficient DNA template for downstream applications. 
The eluted-enriched DNA fragments were sequenced using the Illumina technology 
platform. We prepared the paired–end flow-cell on the supplied cluster station following 
the instructions of the manufacturer.
The reads were aligned to the reference human genome (hg 18, NCBI Build 36.2) by 
Bowtie7 (Supplementary Table S1). Substitution variant calling was performed by searching 
for positions where a variant nucleotide was present in more than 30% of the reads. 
After removing substitutions present with high frequency in dbSNP, the variants located 
in the previously identified TOD linkage interval, Xq27.3-q28, were listed in Table 2. From 
these variants, c.5217G>A, the only variant shared by the two patients, in the FLNA gene 
were selected for further study because; (i) c.5217G>A, the last nucleotide of exon 31, 
was predicted to affect splicing by Human Splicing Finder8. The score of splicing donor 
site dropped from 91.2 to 80.63, indicating the wild type site may not function as usual, 
(ii) mutations in FLNA have been reported to be involved in diseases showing a partial 
phenotypic overlap with TOD9. 
Sanger sequencing results confirmed the presence of c.5217G>A (Figure 2A) and 
c.5850T>C (Figure 2B) in all affected cases (1II:4, 1III:6) in family 1 as well as c.5686+84A>G 
found in an intron, but not in an unaffected individual (1I:2). Further evidence came from 
the analysis of the Italian family where affected cases (2II:4, 2III:5) carry exactly the same 
variant; c.5217G>A, here together with another exonic variant c.5814C>T. Unfortunately, we 
did not have access to material from both parents and therefore we could not determine 
whether the mutations occurred de novo. 
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1II:4 1III:6 2II:4 2III:5 3I:2 3II:4 3 II:5 Patient 1 Patient 2 Patient 3







Age of onset 1 mo 3 mo 7 mo 2 mo birth 3 mo 4 mo
Pigmentary skin anomalies
Face + + - + + + + +
Scalp - - + -
Fibromatosis
Digital fibromas + + - + + + + + + +
Limbs and skeletal system
Synadactyly - - - + + + - - -
Brachydactyly + - + + + +
Clinodactyly - + + + +
Camptodactyly + +
Metacarpal disorganization + + - + + + +
Metatarsal disorganization + + - + + + + +
Limb long bones anomalies - + - + - + + + + +
Articular abnormalities + + - + + + +
Facial and mouth Features
Cleft palate - - - - - + - -
 Upslanting palpebral 
fissures
- - + +
Hypertelorism/Telecanthus + - - + + +
Epicanthic folds - - + + +
Coloboma of Iris       - + - - - - -
Flat/depressed nasal tip - + - - + -
Thick lips/Prominent + - +
Lower lip
Papillomata             - - - -
Multiple frenula + + -
Preauricular pits and tags + -
Table 1. Clinical features of the patients studied in this report.
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NM_002025.2:c.1653A>G AFF2 Silent p.(=) - +
NM_001183.4:c.*461A>C ATP6AP1 3’ UTR p.(=) - +
NM_001009932.1:c.364G>A DNASE1L1 Silent p.(=) + -
NM_001110556.1:c.5217G>A FLNA Silent p.(=) + +
NM_001110556.1:c.5814C>T FLNA Silent p.(=) - +
rs2070825, high frequency 
in a group of multiple 
population
NM_001110556.1:c.5850T>C FLNA Silent p.(=) + - Doesn’t segragate with 
phenotype
NM_004961.3:c.186G>A GABRE Silent p.(=) + -
NM_005342.2:c.166G>C HMGB3 Missense p.(Glu56Gln) - +
NM_005367.4:c.888A>G MAGEA12 Silent p.(=) - +
NM_005362.3:c.455G>T MAGEA6 Missense p.(Ser152Ile) + - Repetitive region
NM_005365.4:c.92C>A MAGEA9 missense p.(Pro31His) + - Repetitive region
NM_001170944.1:c.468C>T PNMA6B Silent p.(=) + -
NM_005629.3:c.324A>G SLC6A8 Silent p.(=) - +
NM_032539.2:c.1002T>C SLITRK2 Silent p.(=) - +
NM_032539.2:c.309G>A SLITRK2 Silent p.(=) - +
NM_001009615.1:c.240C>A SPANXN2 Silent p.(=) + -
NM_014370.2:c.1014G>A SRPK3 Silent p.(=) + -
NM_006280.1:c.430G>A SSR4 Missense p.(Gly144Arg) + -
All of the HGVS numbers were generated with the use of the longest isoforms if multiple transcripts existed.
Table 2: List of all exonic variants with low frequency in the European population in Xq27.3-
Xq28.
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Notably, families 1 and 2 had two distinct variants adjacent to the c.5217G>A mutation, 
making a close and common ancestor highly unlikely. Finally, upon analysis of a third TOD 
family and three unrelated sporadic cases, we identified exactly the same c.5217G>A variant 
again in all patients, but not unaffected family members (1I:2, 3I:1 and 3II:3).
Variant c.5217G>A affects the last nucleotide of exon 31 of the FLNA gene (Figure 2C). At 
protein level, it is not predicted to change the encoded amino acid but as the last nucleotide 
of an exon, it may affect splicing10-12. RNA was isolated from cultured fibroblasts of arm 
skin from 1III:6, removed during a recent orthopaedic procedure under general anaesthesia 
with informed consent. Cells were cultured in standard medium for human fibroblasts 
(DMEM with 10%FBS, 1%Pen/Strep, 1%glucose, 1%glutamax) with 5%CO2 in 37°C. RNA was 
extracted by RNeasy Mini Kit (QIAGEN). cDNA was synthesized from 500ng of total RNA by 
RevertAid RNaseH- M-MuLV reverse transcriptase in a total volume of 20 µL according to 
the protocol provided by the supplier (MBI-Fermentas). Target regions were amplified by RT-
PCR using the primers listed in Supplementary data S2. The products were evaluated using 
Bioanalyzer 2100 DNA chip 1000 (Agilent) according to the manufacturers instruction. RNA 
from patient fibroblasts showed only normal transcripts, both of transcripts 1 (NM_01456) 
and 2 (NM_001110556), differing by insertion of the 24 bp exon 30 in transcript 2. Although 
transcript 1 has been reported as the predominant transcript in controls13, we detected 
about equal expression levels in controls (Figure 3B lane 2-4, 8) and higher expression of 
transcript 2 in patient fibroblasts (Figure 3B lane 1). Both bands were isolated from the 
agarose gel by Qiaquick gel extraction kit (QIAGEN) and analysed by Sanger sequencing. 
Interestingly, we detected no expression of the mutant allele. This could be due to 
nonsense mediated decay (NMD)14 and/or skewed X chromosome inactivation (XCI). To test 
the first possibility, the fibroblasts were treated with cycloheximide15 for 4.5 hours followed 
by RNA analysis using the same procedures as for RNA from untreated cells. The mutant 
allele was still absent in RNA from cycloheximide treated cells. X-inactivation was analysed 
using the Androgen Receptor (AR) Assay16. The assay showed random X-inactivation in 1I:2 
versus 100% X-inactivation of the mutant chromosome in patient 1II:4 (patient 1III:6 was 
uninformative), indicating that the mutant allele was inactivated. 
Fifteen years ago, at the age of 1 year, fibroma tissue was surgically removed and stored 
in liquid nitrogen from the 5th digits of both hands and the 5th toe of the left foot of 
patient 1III:6. We cultured these cells, and analysed RNA. In the fibroma cells we observed 2 
sets of 2 bands (Figure 3B lane 5-7), indicating altered splicing. One set had the same length 
as observed in normal fibroblasts (Figure 3A transcript 1 and 2), the other set was shorter 
(Figure 3A transcript 3 and 4, faint from RNA of tumor in left fifth finger and toe, Figure 3B 
lane 6 and 7 respectively). Note that the fibroma always contains a mixture of tumor and 
normal stroma cells. 
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Sequence analysis showed a deletion removing the last 48 nucleotides of exon 31 (Figure 
3C), resulting in a deletion of 16 amino acids. 
To facilitate clinical diagnostics of FLNA gene mutations we have established a web-based 
FLNA gene variant database using the LOVD software17. In this publicly available database 
we have collected all variants reported in literature thus far (83 in total, see  FLNA mutation 
database), incl. the new variants described here. The c.5217G>A variant detected in TOD 
patients has not been described before; it is neither listed in dbSNP nor in the pilot study 
1 of the 1000 Genomes Project. Finally, >400 chromosomes have been sequenced and the 
mutant allele was not found (data not shown). 
Figure 2: Genomic Structure and mutation analysis of FLNA. (A) c.5217G>A was confirmed by 
Sanger sequencing in all the patients. The unaffected family members and controls carry 
the homozygous normal allele. (B) shows the sequence of c.5850T>C in family 1. (C) FLNA is 
located in Xq28, the target region of linkage analysis. C.5217G>A alters the last nucleotide 
of exon 31 of FLNA.
C 
A B 
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Mutations in FLNA have been reported to cause a wide range of developmental 
malformations in brain, bone, limbs, heart18 and other organs19 in human9, including 
periventricular heterotopia (PVNH) (OMIM 300049)20-24 and OPD spectrum disorders25 
which include otopalatodigital syndrome type 1 (OMIM 311300)26-28 and 2 (OMIM 304120)26; 
29, frontometaphyseal dysplasia (OMIM 305620) 26; 30-31 and Melnick-Needles syndrome 
(OMIM 309350)26-27. Although each of OPD spectrum disorders are characterized by specific 
clinical symptoms, there clearly is a clinical overlap with TOD including a generalized bone 
dysplasia including craniofacial anomalies, digits and long bones9; 32. Interestingly, the most 
conspicuous symptoms of TOD patients are skeletal dysplasia of the limbs and recurrent 
digital fibroma, suggesting a significant role of the FLNA mutation in the TOD phenotype. 
The FLNA gene encodes a cytoskeletal protein, filamin A, which crosslinks actin 
filaments into an orthogonal network and links these to the cell membrane. Within the 
cytoskeleton filamin A also mediates functions relating to cell signaling, transcription 
and development33. Filamin A consists of two calponin homology sequences (CH1 and 
CH2) at the N-terminal and connects with 24 immunoglobin like filamin repeats, divided 
by 2 hinges between repeat 15 and 16, repeat 23 and 24. To check the stability of filamin 
A in patient cells, protein was extracted from both fibroblast and fibroma cells. Western 
blot was performed using mouse anti-human filamin A monoclonal antibody, MAB1680, 
from MILLIPORE. No difference was observed on molecular weight or quantity. Likely the 
difference of 18 amino acids was too small to distinguish by western blot. The c.5217G>A 
mutation is located in a highly conserved position at the DNA level across a wide range of 
vertebrate and invertebrate species except rodent, found in all ten affected patients from 
six different unrelated families. In addition, the mutation introduced abnormal splicing in 
fibroma cells. At protein level, c.5217G>A encodes the second last amino acid of repeat 15, 
which is immediately adjacent to hinge 1. Recent studies demonstrated repeat 9-15 contain 
an F-actin binding domain necessary for high avidity F-actin binding34. Hinge 1 plays an 
important part in maintaining the viscoelastic properties of actin networks35. Moreover, 
this region interacts with many binding partners like TRAF1, TRAF236, CaR extracellular Ca2+ 
receptor37, and FAP5238. As no crystal structure has yet been described for this region, the 
crystal structure of repeat 15 in filamin B(PDB file 2dmb), that shows the highest identity 
(58%) with this region of interest, was used as a template to build a 3D model (Figure 
3D). The model was built using the WHAT IF &Yasara twinset39. Repeat 15 consists of 2 
beta-sheets. The in-frame deletion causes the removal of the top of a beta-strand in the 
middle of one beta-sheet, and of two beta-strands at the side of that sheet (grey part 
of Figure 3D). These residues are likely to form some kind of beta-strand like structure, 
and substantially alter the structure of the highly conserved tertiary structure of filamin 
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repeat 15. Furthermore, this structure will affect the residues following the beta-sheet and 
linking repeat 15 to hinge1. Although there is no way to predict what will happen to those 
linking residues, we  believe it will affect the overall conformation of the protein, and likely 
influence the interaction between filamin A and other molecules. 
Figure 3: Detection of alternative splicing and 3D protein model. (A) Diagram of four FLNA 
transcripts in fibroma cells: transcript 1 and 2, which carry the 48bp deletion at the end 
of exon 31, as well as the normal transcripts 3 and 4. (B) RT-PCR result from Agilent 2100 
Bioanalyzer. Lane 1 is the product of the fibroblasts of 1III:6, which has a predominant 
longer isoform. Lane 2-4 and 8 are four control human fibroblasts. Lanes 5-7 show RT-PCR 
products that  were obtained from fibroma cells of 1III:6, the normal bands from two FLNA 
isoforms, and two extra shorter bands, which are faint in lane 6 (left fifth finger)and lane 
7 (fifth toe of the left foot) , whereas lane 5 (right fifth finger )shows four dark bands. 
(C) Sanger sequencing results of c.5858T>C and c.5217G>A in fibroblast and fibroma cells 
of 1III:6. (D) The 3D model of FLNA domain 15. The deleted 16 amino acids are marked in 
gray. Beta-strands are marked in red. Green represents a turn. Yellow indicates a 3/10 helix. 
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The precise mechanism of TOD remains unclear. However, like other X-linked diseases, X 
chromosome inactivation (XCI) might be a key component of how the disease develops. 
The developmental role of FLNA is borne out by the presence of the skeletal and skin 
malformations at birth. Multiple fibroma on digits start occurring in the first years. Fibromas 
spontaneously stop by the age of five. Skewed XCI is known to vary in different tissues and 
to correlate with age under the pressure of secondary selection40. Several mechanisms may 
contribute to the skewing, including stochastic effects, a selective growth advantage of cell 
that carries either the mutated or the normal allele (secondary cell selection) and genetic 
processes yielding preferential inactivation of specific alleles. Primarily the X inactivation 
choice is random, but during cell proliferation either in all cells or in a tissue specific 
manner, cells that carry an activate mutated allele may have a significant disadvantage, 
are gradually lost or selected against and are thus less represented in the adult female41. 
Disorders caused by defects in FLNA gene often show skewed XCI pattern26, suggesting 
that cells need normal filamin to survive. Several studies in TOD families, showed patients 
had skewed X-inactivation, while unaffected individuals had random inactivation1; 6. We 
examined the X-inactivation pattern in family 1 (1I:2, 1II:4 and 1III:6) and 3 (3I:2, 3II:3, 3II:4 and 
3II:5, Figure 1A) by AR assay. Apart from the uninformative 1III:6, all the patients, 1II:4, 3I:2, 
3II:4 and 3II:5 showed extremely skewed X-inactivation (0/100%), while the normal family 
member 1I:2 showed random X-inactivation (30/70%) together with 3II:3 (50/50%). Since 
there was no mutant allele detectable in the RNA of normal fibroblast, we deduced 1III:6 
also had 100% skewed XCI with the preferential inactivation of the mutant allele. Baroncini 
tested the XCI of 2II:4 and 2III:5, and both showed 100% skewing6. 2II:4 was interpreted by 
the authors as unaffected. However, we assume 2II:4 is a carrier of TOD, as she only has mild 
manifestations (multiple frenula in the mouth). She probably has skewed X-inactivation at 
a very early stage. Overall as well as local X inactivation patterns may influence the severity 
of the phenotype of carrier females and are also associated with selective female survival 
in male lethal X-linked dominant disorders.
Taken together, these data suggest that TOD unique variant c.5217G>A (p.Val1724_
Thr1739del) in the FLNA gene. The variant is not found in other databases, has not been 
seen in other patients with pathogenic FLNA variants, segregates with the disease, and 
locates in Xq28 where the potential mutated gene causing this disorder was mapped 
previously. The mutation was found in six unrelated families. It will affect splicing, and 
causes a deletion of 16 amino acids in protein level. The missing region in the filamin A 
protein is hypothesized to affect or prevent the interaction of filamin A with other proteins.
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Web Resource
Accession numbers and URLs for data presented herein are as follows:
FLNA gene variant database, http://www.lovd.nl/FLNA
SureSelect manual, http://www.genomics.agilent.com/files/Manual/G3360-90020_
SureSelect_Indexing_1.0.pdf
UCSC Genome Browser, http://genome.ucsc.edu/
Online Mendelian Inheritance in Man(OMIM), http://www.ncbi.nlm.nih.gov/entrez/Omim/
RefSeq, http://www.ncbi.nlm.nih.gov/Refseq/, for human FLNA[accession number 
NM_001110556.1], for human chromosome X [accesssion number NC_000023.9]
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/
1000 genome project, http://www.1000genomes.org/page.php
Bowtie, http://bowtie-bio.sourceforge.net/index.shtml
Human Splicing Finder, http://www.umd.be/HSF
YASARA, http://www.yasara.org/
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Total reads 36,010,190 28,960,586
Read F 18,005,095 14,480,293
Read R 18,005,095 14,480,293
Aligned reads 33,054,043 18.948,705
Aligned in pair 30,018,244 11,012,526
Read length 51 51
location Primer sequences (5’-3’) Size (bp)











F:CCTGGGCGTAGGTGTACTGT 416 (short isoform)
440 (long isoform)R:CATCAAGTACGGTGGTGACG
Exon 35-37 DNA, RNA
F:ACATACGCATGGAGTCGTCA 577 (DNA)
294 (RNA)R:TCAACTGTGGCCATGTCACT
Table S1: The overview of the data generated by GAII.
Table S2: F LNA primer list.




Figure S3: The 2100 bioanalyzer traces of RT-PCR on c.5217G>A from lane 1 to 8. The peak
around 15 bp is the lower ladder and the signal round 1500 bp is the upper ladder.
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Abstract
Aarskog-Scott syndrome (ASS) is a rare disorder with characteristic facial, skeletal, and 
genital abnormalities. Mutations in the FGD1 gene (Xp11.21) are responsible for ASS. 
However, mutation detection rates are low. Here, we report a family with ASS where 
conventional Sanger sequencing failed to detect a pathogenic change in FGD1. To 
identify the causative gene we performed whole-exome sequencing in two patients. An 
initial analysis did not reveal a likely candidate gene. After relaxing our filtering criteria, 
accepting larger intronic segments, we unexpectedly identified a branch point (BP) variant 
in FGD1. Analysis of patient-derived RNA showed complete skipping of exon 13, leading to 
premature translation termination. The BP variant detected is one of very few reported so 
far proven to affect splicing. Our results show that, besides digging deeper to reveal non-
obvious variants, isolation and analysis of RNA provides a valuable but under-appreciated 
tool to resolve cases with unknown genetic defects.
Key words
FGD1 protein, Exome sequencing, Aarskog syndrome, RNA splice sites, Branch point 
mutations 




The large scale sequencing of thousands of exomes and genomes from disease cohorts 
using next generation sequencing (NGS) is expected to uncover causal gene variants 
in many thus far unresolved cases. Currently, high-throughput clinical sequencing of 
the entire genome is still too expensive but selective enrichment of genomic regions of 
interest, such as the exome, provides a cost-effective and scalable approach. The normal 
strategy is to compare variants with clear functional consequences (nonsense, frame shift, 
splice site, conserved missense) from several patients/families with identical phenotypes 
and searching for a shared defective gene or from parent-child trios searching for de novo 
variants in the child. The approach has revealed the cause of a range of rare Mendelian 
disorders. However, exome sequencing comes with several disadvantages. It is labor 
intensive (costly), it misses variants outside the targeted (protein coding exons) regions 
and it generates sequence data with a large variability in coverage across the regions 
sequenced, missing 5-15% of the targeted area. Furthermore, to cope with the sheer number 
of variants encountered, choices have to be made regarding the variants that deserve 
follow-up work (truncating/missense variants, intronic variants, splice site variants, etc). 
When the pathogenic consequence of a variant is unclear, the effect has to be studied 
in detail at other levels (e.g. RNA, protein, in vitro functional assay), in other tissues or in 
additional patients/families making the final proof of causality a tremendous effort. In 
many cases this may not be possible at all, e.g. since the function of the gene identified is 
not known or because no other patients are available.
Besides the first nucleotides, intronic regions are usually not studied. This has two main 
reasons: first introns contain many variants yielding too many candidates to follow-up. 
Second, RNA is often not available making it impossible to prove predicted effects on RNA 
splicing.
Aarskog-Scott syndrome (ASS or faciogenital dysplasia, OMIM #305400) is a clinically 
and genetically heterogeneous disorder characterized by proportionate short stature, short 
limbs (usually rhizomelic), broad hands and feet, genital hypoplasia (shawl scrotum) and 
facial dysmorphisms. Mental retardation has been described but is not a common finding 
(Orrico et al., 2005; Kaname et al., 2006; Shalev et al., 2006). Both autosomal dominant and 
recessive inheritance patterns have been demonstrated (Teebi et al., 1988; van de Vooren et 
al., 1983) but currently only one gene has been directly linked to ASS, FGD1 at Xp11.21. Both 
substitutions and deletions have been described in FGD1 in X-linked cases (Shalev et al., 
2006; Bedoyan et al., 2009). 
The FGD1 gene (faciogenital dysplasia 1) is ubiquitously expressed and composed of 
18 exons encoding a 961 amino acid guanine nucleotide exchange factor (GEF), binding 
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specifically to the Rho protein Cdc42. The Cdc42 pathway is involved in regulating cell 
growth and differentiation and plays a role in skeletal development (Pasteris et al., 1997; 
Hou et al., 2003). The protein consists of several important segments such as a proline-rich 
SH3-binding motif, a RhoGEF homology domain (DH), two pleckstrin-homology domains 
(PH) and a FYVE-zinc finger domain (ZF). In ASS, variants have been reported throughout 
the gene, both missense and protein truncating but there is no clear correlation between 
the nature and location of variants and disease severity (Orrico et al., 2007). Most variants 
are private, with the exception of three (c.529dupC, c.1966C>T and several affecting amino 
acid Arg443; www.LOVD.nl/FGD1) (Orrico et al., 2010; Orrico et al., 2004). FGD1 variants are 
found in only ~ 20% of Aarskog-Scott syndrome patients (Orrico et al., 2004). This can be 
attributed to inaccurate clinical diagnosis, the existence of overlapping syndromes (notably 
Noonan, LEOPARD, Teebi hypertelorism and Robinow syndrome) or genetic heterogeneity 
(Bottani et al., 2007). In diagnostics, FGD1 analysis of the entire coding region is performed 
using DHPLC and/or Sanger sequencing and deletion/duplication analysis using MLPA.
Two siblings (III-1 and III-2) from a family of Dutch origin were referred with a clinical 
diagnosis of ASS. The phenotype is summarized in Figure 1 and Table 1 and is illustrated 
in Figure S1. Conventional diagnostic Sanger sequencing revealed no changes in the FGD1 
gene (Greenwood Genetic Center, USA). 
SNP-array analysis of II-2, III-1 and III-2 excluded the presence of large causative deletions/
duplications in the genome, including the region containing FGD1. To resolve the genetic 
basis of ASS in this family, we performed exome sequencing of the two siblings (III-1 and 
III-2). Illumina GAIIX generated 51 nt, paired end reads. A coverage plot can be found in 
Figure 1: Pedigree of the Dutch Aarskog family.
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Table 1: Phenotype overview of the Dutch ASS family.
na = not applicable
III-1 III-2 II-1 I-1
Craniofacial
  Widow’s peak
  Cow’s lick
  Hypertelorisme
  Ptosis
  Downward slant palpebral fi ssures
  Short nose
  Wide philtrum
  Cleft lip and palate
  Underdeveloped maxillae
  Crease below lower lip














































  Short stature
  Short broad hands
  Clinodactyly fi fth fi nger
  Midl interdigital webbing
  Joint laxity
  Contractures of fi ngers








































na = not applicable
Figure S2. Standard filtering parameters were set for variants with a minimal depth of 8 
and initially selecting nonsense, frame shift, splice-site and conserved missense variants 
not present in variant databases (dbSNP, 1000Genomes, in-house exome variants). 
Prioritization of variants with functional consequences in targeted exonic regions (Table 
S1) listed a frameshift insertion in OXGR1 and a missense variant in C9orf72. Additional 
Sanger Sequencing showed that the OXGR1 variant did not cosegregate with the disorder 
in the family. A (GGGGCC)n expansion between exon 1a and 1b in C9orf72 has recently 
been reported to cause frontotemporal dementia and/or amyotrophic lateral sclerosis 
(FTLD/ALS). However, the phenotype of FTLD/ALS is quite different from ASS. Therefore, 
both variants were excluded as candidate genes for AAS. Criteria for variant analysis were 
then relieved to include intronic variants up to 50 bp from the splice sites, yielding three 
candidate variants (Table S2). Unexpectedly, a single nucleotide deletion (c.2016-35del) in 
the FGD1 gene emerged that potentially affects the branch point of the splice acceptor 
site of exon 13. The variant was not present in dbSNP131 or the 1000 Genomes project (May 
2011) and has not been reported in the FGD1 gene variant database (www.LOVD.nl/FGD1), 
which we established in the course of this study. Using Sanger sequencing we confirmed 
the variant in the two siblings. In addition we detected perfect co-segregation with ASS in 
the family (Figure2A).
7
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In Silico analysis predicted the variant to disrupt normal splicing, skipping exon 13, 
disrupting the reading frame and to lead to a premature stop codon (Desmet et al., 2009) 
(Figure 2B). This would result in a truncated protein of 677 amino acids. 
The effect on splicing was analyzed using RNA derived from cultured lymphocytes. RT-
PCR analysis of individuals I-1 (not shown), III-1 (Figure 2C) and III-2 (not shown) showed 
near complete skipping of exon 13. Semi-quantification of skipped products (Agilent 2100 
Bioanalyzer) showed complete skipping in I-1 and III-2, 94% in III-1 and 56% in carrier female 
II-1 (Figure 2D, Figure S3). We did not observe nonsense-mediated mRNA decay (NMD). RT-
qPCR using primers covering exon-exon junctions confirmed these results. Compared 
to three controls, all affected and carrier individuals had a significantly reduced FGD1 
expression (data not shown). 
To explore the general application of exome sequencing for intronic variants, we 
investigated our datasets to give an estimate of the chance to find an intronic variant by 
exome sequencing. Although exome sequencing is not designed to detect intronic variants, 
one can detect them. In our experiment, coverage was sufficient to call variants for ~ 80% 
of the intronic sequences up to position -35 bp (Figure S4A).We projected the number of 
variants detected when sequences up to 100 bp intronic would have been targeted by 
capture (read depth >=8). If probe extension is combined with filtering on conservation 
scores and information from variant databases (dbSNP, 1000 genomes project, inhouse 
exome variants), this would increase the number of candidate variants only marginally, 
making the effort sensible. Figure S4B illustrates this by showing the additional number of 
candidate variants remaining after standard filtering upon inclusion of an increasing part 
of the intron (various distances to the splice site) in our dataset.
Exome sequencing has solved several Mendelian diseases successfully. The obvious 
focus is to look for nonsense, frameshift, splice-site and missense variants and analyze 
the pathogenic consequence of candidate variants. If the variant cannot be classified, 
the effect has to be studied in detail at other levels (e.g. RNA, protein, in vitro functional 
assays). Since RNA is often not available for analysis and since only short intronic segments 
are analyzed, the true fraction of variants disrupting splicing remains largely unknown but 
is estimated between 15-50% (Ward and Cooper, 2010). Every intron contains core sequence 
elements that are essential for splicing: a 5’ splice donor site (SD), 3’ splice acceptor site (SA) 
and a branch point site (BP). In experimentally verified distant BPs the region between the 
BP and 3’ SD is devoid of AG dinucleotides, the so called ‘AG exclusion zone’ (AGEZ) (Gooding 
et al., 2006) . Since BPs reside deeper into the intron, BP variants proven to affect splicing 
are quite rare. Observed consequences of variants in BP sites include exon skipping, intron 
retention and partial intron retention. Several variants have been published that result 
in genetic diseases. Substitutions resulting in disease have so far only been described in 
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Figure 2: Genomic analysis of the mutation. A) Analysis result of GAII-X sequencing, 
displayed in IGV browser. III-1 and III-2 show a single nucleotide deletion, c.2016-35del in 
intron 12 of FGD1. On the left side, DNA Sanger sequencing results confirming the variant 
in the Dutch Aarskog family (III-1 and III-2 versus a WT control). B) A diagram of the normal 
and abnormal splicing in exon 12, 13 and 14. C) Sanger sequencing of the RT-PCR shows a 
skip of exon 13 in individuals III-1 versus a WT control, confirming the branch point variant. 
The skip of exon 13 leads to a 31 bp shorter mRNA. D) The 2100 Bioanalyzer results show 
semi-quantification of skipped products. III-1(lane 1) shows a 94% skip, containing two 
products, a large skipped (163 bp) and a small WT band (194 bp). III-2(lane 2) and I-1(lane4) 
show a 100% skip. II-1 (mother, lane 3) has a 50-50 distribution of WT and skipped products. 
Controls(lane 5~8) only carry the WT band.
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the two most conserved BPs positions, the BP adenosine itself and the -2 position (relative 
to the BP)(Kralovicova et al., 2006). To our knowledge, a deletion of the BP has not been 
described. Useful approaches for follow-up studies of BP variants have been communicated 
(reviewed by Pagani and Baralle (Pagani and Baralle, 2004)). In silico prediction of BP 
variants, combined with segregation studies and RNA analysis is very useful, especially for 
clear disease-associated genes. As an alternative, or in conjunction with RNA analysis, in 
vitro splicing reporter assays using minigene reporter constructs and lariat PCR have been 
used to prove pathogenicity of variants affecting splicing (Gao et al., 2008; Kishore et al., 
2008; Kralovicova et al., 2006).
The deletion of the adenosine at position -35 of FGD1 intron 12 is the first report of an 
insertion or deletion affecting the BP. Our data make it likely that the A represents the signal 
for lariat structure formation; 1) its location matches the usual branch point distance from 
the 3’ SA, 2) its sequence “cTaAc” matches the human branch point consensus sequence 
yUnAy (Gao et al., 2008) , 3) it is conserved (Phastcons score 1), 4) the region between BP 
and SA is devoid of a AG dinucleotide (an AGEZ , Figure S5) (Gooding et al., 2006) and, most 
convincingly, 5) we showed abnormal FGD1 mRNA splicing. Interestingly, since we see a 
nearly 100% skip of exon 13 in males, the flanking ‘A’ residue seems not to act as a BP site. 
As mentioned, diagnostic FGD1 Sanger sequencing was performed in the two siblings 
but failed to identify a causative variant. The 5’ primer used to amplify exon 13 covers 
the deleted A (Figure 2A), but it obviously did not prevent amplification in males and 
therefore the variant went undetected. Based on the guidelines for diagnostic molecular 
testing(American college of medical genetics, 2006), there is no clear consensus on the 
regions that must be included in a standard variant screen. Although the direct splice 
sites (+1 to +6 and -10 bp to -1) are usually included, the branch point is not. An important 
reason for this is that BP is difficult to define (weak consensus sequence). Furthermore, 
RNA is not usually isolated making it difficult to study the effect of any variant detected. 
It is interesting to note that when blood-derived RNA of the patients would have been 
analyzed, exon 13 skipping had been detected, triggering an analysis of introns 12 and 13 
and the detection of the -35delA variant. The fact that the mutation detection rate for FGD1 
variants in clinically diagnosed ASS patients is less than 20%, may be partly due to the 
fact that variants affecting splicing are not routinely investigated. We tested four other 
clinically diagnosed ASS patients with unknown genetic background (3 Dutch, 1 Belgian) 
for c.2016-35del, but no abnormality was found. Since RNA was not available we could not 
perform a RNA analysis.
As we demonstrate here, although exome sequencing is not designed to detect intronic 
variants, they can be partially detected. The intron/exons borders are targeted by the whole-
exome capture kits but it does not include the branch point. Even if it is captured, those 
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variants would be filtered out by the standard strategy to prioritize variants (nonsense, 
splice site, frameshift). Moreover, sufficient coverage for the branch points is required to 
reliably call variants while sequence coverage drops significantly near these sites because 
they only flank the targeted regions. The BP variant in FGD1 was detected and subjected to 
detailed analysis mainly because it had a high coverage and because the gene was known 
to be involved in Aarskog syndrome. Depending on the current capture design, sequences 
can go up to 200 bp into the introns. To ensure ‘standard’ capture of the majority of branch 
points, the exome-kit probe design should be extended with sequences deeper into the 
intron region taking AGEZ regions into account. Sequencing deeper into the intron will 
uncover many more variants most of them probably not affecting splicing at all. However, 
validation of these variants will not be too difficult if they have sufficient coverage. 
In Summary, our findings show that traditional clinical gene sequencing is not perfect and, 
due to practical and cost considerations, may miss causative variants. Application of exome 
sequencing in a diagnostic setting should give a significant increase in the detection of 
pathogenic variants by partially covering the intron-exon flanking regions. Ultimately, only 
full genome sequencing will guarantee that all possible regions are taken into account. 
Our data indicate that variant analysis in exome sequencing should include analysis of 
intronic variants, with special attention to branch point sites. In addition, RNA should 
never be neglected as a valuable source to confirm variants that may affect splicing or 
to detect such variants directly. In fact, sequencing RNA isolated from the same blood 
sample as currently used to extract the DNA for exome/genome sequencing may provide 
an attractive, cost-effective approach when no obvious pathogenic variants are identified.
Acknowledgements 
The authors have no conflict of interest to declare.
We are grateful to the family, clinicians, and researchers who contributed to this study. 
Professor R.C.M. Hennekam is acknowledged for establishing the clinical diagnosis of 
Aarskog-Scott syndrome in this family. We thank Dr. E.K.Bijlsma, Dr N.S. den Hollander, Dr. A. 
van Haeringen and Dr. R.McGowan for contributing patient samples not directly used in this 
study and the technicians in the laboratory of diagnostic genome analysis for their help in 
lymphocyte culturing. Dr. P.A.C. ‘t Hoen is acknowledged for his advice and critical reading 
of the manuscript and J. Laros for the bioinformatic analysis. Y. Sun is supported by China 
Scholarship Council. This work was supported by the EC’s 7th Framework Programme under 
grant agreement nºs 223026 (NMD-chip), 223143 (TechGene) and 200754 (GEN2PHEN).
7
hoofdstuk 7a.indd   159 10-12-12   10:01
References
160
1.  American college of medical genetics. 2006. Practice guidelines for Sanger Sequencing Analysis 
and Interpretation . 
2.  Bedoyan JK, Friez MJ, DuPont B, Ahmad A. 2009. First case of deletion of the faciogenital dysplasia 
1 (FGD1) gene in a patient with Aarskog-Scott syndrome. Eur J Med Genet 52:262-264.
3.  Bottani A, Orrico A, Galli L, Karam O, Haenggeli CA, Ferey S, Conrad B. 2007. Unilateral focal 
polymicrogyria in a patient with classical Aarskog-Scott syndrome due to a novel missense 
mutation in an evolutionary conserved RhoGEF domain of the faciogenital dysplasia gene FGD1. 
Am J Med Genet A 143A:2334-2338.
4.  Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. 2009. Human Splicing 
Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67.
5.  Gao K, Masuda A, Matsuura T, Ohno K. 2008. Human branch point consensus sequence is yUnAy. 
Nucleic Acids Res 36:2257-2267.
6.  Gooding C, Clark F, Wollerton MC, Grellscheid SN, Groom H, Smith CW. 2006. A class of human 
exons with predicted distant branch points revealed by analysis of AG dinucleotide exclusion 
zones. Genome Biol 7:R1.
7.  Hou P, Estrada L, Kinley AW, Parsons JT, Vojtek AB, Gorski JL. 2003. Fgd1, the Cdc42 GEF responsible 
for Faciogenital Dysplasia, directly interacts with cortactin and mAbp1 to modulate cell shape. 
Hum Mol Genet 12:1981-1993.
8.  Kaname T, Yanagi K, Okamoto N, Naritomi K. 2006. Neurobehavioral disorders in patients with 
Aarskog-Scott syndrome affected by novel FGD1 mutations. Am J Med Genet A 140:1331-1332.
9.  Kishore S, Khanna A, Stamm S. 2008. Rapid generation of splicing reporters with pSpliceExpress. 
Gene 427:104-110.
10.  Kralovicova J, Lei H, Vorechovsky I. 2006. Phenotypic consequences of branch point substitutions. 
Hum Mutat 27:803-813.
11.  Orrico A, Galli L, Buoni S, Hayek G, Luchetti A, Lorenzini S, Zappella M, Pomponi MG, Sorrentino V. 
2005. Attention-deficit/hyperactivity disorder (ADHD) and variable clinical expression of Aarskog-
Scott syndrome due to a novel FGD1 gene mutation (R408Q). Am J Med Genet A 135:99-102.
12.  Orrico A, Galli L, Cavaliere ML, Garavelli L, Fryns JP, Crushell E, Rinaldi MM, Medeira A, Sorrentino 
V. 2004. Phenotypic and molecular characterisation of the Aarskog-Scott syndrome: a survey of 
the clinical variability in light of FGD1 mutation analysis in 46 patients. Eur J Hum Genet 12:16-23.
13.  Orrico A, Galli L, Faivre L, Clayton-Smith J, Azzarello-Burri SM, Hertz JM, Jacquemont S, Taurisano 
R, Arroyo C, I, Tarantino E, Devriendt K, Melis D, Thelle T, Meinhardt U, Sorrentino V. 2010. Aarskog-
Scott syndrome: clinical update and report of nine novel mutations of the FGD1 gene. Am J Med 
Genet A 152A:313-318.
hoofdstuk 7a.indd   160 10-12-12   10:01
References
161
14.  Orrico A, Galli L, Obregon MG, de Castro Perez MF, Falciani M, Sorrentino V. 2007. Unusually 
severe expression of craniofacial features in Aarskog-Scott syndrome due to a novel truncating 
mutation of the FGD1 gene. Am J Med Genet A 143:58-63.
15.  Pagani F, Baralle FE. 2004. Genomic variants in exons and introns: identifying the splicing spoilers. 
Nat Rev Genet 5:389-396.
16.  Pasteris NG, Buckler J, Cadle AB, Gorski JL. 1997. Genomic organization of the faciogenital dysplasia 
(FGD1; Aarskog syndrome) gene. Genomics 43:390-394.
17.  Shalev SA, Chervinski E, Weiner E, Mazor G, Friez MJ, Schwartz CE. 2006. Clinical variation of 
Aarskog syndrome in a large family with 2189delA in the FGD1 gene. Am J Med Genet A 140:162-
165.
18.  Teebi AS, Naguib KK, Al-Awadi S, Al-Saleh QA. 1988. New autosomal recessive faciodigitogenital 
syndrome. J Med Genet 25:400-406.
19.  van de Vooren MJ, Niermeijer MF, Hoogeboom AJ. 1983. The Aarskog syndrome in a large family, 
suggestive for autosomal dominant inheritance. Clin Genet 24:439-445.
20.  Ward AJ, Cooper TA. 2010. The pathobiology of splicing. J Pathol 220:152-163.
7
hoofdstuk 7a.indd   161 10-12-12   10:01
Chapter 7  |  Exome sequencing identifies a branch point variant in Aarskog-Scott syndrome
162
Patient DNA
Blood samples of patients and relatives were collected and used for segregation analysis. 
Consent to genetic testing was obtained from adult probands or parents in the case of 
minors.
DNA and RNA Analysis
DNA was extracted from whole blood following standard protocols. Leucocyte RNA with or 
without cycloheximide (CHX) treatment was isolated from blood using Nucleospin RNA II 
kit (MACHEREY-NAGEL) following the official protocol. cDNA was synthesized from 500 ng 
of total RNA by RevertAid RNaseH-M-MuLV reverse transcriptase in a total volume of 20 μl 
according to the protocol provided by the supplier (MBI-Fermentas). Target regions were 
amplified by RT-PCR (primer sequences are available upon request). The products were 
evaluated with the Bioanalyzer 2100 DNA chip 1000 (Agilent), according to the manufac-
turer’s instructions. 
SNP arrays
SNP arrays (1M-Duov3-0 Illumina Inc., San Diego, CA) were performed and a total of 750 ng 
DNA was processed according to the manufacturer's instructions. SNP copy number (log 
R ratio) and B-allele frequency were assessed for II-2, III-1 and III-2 to exclude large copy 
number variations (CNVs) as a possible genetic cause. 
Mutation detection by exome sequencing
To resolve the genetic basis of ASS in this family, we performed exome sequencing of the 
two siblings (III-1 and III-2) using the SureSelect human all exon kit v2 (Agilent), following 
the manufacturer’s instructions. In brief, 5 ug genomic DNA was fragmented to 300-800 
bp using a Covaris S-series and Illumina pair-end adapters were ligated to the fragments. 
500 ng adapter ligated DNA was hybridized with 500 ng SureSelect probe mix. Sequencing 
(one lane per patient) was performed on the Illumina GAIIX. All reads were aligned with 
BWA-0.5.8 (Li and Durbin, 2010) to the human reference genome hg19. Variant calling, 
including both single nucleotide substitutions (SNVs) and small insertions, deletions 
and indels, were done by Samtools-0.1.12 (Li et al., 2009)  followed by annotation using 
SeattleSeq Annot.131. 
Supplementary Material
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Sanger sequencing
PCR was performed by using Phire Hot Start II DNA polymerase (Finnzyme) following the 
official protocol. Primers used in PCR reactions are available upon request. PCR products 
were first purified by QIAquick PCR purification kit (QIAGEN), then mixed with 25 pmol 
of the forward or reverse primers respectively and sequenced by the Applied Biosystems 
96-capillary 3730XL system. 
In Silico Analysis
Prediction of a splice effect was tested using the Human Splicing Finder (HSF) tool which 
gives a position Weight matrices-derived scores (HSF) for potential splice sites (Desmet et 
al., 2009), and also integrates the results from the MaxEnt program.
Accession Numbers
GenBank reference sequences: FGD1: NM_004463.2
UNIPROT: FYVE, RhoGEF and PH domain-containing protein 1: P98174 
7
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III-1 III-2
Unique genomic variants 74019 43209
Exonic + 5’ and 3’-SS 25642 21491
In sureselect 38M probeset 20080 20187
Depth >= 8 18378 18990
Not coding synonymous 8394 8556
Not validated DbSNP/1K 570 672
Not present In house database 53 169
Conserved variantsa 30 62
Variants present in two sibs 2
a phylop >3 for SNVs, Phastcons >0.8 for indels
Sample Variant Gene Function Depth dbSNP OMIM
III-1 NM_018325.2:c.607G>C C9orf72 missense 9 none No
III-2 NM_018325.2:c.607G>C C9orf72 missense 9 none No
III-1 NM_004463.2:c.2016-35delA FGD1 intron  11 none Yes
III-2 NM_004463.2:c.2016-35delA FGD1 intron  11 none Yes
III-1 NM_080818.3:c.512_513insA OXGR1 frameshift 43 none No
III-2 NM_080818.3:c.512_513insA OXGR1 frameshift 67 none No
Table S1: Standard filtering for exonic regions.
Table S2: Reported variants after standard analysis for intronic positions up to -50 bp.


































































































































hoofdstuk 7a.indd   165 10-12-12   10:01
Chapter 7  |  Exome sequencing identifies a branch point variant in Aarskog-Scott syndrome
166
Figure S2: Coverage plots of GAIIX sequencing for III-1 and III-2.
Figure S3: The 2100 Bioanalyzer Traces of RT-PCR show semi-quantification of skipped products. 
The peaks represented are the lower ladder (15 bp) and upper ladder (1500 bp),
the skipped FGD1 product (163 bp) and the WT product.
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Figure S4: Application of exome sequencing for detection of intronic variants. 
A) Intronic coverage plot for a range of distances to the splice site in our dataset. 
Percentage of the introns covered (minimal depth 8) decreases with an increasing distance 
from splicesite. B) Calculation of the number of filtered variants upon inclusion of intronic 
variants by a range of distances to the splice site (depth >8).
Figure S5: Overview of splice elements of FGD1 exon 12-13. 5’splice site (GU dinucleotide), 
branch point sequence YUNAY with adenine for lariat formation, AG exlusion zone (AGEZ), 
polypyrimidine tract (ppt) and 3’splice site (AG dinucleotide).
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Abstract
We identified de novo truncating mutations in ARID1B in three individuals with Coffin-Siris 
syndrome (CSS) by exome sequencing. Array-based copy-number variation (CNV) analysis 
in 2,000 individuals with intellectual disability revealed deletions encompassing ARID1B in 
three subjects with phenotypes partially overlapping that of CSS. Together with published 
data, these results indicate that haploinsufficiency of the ARID1B gene, which encodes an 
epigenetic modifier of chromatin structure, is an important cause of CSS and is potentially 
a common cause of intellectual disability and speech impairment.




Coffin-Siris syndrome (OMIM %135900, CSS)1 is characterized by developmental delay, 
severe speech impairment, coarse facial features, hypertrichosis, hypoplastic or absent 
fifth finger- or toe nails2 and agenesis of the corpus callosum (Supplementary Table 1). Few 
published patients fulfill the complete spectrum of the CSS phenotype and it is debated 
whether all CSS patients have the same syndrome.  CSS is generally assumed to display 
autosomal recessive inheritance, although autosomal dominant inheritance has not been 
formally excluded3, 4. 
To identify the genetic cause of CSS we performed whole exome sequencing in one 
patient-parent trio and two sporadic patients with a clinical CSS diagnosis all diagnosed 
in one hospital by the same clinical geneticist (Fig. 1, Supplementary note, Supplementary 
Fig. 1, and Supplementary Tables 1 and 2, Supplementary methods). Exome sequencing data 
are available upon request. Using the GATK sequence analysis pipeline5, 6 we identified 
12,722- 14,642 exonic/splice site variants per individual. Filtering steps using variant 
databases (dbSNP132 and the 1000 genomes project database) and a selection for coding 
regions, revealed variants in 34 genes that were shared by all three patients. Filtering for 
recessive inheritance (discarding all genes with only one heterozygous variant) showed 
that no gene in agreement with a recessive inheritance model was shared between the 
patients. Accepting dominant inheritance, we queried heterozygous and de novo variants 
and identified ARID1B as the only possible affected gene (Supplementary Table 3). All 
variants truncate the ARID1B reading frame (two nonsense variants -c.5329A>T,p.Lys1777X 
and c.3223C>T,p.Arg1075X), one frameshift -c.4619_4628del,p.Gln1541ArgfsX35-, Table 1). 
The mutations were validated using Sanger sequencing and shown to occur de novo in all 
three patients (Supplementary Fig. 2). Since thus far an autosomal recessive inheritance 
could not be ruled out, the parents of a CSS patient received a recurrence risk of 10%7. The 
identification of de novo mutations in ARID1B in CSS patients, allowed us to reduce this risk 
to 1-2%8.
When we queried our in-house database for patients with potential copy number variants 
(CNVs) including ARID1B we identified three patients with a deletion in 2000 subjects 
screened for intellectual disability (Fig.1, Supplementary Fig. 1 and 2, Supplementary 
Table 1). This cohort consists of patients with intellectual disability and/or congenital 
malformations (syndromic and non-syndromic) referred for array-based CNV analysis. In 
comparison, we found six patients with the relatively frequent 22q11.2 duplication in this 
cohort. Patient four has a de novo 2.72 Mb deletion of band 6q25 encompassing ARID1B, 
C6orf35, ZDHHC14, SNX9 and SYNJ2. 
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Patient five has a de novo 0.73 Mb deletion encompassing ARID1B, C6orf35 and ZDHHC14. 
Patient six has a de novo deletion of 0.88 Mb encompassing the same genes as patient 
five. Analysis of the phenotypes of these patients shows that, similar to our CSS patients, 
they have moderate to severe intellectual disability and severe speech delay. These 
patients also share facial similarities with the CSS patients (Figure 1) but lack the typical 
CSS abnormalities, such as hypoplastic or absent finger- or toenails. The CSS diagnosis was 
considered only in patient four because of her hypoplastic fingernails (Supplementary 
Table 1). Halgren et al.9, describe eight patients with haploinsufficiency of ARID1B (in one 
subject the gene was disrupted by a reciprocal translocation). An additional disruption of 
ARID1B as well as a de novo intragenic deletion have been reported in patients with either 
corpus callosum agenesis or autism9, 10. Although the sizes of the published deletions range 
Figure 1: Facial features of all patients. Top, left to right: Patient 1 at 4.5 years, patient 2 
at 2,5 years, patient 3 at 3 years. Bottom, left to right: Patient 4 at 3.5 years , patient 5 at 
45 years, patient 6 at 3,5 years. All patients share coarse facial features, thick eyebrows 
and broad nasal tips. For further details see Supplementary Table 1. The parents or 
legal guardians of all affected individuals gave consent for publication of the clinical 
photographs.
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from <1 Mb to > 14 Mb, the phenotypes of the patients largely overlap with those of our 
CSS patients, with the exception of the typical fifth finger CSS abnormalities. Disruption of 
ARID1B therefore seems to be the main driver of the observed phenotype and CSS should be 
considered in all patients with intellectual disability and speech impairment, particularly in 
combination with agenesis of the corpus callosum. Based on these findings we conclude 
that haploinsufficiency of ARID1B is likely to be an important cause of CSS.
The public database DECIPHER (http://decipher.sanger.ac.uk) contains 12 patients with 
haploinsufficiency of ARID1B (including the three described here and those described by 
Halgren et al.). Since all deletions and mutations published thus far have been de novo, 
disease penetrance is expected to be high. No truncating or splice-site mutations are 
reported in the 1000 genomes project, nor in the ~ 5400 exomes on the Exome Variant 
Server (http://evs.gs.washington.edu/EVS/ ). However, the Database of Genomic Variants 
harbors two deletions including exon 1 and exon 2-20 of the ARID1B respectively. This could 
signify reduced penetrance, but an alternative explanation would be that these deletions 
represent a technical artifact. Both deletions were not validated using alternative methods.
Together with ARID1A, ARID1B encodes for ARID (AT rich interactive domain), a subunit of 
the BAF complex. BAF (Brahma associated factor) is one of the two main components of 
the Switch/sucrose nonfermentable (SWI/SNF)-like chromatin remodeling complex. They 
act as epigenetic modifiers by altering the structure of chromatin to facilitate access of 
Patient
(DECIPHER ID)
Chr Position Size of 
deletion
cDNA position Protein Position Exon phyloP 
score
1 6 g.157527604A>T - c.5329A>T p.Lys1777X 20 2.9
2 6 g.157502190C>T - c.3223C>T p.Arg1075X 12 1.9
3 6 g.157522346_157522356del - c.4619_4628del p.Gln1541ArgfsX35 18 3.0
4 (248472) 6 155,797,565 - 158,517,307 2.72 Mb - - -
5 (250455) 6 157,079,676 - 157,806,675 0.73 Mb - - -
6 (257917) 6 157,144,644 - 158,028,969 0.88 Mb - - -
Variants are mapped to the hg19 reference genome. Deletion size represents the maximum deletion. All variants occurred 
de novo. Chr.,chromosome. Subjects 4 and 5 were published previously 9.
Table 1: Overview of the detected variants and CNVs affecting ARID1B.
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transcription factors to DNA. ARID1A and ARID1B proteins have antagonistic functions 
and they are both important for the regulation of the cell cycle. Although ARID1B is 
predominantly expressed in differentiated cell-types, it has also been suggested to be 
involved in early development of the brain11. ARID1A is more abundantly expressed in 
embryonic tissue and somatic mutations have recently been related to gastric cancer12. 
Recently, Gilissen et al13 remarked that histone modifying proteins seem to have a dual 
role in developmental disorders and malignancies. One could hypothesize that activating 
mutations in ARID1A might give a clinical phenotype similar to CSS.  
In conclusion, CSS can be added to a growing list of syndromes characterized by congenital 
malformations, and intellectual disability that are caused by mutations in epigenetic genes 
that encode modifiers of chromatin structure14, 15.
Accession code. Data for ARID1B is deposited in RefSeq under the 
accession code NM_020732.3.
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Supplementary Table 1: Patient characteristics. Present +, Absent -, not tested/observed: ?. 
Patients 1-3 fulfill the diagnostic criteria for CSS since they have either fifth ray abnormalities or 
hypoplastic phalanges in their toes. Patients with deletions of ARID1B were not noticed to have 
these abnormalities, the main reason why they were not diagnosed with CSS. In retrospect a 
subtle degree of fifth finger/nail hypoplasia is discernable in patient 5. 

Supplementary information
The parents of patients 1-3 gave informed consent to participate in this study. The parents 
or legal guardians of all patients gave consent for publication of the clinical photographs. 
All DNA samples were isolated from peripheral blood leucocytes according to standard 
techniques.
Samples for next generation sequencing were prepared according to the manufacturer’s 
instructions. Target enrichment was performed using Agilent’s 50 Mb Sureselect v2 
exome capture kit. Paired-end reads with a length of 100 nucleotides were sequenced on 
Illumina’s Hiseq 2000. Sequencing statistics are summarized in Supplementary Table 2. 
BWA1 was used to align the short reads to the reference genome (hg19), followed by GATK2 
base quality score recalibration, INDEL realignment and duplicate removal. SNP and INDEL 
discovery and genotyping for each sample were performed separately using standard 
hard filtering parameters for INDELS and variant quality score recalibration3 for SNP calls 
as indicated on the GATK website (http://www.broadinstitute.org/gsa/wiki/index.php/
Best_Practice_Variant_Detection_with_the_GATK_v3). Because of the low coverage of our 
data two modifications were made: (1) the minimum quality for variant calling was set 
at 20 (default 30) and (2) the minimum number of reads supporting an indel was set at 3 
(default 6). Variants were annotated using Seattleseq (http://gvs.gs.washington.edu/) and 
in-house developed software.




1 2 3 4 5 6
Gender female female female female male female
Age at presentation 4.5 years 6 years 3 years 2 years 46 years 3.5 years
Mutation/CNV ARID1B mutation mutation mutation deletion deletion deletion
Inheritance of mutation de novo de novo de novo de novo de novo de novo
Birth (gestational age) 42 40 39 39+4 At term 41+1
Birth weight (g) 3370 3720 normal 2770 3800 2722
OFC at birth (cm) ? 36.9 ? ? ? 35
Intellectual disability (mild, moderate, severe) severe severe moderate severe severe moderate
Speech delay (mild, moderate, severe) severe severe severe no speech no speech moderate
Coarse facial features + + + + + -
Thick eyebrows + + + + + +
Low frontal hairline + + + - - +
Hypertrichosis + + + - - -
Joint laxity + + - - + ?
Brachydactyly + + - - - -
Brachydactyly fifth finger + + - - - -
Hypoplastic nails - - - + - -
Hypoplastic nail fifth finger - + + - - -
X-ray hand/foot performed + + + - - -
Missing/hypoplastic phalanx of  toes - + + ? ? ?
MRI performed + + + - - +
Agenesis of the corpus callosum + partial + ? ? +
Height (SDS) at last visit -2,5 -1 0 -1,5 -3,5 -2.6
Weight (SDS) at last visit 0 0 +1 -3,0 0 0.3
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Discoveries made in the 20th century had a major impact in genetics. In less than 60 years, 
the field has moved from discovering the structure of DNA to potentially identifying all the 
variants in an individual’s genome. Current (diagnostic) research focuses on identifying the 
genetic basis of disorders, both at the fine (sequence variants) and large scale (structural 
variants). While Sanger sequencing has been the golden standard for detection of sequence 
variants for many years, replacement by whole exome sequencing (WES) is already taking 
place, soon to be followed by whole genome sequencing (WGS). WES now merely focuses 
on detection of sequence variation but, although limited, allows detection of structural 
variation as well. For detection of structural variation, conventional karyotyping has been 
replaced by microarray platforms, and the resolution of the technique has increased from 
the 5-10 Mb level towards the kilobase level. With NGS, even smaller structural variation will 
be detected. For balanced rearrangements and complex rearrangements, although WGS 
can identify breakpoints, conventional karyotyping and FISH are still valuable techniques. 
Several techniques described in this thesis have made their way into clinical diagnostic 
laboratories. Chapters in this thesis show that each technique has specific applications, 
and which technical approach to use depends on the resolution and throughput of the 
technique in combination with the strategy for the identification of the disease gene. 
While chapter 2 and chapter 4 describe more methodological work on techniques to detect 
sequence variation and copy number variation, chapters 3 and 5 describe the application of 
these techniques to the identification of pathogenic variants. Chapter 6 and 7 reflect the 
rapid introduction of NGS and the successful application of exome sequencing in clinical 
genetics. 
Technological innovations are ongoing. For some of the research published in this thesis 
we would now already apply other techniques. For instance, the development of a 1400-
plex bead assay to screen for CNVs in patients with intellectual disability (chapter 2) is 
now obsolete, as microarrays made their way into diagnostic laboratories. However, this 
targeted approach can still be considered useful to circumvent dilemmas like the occurrence 
of unsolicited findings connected to genome-wide screening. Detailed delineation of 
microdeletion/microduplication syndromes (chapter 3) is time consuming, and exome 
sequencing will probably aid in establishing genotype-phenotype correlations within these 
patients. Exome sequencing of mentally retarded patients with unknown aetiology may 
reveal pathogenic variants in genes previously described in microdeletion/microduplication 
intervals. This has been the case for Coffin-Siris syndrome (chapter 8) where pathogenic 
variants in ARID1B were identified in patients using exome sequencing. This gene was 
previously described in patients carrying a larger deletion affecting ARID1B, indicating 
haploinsuffiency as the causative effect. Additionally, in some of the cases, exome 
sequencing will allow detection of pathogenic variants on the other allele in genes within 
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microdeletion/microduplication intervals, confirming a recessive mode of inheritance. 
Gene identification in Mendelian disorders 
In general, knowledge of advantages and disadvantages of different laboratory techniques 
will aid in setting up experiments, and allows a critical assessment of subsequent findings. 
The identification of genes responsible for Mendelian disorders enables molecular diagnosis 
of patients, as well as testing gene carriers and prenatal testing. Uncovering genetic 
defects underlying monogenic inherited diseases (this thesis) requires a broad knowledge 
of genetics. Strategies to identify pathogenic variants include assumptions on inheritance 
patterns (dominant, de novo dominant, recessive, X-linked), careful selection of cases based 
on phenotype, collection of families and choosing the best experimental approach. 
Several strategies for gene identification can be chosen, such as a straightforward candidate 
gene approach or positional cloning. Previous strategies such as linkage analysis combined 
with segregation studies and homozygosity mapping have proven successful. Candidate 
genes within identified genomic loci can then be studied using Sanger sequencing. The 
combination of classic strategies with novel techniques has proved to be valuable in KFSD 
research (chapter 4). Data from previously performed linkage analysis were combined 
with SNP array data to reduce the critical interval of the locus. HRMA was then used as a 
screening method to identify the pathogenic variant in the candidate genes. There is no 
doubt that, in this case, X-exome sequencing would have performed equally in identifying 
the pathogenic variant and would have been faster. This strategy was applied in TOD 
(Chapter 6), where a splice-site variant was identified in the linkage interval 1. Remarkably, 
the variant was missed using other techniques. The effect of the variant on gene splicing 
could only be shown on patient-derived tumour tissue that had been stored for 15 years. 
This story illustrates several problems related to sequence variation. Not only can a variant 
remain undetected due to technical failure, it is also quite possible that a variant is indeed 
detected, but not recognized as being pathogenic. 
The underlying gene defect is still unknown for many rare monogenic diseases but the 
development of WES has allowed us to resolve many more cases. In particular, de novo 
variants for sporadic cases of previously unknown genetic disorders were identified 2-6. 
Genome-wide techniques such as SNP arrays have already changed our approach to genetic 
disorders and this will continue as the use of WES/WGS will eventually become a standard 
technique in clinical diagnostic laboratories. The identification of causative variants in 
patients moved from clinical recognition of a syndrome and collecting patients with 
overlapping clinical features (phenotype-driven research), towards collecting patients with 
similar genomic aberrations and, secondly, delineating the phenotypic overlap (genotype-
9
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driven research). The research on Coffin-Siris syndrome (chapter 8) reflects the success of 
accurate phenotyping of several sporadic patients and searching for a shared defective gene 
under assumption of different inheritance patterns. The fact that this syndrome is now 
proven to be de novo instead of, as assumed, following autosomal recessive inheritance has a 
major impact on recurrence risk for parents. The identification allowed us to reduce this risk 
from 25% to 1-2%. The success of identifying pathogenic variants in a single gene, in multiple 
unrelated patients with a similar phenotype, is highly dependent on the involvement of a 
clinical geneticist. Therefore, selection of patients for WES should be performed in close 
collaboration between molecular and clinical geneticists. 
The discovery of causal variants and candidate genes responsible for Mendelian disorders 
and complex disorders will also help in understanding their biological function. 
In addition to WES, experiments can be performed to provide more insight into disease 
mechanisms. For instance, KFSD (chapter 5), TOD (chapter 6), and AAS (chapter 7) all show 
X-linked inheritance. In principle, females have random X-inactivation. Thus, for some 
X-linked disorders, carrier females may show variable and usually milder symptoms of the 
disease, based on the pattern of X-inactivation. The X-inactivation studies performed for 
KFSD and TOD showed imbalances in allelic expression, perfectly matched with skewed 
levels of X-inactivation. In addition, for KFSD, functional in vitro assays were developed 
to prove that the identified variant leads to loss of proteolytic function of the MBTPS2 
protein. For AAS, the putative branch point variant was proven to have an effect on splicing 
by performing RNA analysis. Together, these experiments were critical for understanding 
the disease mechanism and explaining the severity of phenotype in these disorders. For 
Coffin-Siris syndrome, functional assays are being developed to provide more insight into 
epigenetic modifications in the SWI/SNF complex. 
Advantages and disadvantages in variant detection with WES
Currently, high-throughput sequencing of the entire genome is still too expensive to be 
applied in a clinical setting, so a targeted approach such as exome sequencing is the most 
practical approach towards finding causative variants for genetic disorders. However, 
NGS is becoming cheaper at an accelerating rate and whole genome sequencing will soon 
become affordable. 
Exome sequencing comes with several disadvantages. It is labour intensive, and includes 
many steps, with risks of sample swaps and pipetting errors. There is significant variability 
in capturing efficiency, leading to variability in coverage across the genome. Low input 
yield and preferential amplification of shorter sequences in the PCR step leads to 
overrepresentation of one allele, and some reads will be exact copies of each other (PCR 
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duplicates). This will result in problems regarding variant detection in samples. Removal of 
these duplicates is possible during data analysis, but insufficient coverage due to capture 
inefficiency cannot be disregarded. An adequate depth is especially critical for identifying 
heterozygote variants in de novo dominant disorders, or recessive disorders caused by 
compound heterozygosity. Standards for generation of high-quality exome sequence data 
are rapidly emerging 7, 8 but there are no clear guidelines yet on the number of reads needed 
for identification of heterozygote SNV calls, and thresholds are determined by the user 
when performing data analysis.
Another challenge of NGS is read length. Current NGS machines produce shorter read 
lengths than Sanger sequencing, which makes the assembly of repeat-rich sequences more 
difficult 9. Together with mapping difficulties, this leads to missed variants or an excess 
of variant calls 10. Paired-end sequencing (where sequences are retrieved from both ends 
of the same molecule) helps in reducing mapping errors although indels and structural 
variants remain challenging. To solve this, other computational methods (read-pair, read-
depth, split-read) have been developed 11, 12. False positives SNV calls most often arise from 
incorrect mapping and sequencing errors. Sequencing errors can be removed by comparing 
the test sample to previously sequenced samples, stored in an in-house-database (INHDB). 
Although detection of structural variants with WES is possible 13, conventional techniques 
such as karyotyping, FISH, array-CGH and SNP-arrays will still provide useful information on 
structural variation until WES or WGS becomes a routine diagnostic approach.
The human reference genome plays an important role in several steps of WES. It is used 
to design chemically synthesized nucleic acid molecules and to design probes to capture 
regions of interest in the pool of nucleic acids (DNA or RNA). This means that targeted assays, 
such as WES, do not cover unknown or yet-to-be-identified exons, regulatory sequences or 
evolutionary conserved coding regions 10. Moreover, if causal variants lie within exons that 
are not targeted, they will not be identified. This shortcoming of incomplete capture has 
occurred in the first attempts by several groups, including our own, to identify the genetic 
cause for Kabuki syndrome 2.
WES is not targeted towards intronic sequences, promoter or enhancer elements. In 
routine diagnostics, apart from the direct splice sites, causative variants outside coding 
regions are not studied. Therefore the true fraction of variants disrupting splicing remains 
largely unknown. However, the research that was performed for Aarskog-Scott syndrome 
(Chapter 7) shows that WES can be used to identify intronic variants up to -200 bp from 
the splice site with sufficient coverage, although it is not specifically designed to do so. A 
branch point variant was identified that was missed with Sanger sequencing. Detection of 
branch site variants is possible with WES due to probe overhang. Future probe design for 
targeted WES approaches may take advantage of this finding. On the other hand, if there is 
9
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a continuous demand to increase the coverage or size of targeted regions, whole genome 
sequencing is probably the best option in the long run. The disadvantage of extending into 
the non-coding sequences will be the large number of variants detected, and the need to 
verify aberrant splicing using RNA analysis which is not always possible if the gene is not 
expressed in available cells.
Whole genome sequencing (WGS) using a paired-end approach should eventually allow the 
identification of all types of currently known genomic variation in a single experiment, and 
will gradually replace WES. Improving NGS techniques and lowering the costs, together with 
the development of affordable analysis software to cope with the millions of variants called 
per genome, is essential to pave the way for diagnostic application of WGS. Development of 
software that can combine data from several sources containing information on reported 
variants has a high priority.
Interpretation of variants using NGS
The more we learn about the human genome, the more we are confronted with the need 
to separate ‘the wheat from the chaff’ i.e. distinguishing pathogenic variants from neutral 
variants. In NGS experiments, individual sequences are aligned to a reference genome. The 
choice for a specific reference genome (for instance Caucasian or Yoruba) will significantly 
influence variant detection in the sample of interest. It is important to realize that the 
human reference genome does not represent any one person’s genome, but merely 
comprises of a mix of sequences from different chromosomes as well as individuals. This 
means that the human reference genome also contains variations from several donors, 
including somatic variants. Moreover, the haploid reference sequence has a bias toward a 
European population background (International Human Genome Consortium, 2004).
In general, variant positions are compared between the sample of interest and the 
reference, followed by a number of filtering steps to separate benign variants from 
potential pathogenic variants. The main strategy employed to identify causative variants in 
WES is to focus on variants with clear functional consequences (nonsense variants, splice-
site variants, frameshift, conserved missense and indels). Depending on the enrichment 
kit, the sequencing platform and the pipeline used for mapping, alignment and variant 
calling, approximately 20000-50000 variants are identified per exome. After filtering 
noncoding and synonymous variants, the number of variants remaining is ~5000 14.  For 
Mendelian disorders, most of the common and less likely causal variants can be efficiently 
removed using data from control databases and prediction tools, and between 150-500 
non-synonymous and splice site variants remain to be prioritized as potentially pathogenic 
15. Downstream analysis is based on certain assumptions of inheritance (e.g. dominant, 
recessive, de novo) Further filtering strategies are needed to find the causative variant. The 
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success rate also depends on prior genetic mapping approaches (linkage, homozygosity 
mapping, CNV analysis) and availability of other patients and/or family members. This 
means that exome sequencing is highly suitable for cases where linkage intervals had been 
established, but the causal variant could not be found. 
For some Mendelian disorders where the classic linkage study design was unsuitable and 
a candidate gene approach was not possible or unsuccessful (in very small families, in a 
few unrelated cases from different families, or even in sporadic cases), exome sequencing 
also offers opportunities. As there is no candidate genomic locus known, choices have to be 
made regarding the variants that deserve follow-up work, and proof of pathogenicity has 
to be obtained. This will require even closer collaboration between clinical and molecular 
geneticists. Segregation studies are often used to establish co-inheritance with the putative 
causal variant. For non-coding genomic variants, genomic information alone is not enough 
to prove pathogenicity. Sequencing RNA isolated from the same blood samples used to 
extract DNA may provide an attractive approach. Functional studies on RNA and protein 
(animal models, in vitro assays) will become even more important. 
Interpreting new findings and translating these to practical healthcare remains a challenge. 
In addition to an increase in sequence variants, there is currently little experience in 
interpreting small structural variants, and the interpretation of somatic changes on 
a large scale. A number of studies have successfully applied WES to study effects of 
somatic mutations and/or epigenetic regulation and mosaicism, especially in cancer 
development 16-18. 
With the discovery of new SNVs and CNVs in the DNA diagnostic laboratories, the need 
for practical guidelines on interpretation of genomic variation increased. Both molecular 
geneticist, cytogeneticists and clinical geneticists are learning to deal with the benefits 
and drawbacks of applying new techniques in daily clinical practice. Communicating the 
consequences of unclassified variants is often ambiguous, and efforts should be made 
to obtain reasonable certainty on the clinical consequences of the variant. Database 
information (e.g. LOVD, OMIM, Decipher, DGV 19-23) outcomes, or even suggestions for 
further studies (e.g. functional studies on RNA or protein, segregation studies) and in silico 
predictions on functional consequences of the variant are useful information to include 
in the analysis report. Communication of unclassified variants requires special attention 
because the information given is often not completely understood or misinterpreted by 
patients and their family 24. 
Unanticipated chance findings that are medically relevant (incidental findings) will provide 
further challenges for counselling. In general, it is very difficult to discuss the disclosure of 
particular findings to the counselee beforehand, as the spectrum of possibilities is immense. 
However, as exome sequencing is making its way in the diagnostic field, improved guidelines 
9
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for proper informed consent are being developed. One way to minimize these challenges is 
to analyse only known genes or a disease-specific gene set. This, however, means missing 
an opportunity to find novel disease loci or make a different diagnosis, especially in clinically 
and genetically heterogeneous disorders. 
An additional formidable challenge is correlating low frequency sequence variants and CNVs 
to multifactorial diseases such as intellectual disability, autism, schizophrenia, and many 
other disorders.  For complex disorders, Genome-Wide Association Studies (GWAS) have 
aimed to associate common variants to common diseases by studying large case-control 
cohorts. However, most of these associated SNVs have a very small effect, and confer a 
small risk to disease 25. Identification of all variants in an individual with a common disease, 
for example autism, may reveal more rare functional variants that have a strong impact 
on disease, sometimes within a protein network 26. On the other hand, many of these risk 
variants are not recurrent but de novo. Thus, both de novo and extremely rare inherited 
SNVs and CNVs contribute together to the overall genetic risk. This means that disorders 
with extreme genetic heterogeneity require the analysis of very large numbers of clinically 
well-defined patients and extensive sequence data for validation, because the study of 
individual families will not answer which combinations may or may not be pathogenic 26, 27. 
It is currently impossible to predict the outcome of a pregnancy of a foetus carrying a CNV/
SNV of this type. Since microarray analysis is increasingly used also in the prenatal setting, 
such findings create difficult problems in genetic counselling.
In addition, by extending family studies of these apparent strong risk factors for congenital 
malformation and intellectual disability we will identify young healthy carriers who will 
want to know the risk of disability in their offspring, and will ask for accurate prenatal 
diagnosis. The knowledge gained from studying Mendelian disorders and complex diseases 
will eventually complement each other and aid in genetic counselling.
Databases
Studies on healthy and disease cohorts have identified many variants, which are stored 
in several databases to enhance clinical interpretation of unclassified variants (SNVs, 
CNVs). Accumulation of unclassified variants led to the need of dedicated locus specific 
databases (LSDBs) to enhance clinical interpretation. For all disorders studied in this thesis 
(KFSD-MBTPS2, TOD-FLNA, Aarskog-Scott syndrome-FGD1, Coffin Siris syndrome-ARID1B), 
LSDBs have been set-up and are publicly available. Variant information can be stored and 
easily queried by users worldwide, and are subject to editorial screening by curators. In 
theory, storage in databases available on the internet is effective. In practice, however, 
a large number of different databases have emerged, leading to the lack of centralised 
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data storage. Data on genomic variation becomes scattered, depending on where the 
user decides to upload their experimental data. This could be solved by reaching definite 
(international) agreements on sharing of variants by laboratories, and honouring the 
existing commitments. Larger and more general data repositories (including NCBI and 
UCSC) have requested of locus-specific variant databases (LSDBs) to share their data 28. 
The HGMD represents an attempt to collate known gene lesions responsible for human 
inherited disease 29. HGMD also includes some variant data from those LSDBs that are in 
the public domain. Researchers and diagnosticians, genetic counsellors and physicians can 
use this information of practical diagnostic importance. The need for large, trustworthy 
databases will only increase when the use of next generation sequencing for diagnostic 
purposes gains in popularity.
Conclusion
This thesis outlines the rapid development of molecular techniques for detecting genomic 
variation. It describes advantages and disadvantages of specific techniques, and shows their 
application in the search for pathogenic variants in patients with genetic disorders. Next 
generation sequencing brings genetics into a new era of identifying sequence and structural 
variants in the context of disease. Both the techniques itself and the associated analysis tools 
will continue to improve in the future, eventually resulting in an approach that can detect 
all genomic variation in one assay. Every technical advance in genetic analysis has revealed 
a new level of variation within our genome i.e. initially chromosomal variation, then copy 
number changes of decreasing size, down to nucleotide level. As further methodological 
developments can be anticipated, it is reasonable to assume that there are additional levels 
of genomic complexity still to be revealed. Through identification of new disease genes, 
the NGS techniques will increase our knowledge of the molecular pathogenesis of genetic 
disorders. Interpreting these data and translating findings to improve healthcare will be a 
great challenge. The availability of new techniques for genomic analysis, and the associated 
benefits for patients, should be balanced against each patient’s right not to know what their 
genome contains. Collaboration between research and diagnostics is pivotal for determining 
the most appropriate protocols for returning information to counselees. With NGS, the 
focus in clinical genetics the coming years will shift from identification to interpretation 
of variants, requiring more follow-up work. Further technical advances are necessary to 
enable investigation of other genetic mechanisms, including somatic mutations, epigenetic 
dysregulation and polygenic disruption, each of which is likely to account for a significant 
proportion of disease.
9
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Variation in structure and composition of the DNA are found throughout our genome. All 
types of variation are collectively called ‘genomic variation’. Identification and analysis 
of genomic variation is important to distinguish neutral variants (‘non pathogenic’) from 
variants involved in disease (‘pathogenic’). Identification of new disease genes will increase 
our knowledge of the molecular pathogenesis of genetic disorders. Every technical advance 
in genetic analysis has revealed new levels of variation, ranging from single nucleotide 
differences to full chromosome changes. Chromosome changes larger than 5-10 Mb in size 
can be detected by conventional karyotyping. Other techniques, notably Fluorescent  in situ 
hybridisation (FISH), Array comparative genome hybridisation (Array-CGH), and SNP-arrays 
but also amplification methods such as Multiplex ligation-dependent probe amplification 
(MLPA) allow the detection of aberrations below the resolution of conventional karyotyping. 
These submicrosopic changes are called copy number variations (CNVs). High resolution 
melting curve analysis (HRMA) and Sanger sequencing are used to study alterations at the 
single nucleotide level (sequence variation). The application of new technologies, whole 
exome sequencing (WES) and whole genome sequencing (WGS) aid in bridging the technical 
divide between quantitative (CNV) and qualitative DNA differences (sequence variants). As 
new DNA methods are applied, increasing numbers of variants with unclear significance to 
disease (UVs) are identified and choices have to be made regarding the variants that deserve 
follow-up work. When the pathogenic consequence of a variant is unclear, the effect has to 
be studied in detail at other levels (functional studies, RNA studies, in silico analysis tools, 
and databases). This research described in this thesis outlines the rapid development and 
application of molecular techniques for detecting (pathogenic) genomic variation in the 
context of genetic disorders.
Chapter 1 provides a general introduction to human genetics and the different types of 
genomic variation, in relation to health and disease. An overview of cytogenetic and molecular 
techniques was given, and the advantages and disadvantages of several techniques were 
discussed. Options for interpretation and classifications of variants are summarized.
In Chapter 2, methods to detect CNVs in the human genome are reviewed. A 1400-plex 
targeted CNV assay was designed to study 320 patients with intellectual disability. In 9% of 
the analysed cases, a pathogenic CNV was found. Furthermore, HRMA was used as a new 
method to confirm the presence of CNVs detected using SNP-arrays.
In Chapter 3, Array-CGH and SNP-array were used to delineate a de novo chromosome 19p 
deletion in a patient with intellectual disability, Split Hand Foot Malformation (SHFM) and 
Tetralogy of Fallot. In addition to this case study, MLPA was used to study the presence 
of copy number changes in genes within the deletion interval in 21 other SHFM patients. 
Based on its function, EPS15L1 was postulated as a candidate gene for Split-Hand-Foot-
Malformation (SHFM).
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In the following chapters (4 and 5) several applications of HRMA are discussed and show 
the succes of HRMA as a presequence screening technique. HRMA was used to identify 
MBTPS2 as the causative gene for Keratosis Follicularis Spinulosa Decalvans (KFSD). In three 
families (Dutch, American and English), a missense mutation was identified. Functional 
studies have demonstrated this mutation to be pathogenic. Studying X-inactivation (XCI), 
differences in allelic expression could be correlated to the clinical phenotype of carrier 
females. Mutations in MBTPS2 have also been described in Ichthyosis Follicularis Atrichia 
Photophobia (IFAP) syndrome, a syndrome that shows clinical overlap with KFSD.
Chapter 6 describes three families with Terminal Osseous Dysplasia (TOD) where X-exome 
sequencing was applied to identify the causative gene, FLNA, in the linkage interval on 
Xq27.3-q28. The missense variant was predicted to affect splicing. Initial RNA analysis in 
patient-derived fibroblasts did not detect expression of the mutant allele. Additional RNA 
analysis in 15-year-old fibroma tissue showed alternative splicing confirming activation 
of a cryptic splice site, and results in an in-frame deletion. To study the pathogenetic 
mechanism of the FLNA mutation in TOD, a 3D protein model was built indicating that the 
deleted region affects or prevents important protein-protein interactions. XCI patterns in 
patients were established and suggest early skewing with preferential inactivation of the 
mutant allele is key to disease development.
Chapter 7 illustrates the use of WES to identify the causative gene in a family with Aarskog-
Scott syndrome. A branch point variant (-35 bp intronic) in FGD1 was identified that was 
missed with conventional Sanger sequencing. RNA analysis confirmed an effect on splicing. 
This work shows, although WES is not specifically designed to do so, deeper intronic 
variants can be detected.
In Chapter 8 mutations in the SWI/SNF chromatin remodelling complex ARID1B were 
identified as the genetic cause of Coffin-Siris syndrome (CSS). One case-parent trio and two 
sporadic patients were studied according to a recessive inheritance model using WES. After 
initial analysis did not reveal causative variants, a dominant inheritance model identified 
De novo truncating mutations in all patients. By excluding an autosomal recessive 
inheritance pattern for CSS, the recurrence risk for parents with a child diagnosed with CSS 
could be reduced to 1-2%. Mutations in other genes affecting the SWI/SNF complex have 
been published in CSS patients (Tsurusaki et al, Nat Genet. 2012; 44(4):376-378), in other 
syndromes (Clapier et al, Annu Rev Biochem. 2009;78:273-304) and are associated with 
tumorigenesis (Wilson et al, Nat Rev Cancer. 2011;11(7):481-92  and Wang et al, Nat Genet. 
2011;43(12):1219-23 ), indicating that mutations in chromatin remodelling factors contribute 
significantly to human diseases.
Finally, in Chapter 9 the evolution of techniques, strategies for gene identification and 
variant interpretation are discussed. 
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Ons genoom toont variatie in structuur en samenstelling van het DNA. Alle soorten 
variatie tezamen worden ‘genomische variatie’ genoemd. De identificatie en analyse van 
genomische variatie is belangrijk om neutrale varianten (‘niet-pathogeen’) te onderscheiden 
van varianten die een rol spelen bij ziekten (‘pathogeen’). Identificatie van nieuwe ‘ziekte-
genen’ zal onze kennis van de moleculaire pathogenese van genetische aandoeningen 
vergroten. Iedere technische vooruitgang in de genetische analyse openbaarde nieuwe 
niveaus van variatie, uiteenlopend van enkelvoudige nucleotide verschillen tot volledige 
veranderingen in het chromosoom. Veranderingen in het chromosoom die groter zijn 
dan 5-10 Mb zijn op te sporen met de gebruikelijke karyotypering. Andere technieken 
maken het mogelijk om kleinere afwijkingen te ontdekken, die zich onder de resolutie 
van de conventionele karyotypering bevinden. Dit betreft met name Fluorescent in situ 
hybridisation (FISH), Array comparative genome hybridisation (Array-CGH) en SNP-arrays, 
maar ook andere methoden zoals Multiplex ligation-dependent Probe Amplification 
(MLPA). Deze submicroscopische veranderingen heten CNV’s: copy number variations. 
High resolution melting curve analysis (HRMA) en Sanger sequencing zijn ontwikkeld 
om nucleotide veranderingen (sequence variatie) te detecteren. Toepassing van nieuwe 
technologieën als Whole-exome sequencing (WES) en whole genome sequencing 
(WGS) helpen om de technische leemte te overbruggen tussen kwantitatieve (CNV) en 
kwalitatieve (sequentie-varianten) DNA-verschillen. 
De toepassing van nieuwe DNA-methoden resulteert in toenemende mate in de ontdekking 
van varianten waarvan de betekenis voor ziekten onduidelijk is (‘unclassified variants’) en 
dit vraagt om het maken van keuzes in de varianten die vervolgstudie verdienen. Als er 
onduidelijkheid bestaat over de pathogene consequentie van een variant moet het effect 
in detail worden bestudeerd op andere niveaus (functionele studies, RNA-studies, in silico 
analyses en databases).
Dit promotieonderzoek beschrijft de ontwikkeling en de toepassing van moleculaire 
technieken voor het ontdekken van (pathogene) genomische variatie in de context van 
genetische aandoeningen.
Hoofdstuk 1 voorziet in een algemene introductie in humane genetica en de verschillende 
typen van genomische variatie in relatie tot ziekte en gezondheid. Het geeft een overzicht 
van cytogenetische en moleculaire technieken en bespreekt de voordelen en de nadelen 
van verschillende technieken. Opties voor interpretatie en classificatie van varianten zijn 
toegevoegd.
Hoofdstuk 2 bespreekt methoden om CNV’s in het menselijk genoom te vinden. Voor de 
bestudering van 320 patiënten met verstandelijke beperking werd een specifieke 1400-
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plex array ontwikkeld. In 9% van deze populatie werd een pathogene CNV gevonden. 
Bovendien werd HRMA gebruikt als nieuwe methode om CNVs te bevestigen, die eerder 
met arrays gevonden waren. 
Hoofdstuk 3 rapporteert over het gebruik van Array-CGH en SNP-array voor de beschrijving 
van een de novo chromosoom 19p-deletie bij een patiënt met verstandelijke beperking, Split 
Hand Foot Malformation (SHFM) en Tetralogie van Fallot (hartafwijking). Als aanvulling op 
deze casus werden 21 andere SHFM-patiënten bestudeerd met MLPA om de aanwezigheid 
van CNVs te onderzoeken in genen binnen het deletie-interval. EPS15L1 werd op grond van 
zijn functie aangemerkt als kandidaat-gen voor Split Hand Foot Malformation (SHFM).
De hoofdstukken 4 en 5 bespreken verscheidene toepassingen van HRMA en demonstreren 
het succes van HRMA als pre-sequencing-techniek. Met behulp van HRMA werd gevonden 
dat mutaties in het MBTPS2-gen verantwoordelijk zijn voor het ontstaan van Keratosis 
Follicularis Spinulosa Decalvans (KFSD). In drie families (Nederlands, Amerikaans en Engels) 
werd een missense mutatie geïdentificeerd. Functionele studies toonden aan dat dit een 
pathogene mutatie is. Bij bestudering van de X-inactivatie konden verschillen in allelische 
expressie gekoppeld worden aan het klinische phenotype van vrouwelijke dragers. 
Mutaties in MBTPS2 zijn ook beschreven in het Ichthyosis Follicularis Atrichia Photophobia 
(IFAP) syndroom, dat klinisch overlap toont met KFSD.
Hoofdstuk 6 beschrijft drie families met Terminal Osseous Dysplasia (TOD), waarbij 
X-exoom sequencing werd toegepast om de genetisch oorzaak voor deze aandoening 
op te sporen. In voorgaande studies werd een locatie gevonden op het X-chromosoom 
(Xq27.3-q28 ) waarin het veroorzakende gen zou kunnen liggen. Met behulp van WES 
werd een missense-variant gevonden in het FLNA-gen. De voorspelling was dat deze 
variant splicing zou veroorzaken. Aanvankelijk toonde RNA-analyse in huidcellen van de 
patiënt geen expressie van het mutante allel. Echter, aanvullende RNA-analyse in 15 jaar 
oud fibroomweefsel bevestigde de activering van een cryptische splice-site, resulterend in 
een deletie, die het leesraam niet verstoort. Om het pathogenetische mechanisme van de 
FLNA-mutatie in TOD te bestuderen, werd een 3D-eiwit model gebouwd. Hieruit bleek dat 
de deletie leidt tot het verlies van aminozuren die belangrijk zijn voor de eiwitstructuur en 
dat dit mogelijk belangrijke eiwit-eiwit-interacties beïnvloedt. In de patiënten en gezonde 
familieleden werd naar hun X-inactivatie patroon gekeken. Hierbij werd vastgesteld dat 
in patiënten het X-chromosoom met het mutante allel volledig geïnactiveerd was, terwijl 
gezonde familieleden een willekeurige inactivatie van een van de twee X-chromosomen 
toonden. Dit suggereert dat er al vroeg in de ontwikkeling selectie plaatsvindt tegen 
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cellen met expressie van een mutant FLNA-eiwit en dat dit een belangrijke rol speelt bij de 
ontwikkeling van de ziekte.
Hoofdstuk 7 belicht het gebruik van WES bij het opsporen van de genetische oorzaak in 
een familie met het Aarskog-Scott-syndroom. Hierbij werd een branchpoint-mutatie in 
het FGD1-gen gevonden (-35 bp intronisch), die met Sanger sequencing in een diagnostisch 
laboratorium niet werd gevonden. RNA-analyse bevestigde een effect op splicing. Dit werk 
laat zien dat WES geschikt is om diepere intronische varianten te detecteren, hoewel de 
techniek daarvoor niet specifiek ontworpen is.
Hoofdstuk 8 beschrijft de ontdekking van mutaties in het ARID1B-gen, een SWI/SNF 
chromatin-remodelling complex, als de genetische oorzaak van het Coffin-Siris-syndroom 
(CSS). Eén casus van een trio (ouders+kind) en twee sporadische patiënten werden met WES 
getest, uitgaande van een autsomaal recessief overervingsmodel. Nadat initiële analyse 
geen relevante varianten opleverde, werd een dominant overervingsmodel toegepast. 
Hierbij werden de novo truncerende mutaties gevonden in alle patiënten. Door aan te tonen 
dat CSS geen autosomaal recessief overervende aandoening is, kon het herhalingsrisico 
voor ouders op een volgend kind met CSS worden teruggebracht tot 1-2%. Ook in andere 
CSS-patiënten, in patiënten met andere syndromen en voor bepaalde vormen van kanker 
zijn mutaties beschreven in genen die betrokken zijn bij SWI/SNF chromatin remodelling. 
Dit wijst erop dat mutaties in chromatine-remodelling factoren een significante bijdrage 
leveren aan menselijke ziekten.
In hoofdstuk 9 wordt de ontwikkeling van technieken bediscussieerd met de daarmee 
gepaard gaande strategieën om ziektegenen op te sporen en de betekenis van varianten 
te interpreteren.
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409 maanden nadat ik het eerste levenslicht zag is het zover: het is voltooid, verricht, 
uitgevoerd, afgerond, beëindigd, afgemaakt, vervuld, tot stand gebracht, bewerkstelligt, 
‘gecheft’. Mission accomplished. 
Velen hebben hierbij een rol gespeeld:
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Martijn, als hoofd van de afdeling Klinische Genetica, en als mijn promotor, heb je 
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flexibiliteit in dit traject. Johan, als mijn tweede promotor, heb je mij een plek geboden in het 
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al het (reeds) verrichte onderzoek dat nodig was om het gen voor KFSD te vinden. 
Yu and Rowida, thanks for the pleasant collaboration. As part of the Breuning research-
group, I think we’ve stuck together and share some really nice papers because of this.
All colleagues from Lab-J, you have all contributed tot his thesis in one way or the other. 
There has always been support for presentations, help in the lab, useful work discussions 
and social events. All (former) fellow-PhD students thanks for your support. Especially 
Maaike, Dwi, Pietro, Herman and Eddy. Thank you for your friendship.
I’d like to thank my Lab-J room mates: Matt, Ivo and Michel for the beers, for trying to 
introduce met to “pearle” and linux (but failed to convince me) and many other things. 
Annemieke (and later Isabella), thanks for ‘adopting’ me. Naast het feit dat ik veel van jullie 
heb geleerd, was het erg gezellig. Huntington-groupers (Willeke, Menno, Tassos, Barry & 
Melvin (master of pixels), bedankt voor het jarenlang delen van het lab en het bijbrengen 
van inventieve western blot technieken. Peter-Bram, de reis naar Kentucky na het ASHG 
was een uitdaging, maar hebben we precies gered en gaf ons mooi de tijd om (bij) te 
praten. Dank voor alles! 
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LGTC-ers, bedankt voor jullie hulp bij diverse zaken. Yavuz en Rolf ,fijn dat ik altijd bij jullie 
terecht kon met technische vragen (en niet-technische) en acute tekorten aan platen en 
reagentia.
Margot, Stefan en Marjolein. Jullie hebben me als “de nieuwe Stefan” meteen op weg 
geholpen met de experimenten zoals MLPA en de MR-goldengate array en hebben de 
basis gelegd voor de eerste publicaties. Stefan, special thanks to you for your useful 
comments, correcting my english and your great sense of humour. Marjolein, super dat jij mijn 
paranimf wil zijn. Het is heel waardevol om zo’n positieve, gezellige collega te hebben 
die de ins- and outs, up’s and down’s van promoveren kent. Daarnaast ben je natuurlijk 
gesequenced en dan tel je pas echt in de wereld van genetica. Ik hoop dat we nog lang 
kunnen samenwerken!
Alle collega’s van de kliniek, ook jullie input en hulp is zeer belangrijk geweest voor de 
totstandkoming van dit proefschrift. Jullie enthousiasme voor de patiëntenzorg is 
inspirerend en ik hoop dat we samen in de toekomst klinische kennis en research kunnen blijven 
combineren. Lieve mede-AIOS; de meesten van jullie weten hoe het is om je opleiding te 
combineren met het voltooien van een proefschrift. Dank voor jullie steun. Dietje, het was 
fijn om een kamergenoot te hebben die in hetzelfde schuitje zat! Marije, pita omonia says 
it all. Gijs, dank voor al je (exome) inzet, het heeft een prachtig Nature Genetics artikel 
opgeleverd. Ik hoop dat we ook in de toekomst gezamenlijke doelen kunnen realiseren.
Staf (i.o.) en analisten van het LDGA, bedankt voor de samenwerking. Ook jullie hebben op 
allerlei manieren bijgedragen aan de totstandkoming van een aantal artikelen.
Mijn studenten Ingeborg, Tobias en Lisa wil ik bedanken voor hun inzet. Al hun werk heeft 
bijgedragen aan mijn publicaties. 
Maanden 276-409
Lieve Kirsten (Chica), heel erg leuk dat jij vandaag mijn paranimf bent! Dank voor je humor, 
interesse, gesprekken (medisch en niet-medisch) en overall enthousiasme. 
Maanden 181-409
DFN (Anne-Marleen, Martine, Annemarie, Marieke, Marsha, Gabrielle en Janneke), 
ontzettend bedankt voor alle gezellige etentjes, jullie verhalen en interesse in “mijn  
avonturen”! 




Pap, mam, Jan Joost (& Marjolein +2), Niels (& Annemieke). Dank voor jullie 
belangstelling, steun, motiverende woorden en hulp in al deze 409 maanden. Mam, ex-
tra dank voor je inzet en input voor het perfectioneren van mijn proefschrift! Josje, be-
dankt voor je 409 maanden vriendschap (+2 dagen (eigen)wijsheid). Marinde, 313 maanden 
belevenissen, en ja.. “dat boekje” is nu eindelijk af. F.F.!
Maanden 288-409
Thea en familie van Meggelen, jullie hebben altijd naar de voortgang van mijn proefschrift 
geïnformeerd, dank! 
Lieve Bassy, jij hebt alle jaren onderzoek van dichtbij meegemaakt, met bijbehorende 
successen (live vanuit Washington) en dieptepunten. Jouw zorgzaamheid, geduld, 
luisterend oor èn kritische blik zijn onmisbaar!–x-
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Chapter 1
Figure 1a: Types of variation in 
the human genome (sequence 
view). These can be single base 
changes (substitution, deletions, 
and insertions) or involve larger 
segments of DNA (deletions, 
insertions, inversions, indels, 
and duplications). Adapted from 
Frazer et al 17
Figure 1b: Types of variation in the human genome (chromosome view). Examples of structural 
variation. 1) transposition-transfer of segment of DNA to a new position. 2) translocation-
balanced event where two DNA segments are interchanged. 3) Copy number variation: deletion 
and duplication-loss or gain of DNA segments.
Figure 2: Conceptual curves of 
SNV and CNV characteristics. 
Projected frequencies in the 
population for SNVs (dashed 
grey) and CNVs (blue) show 
the relation between genomic 
variation and a spectrum of 
phenotypic impact. Adapted 
from Buchanan et al 28.
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Chapter 2
Figure 1: 1400-plex CNV bead assay. A) Strength of 
signal for probes on the X-chromosome obtained in 
males (M, X-axis) versus females (F, Y-axis). Signals 
are clearly different yet the difference in F:M signal 
obtained is not 1:0.5 as expected but 1:~0.7
Figure 2: Fast-MLPA. Detection of a trisomy 21 (top left), Turner (45, X0; top right) and 49, XXXXY 
case (bottom) using fast-MLPA.
Figure 3: hrMCA CNV. High-resolution Melting Curve Analysis of two DNA samples being 
homozygous for the opposite SNP-alleles (rs213950:G>A) mixed in different proportions (from 8:0 
to 0:8). The difference plots of all mixes can be easily discriminated, giving a sensitivity of at least 
12.5%, suggesting that octaploid alleles could be typed.
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Chapter 3
Figure 1: Clinical features of the index patient. (A) Phenotype of the patient (here six years old) 
with subtle facial features including a wide mouth, fair hair and light skin. Central ray deficiencies 
as detected at birth. Left foot (B) with a cleft, hypoplasia of the second digit and a nubbin 
representing the third digit. Right foot (C) with a proximally placed first digit and presence of 
digit V. Digits II-IV are absent. Right hand (D) with a central cleft leading to absence of the third 
digit. Digit IV and V show cutaneous syndactyly.
Figure 2: (A) Array-CGH showed one deleted BAC clone (RP11-413M18) on 19p13.11 at 16.8 Mb 
with a maximal deleted size of 1.44 Mb. (B) SNP array refined the deletion from rs10411936 (19: 
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Chapter 4
Figure 4: CA repeat analysis using 
HRMA. Six different DNA samples 
were analyzed in duplicate, 
all heterozygotes. Top panel: 
normalized temperature shifted 
melting curves. Bottom panel: 
derivative plot. Allele lengths were 
1=18/21, 2=17/21, 3=14/17, 4=14/18, 
5=15/21, 6=14/21.
Figure 6:  HRMA as alternative for gel electrophoresis. A: Analysis of a series of five different PCR 
fragment; because the fragments have clearly different melt profiles all five fragments can be 
analyzed in one analysis. When the melt profiles partly overlap, analysis can be done per fragment. 
B: Analysis of a PCR performed on 96 different samples. Some PCRs failed (only background) 
fluorescence, yield of the others can be estimated from the level of fluorescence. Purity, including 
absence of primer dimers, can be checked by analysis of the HRMA difference plots (not shown). 
C: HRMA after insert PCR of 384 phage display clones after second round selection. Several clear 
groups of melt profiles are identified, an indication that the clones contain identical inserts. Note 
that to identify all groups present, clones recognized after a first analysis need to be removed and 
software grouping must be repeated. This procedure has to be repeated until no further groups 
are recognized.
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Chapter 5
Figure 2: The KFSD locus. 
The KFSD linkage locus was 
redefined at Xp22.12-Xp22.11. 
High Resolution Melting curve 
Analysis (HRMA) identified 
MBTPS2 as a candidate gene 
in the Dutch KFSD family. 
The detected variant in 
MBTPS2 is indicated in red/
gray. Previously identified 
mutations in IFAP syndrome 
are indicated in black. 
Figure 4: Complementation assay and luciferase reporter 
assay. Functional studies of the c.1523A>G (p.Asn508Ser) 
variant using an in vitro assay testing sterol responsiveness. 
A. Complementation assay: Growth of stably transfected 
CHO-K1-M19 cells (lacking hamster MBTPS2) was measured in 
cholesterol rich medium (blue) and cholesterol deficient medium 
(red). The proportion of cells capable of growth is documented 
as framed photographs of the cultures and, graphically in bars 
by counts of growing stably transfected cells. Colours indicate 
absence (red) or presence (blue) of sterols. B. Luciferase reporter 
assay: luciferase activity functions as an indirect measure of 
the ability of MBTPS2 mutants to restore sterol-regulated 
transcriptional activity in transfected CHO-K1-M19 cells. Cells 
transfected with the c.1523A>G (p.Asn508Ser) variant are less 
able to restore sterol-regulated transcription compared to wild 
type when transferred from a cholesterol rich (blue bars) to a 
cholesterol deficient medium (red bars).
A 
B 
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Figure 3: MBTPS2 mutation analysis in the Dutch KFSD family. a) Sanger sequencing of exon 11 in 
the MBTPS2 gene identified a c.1523A>G (p.Asn508Ser) in all affected males of the Dutch KFSD 
family, not present in WT controls. The variant co-segregates with the disease in this family; 
affected male (VI-20) c.1523A>G , carrier female (VI-27) c.1523AG and unaffected male (VII-6) 
c.1523G. b) RNA analysis in fibroblasts in the Dutch KFSD family. cDNA sequencing in fibroblasts 
confirmed the presence of the c.1523A>G variant in an affected male. Carrier females (VI-19, VII-
11, VI-27, and VII-10) showed variability in the expression of the mutated and the wild type allele.
Figure S1: MBTPS2 levels in KFSD 
males compared to control males.
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Figure S2: Skin biopsies stained with αMBTPS2 (brown) with (A) and without Hematoxylin 
(B). 40x and 20x magnification. 
Epi=epidermis, SC=stratum corneum, SG=stratum granulosum, SS=stratum spinulosum, 
SB=stratum basale. 
Figure S3: Skin biopsy stained with 
αKeratin-10 (A) and only counterstaining 
with Hematoxylin (B). 20x and 10x 
magnification. Keratin-10 is expressed 
in the epidermis, except the stratum 
basale.
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Chapter 6
Figure 1: The pedigrees and the phenotype of family 3. (A) The pedigrees investigated in 
this study, in family 3 X inactivation patterns show the silencing of the X chromosome 
which carries the mutant allele. (B) shows the hands of 3I:2. (C) Multiple frenula of 3II:4. (D) 
The right hands of 3II:4. She has clinodactyly and digital fibroma. (E) shows the right upper 
accessory frenulum of 3II:5. (F) The right hand of 3II:5. 
Figure S4: Cellular localisation of MBTPS2 in fibroblasts. There is no difference between a control 
male (a) and a male KFSD patient VII-12 (b). MBTPS2 (green fluorescence) is found both in the 
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Figure 3: Detection of alternative splicing and 3D protein model. (A) Diagram of four FLNA transcripts in 
fibroma cells: transcript 1 and 2, which carry the 48bp deletion at the end of exon 31, as well as the normal 
transcripts 3 and 4. (B) RT-PCR result from Agilent 2100 Bioanalyzer. Lane 1 is the product of the fibroblasts 
of 1III:6, which has a predominant longer isoform. Lane 2-4 and 8 are four control human fibroblasts. Lanes 
5-7 show RT-PCR products that  were obtained from fibroma cells of 1III:6, the normal bands from two FLNA 
isoforms, and two extra shorter bands, which are faint in lane 6 (left fifth finger)and lane 7 (fifth toe of 
the left foot) , whereas lane 5 (right fifth finger )shows four dark bands. (C) Sanger sequencing results of 
c.5858T>C and c.5217G>A in fibroblast and fibroma cells of 1III:6. (D) The 3D model of FLNA domain 15. The 
deleted 16 amino acids are marked in gray. Beta-strands are marked in red. Green represents a turn. Yellow 
indicates a 3/10 helix. Random coils are colored in cyan. 
Figure 2: Genomic Structure and 
mutation analysis of FLNA. (A) 
c.5217G>A was confirmed by Sanger 
sequencing in all the patients. The 
unaffected family members and 
controls carry the homozygous 
normal allele. (B) shows the 
sequence of c.5850T>C in family 1. (C) 
FLNA is located in Xq28, the target 
region of linkage analysis. C.5217G>A 
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Figure S2: Coverage plots of GAIIX sequencing for III-1 and III-2.
Chapter 7
Figure S3: The 2100 bioanalyzer traces of RT-PCR on c.5217G>A from lane 1 to 8. The peak
around 15bp is the lower ladder and the signal round 1500bp is the upper ladder.
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Figure 2: Genomic analysis of the mutation. A) Analysis result of GAII-X sequencing, displayed in 
IGV browser. III-1 and III-2 show a single nucleotide deletion, c.2016-35del in intron 12 of FGD1. On 
the left side, DNA Sanger sequencing results confirming the variant in the Dutch Aarskog family 
(III-1 and III-2 versus a WT control). B) A diagram of the normal and abnormal splicing in exon 12, 13 
and 14. C) Sanger sequencing of the RT-PCR shows a skip of exon 13 in individuals III-1 versus a WT 
control, confirming the branch point variant. The skip of exon 13 leads to a 31 bp shorter mRNA. 
D) The 2100 Bioanalyzer results show semi-quantification of skipped products. III-1(lane 1) shows 
a 94% skip, containing two products, a large skipped (163 bp) and a small WT band (194 bp). III-
2(lane 2) and I-1(lane4) show a 100% skip. II-1 (mother, lane 3) has a 50-50 distribution of WT and 
skipped products. Controls (lane 5~8) only carry the WT band.
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Figure S3: The 2100 Bioanalyzer Traces of RT-PCR show semi-quantification of skipped 
products.  The peaks represented are the lower ladder (15 bp) and upper ladder (1500 bp),
the skipped FGD1 product (163 bp) and the WT product.
Figure S1: Phenotype of the two Aarskog siblings (III-1, III-2) and their maternal grandfather 
(I-1). Facial features are illustrated at age 8 years and 13 years (III-1) and at age 6 years and 
11 years (III-2). Craniofacial features, skeletal and genital features are described in Table 1.
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Figure S4: Application of exome sequencing for detection of intronic variants. 
A) Intronic coverage plot for a range of distances to the splice site in our dataset. 
Percentage of the introns covered (minimal depth 8) decreases with an increasing distance 
from splicesite. B) Calculation of the number of filtered variants upon inclusion of intronic 
variants by a range of distances to the splice site (depth >8).
Figure S5: Overview of splice elements of FGD1 exon 12-13. 5’splice site (GU dinucleotide), 
branch point sequence YUNAY with adenine for lariat formation, AG exlusion zone (AGEZ), 
polypyrimidine tract (ppt) and 3’splice site (AG dinucleotide).
EXTRA KATERN-16 pags kleuren figs.indd   14 10-12-12   9:59
Supplementary Figure 1:  Additional features in the CSS patients. Hypertrichosis in patients 1 (A) 
and 2 (B). Agenesis of the corpus callosum in patient 1 (thin arrow, thick arrow points to a small 
part of the corpus callosum that is present) (C). Brachydactyly of the fifth finger in patient 2 (D), 








Figure 1: Facial features of all patients. Top, left to right: Patient 1 at 4.5 years, patient 2 at 2,5 
years, patient 3 at 3 years. Bottom, left to right: Patient 4 at 3.5 years , patient 5 at 45 years, 
patient 6 at 3,5 years. All patients share coarse facial features, thick eyebrows and broad 
nasal tips. For further details see Supplementary Table 1. The parents or legal guardians of all 
affected individuals gave consent for publication of the clinical photographs.
EXTRA KATERN-16 pags kleuren figs.indd   15 10-12-12   9:59
Supplementary Figure 2: On the left the raw data around the pathogenic variant in the Integrative 
Genomics Viewer3 for each of the 3 patients. Arrows indicate the location of the variant. On the right the 
Sanger sequencing validation results.
Supplementary Figure 3: Top: Plot of the genomic deletions detected in patients 4 to 6. Red dots represent 
the raw data, the blue line represents the calculated CNV score. All deletions are de novo (data of parents 
not shown). No other possibly pathogenic CNVs were found in these patients. Bottom: graph of the size 
and location of each of the deletion.
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